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Abstract 
 
The influenza A virus non-structural (NS1) protein is multifunctional, and during 
virus-infection NS1 interacts with several factors in order to manipulate host-cell 
processes. This study reports that NS1 binds directly to p85β, a regulatory subunit of 
phosphoinositide 3-kinase (PI3K), but not to the related p85α. Expression of NS1 was 
sufficient to activate PI3K and cause the phosphorylation of a downstream mediator 
of PI3K signalling, Akt. However, in virus-infected MDCK cells, the kinetics of Akt 
phosphorylation did not correlate with NS1 expression, and suggested that negative-
regulation of this signalling pathway occurs subsequent to ~8h post-infection. 
 
Mapping studies showed that the NS1:p85β interaction is primarily mediated by the 
NS1 C-terminal domain and the p85β inter-SH2 (Src homology 2) domain. 
Additionally, the highly conserved tyrosine at residue 89 (Y89) of NS1 was found to 
be important for binding and activating PI3K in a phosphorylation-independent 
manner. The inter-SH2 domain of p85β is a coiled-coil structure that acts as a scaffold 
for the p110 catalytic subunit of PI3K. As NS1 does not displace p110 from the inter-
SH2 domain, a model is proposed whereby NS1 forms an active heterotrimeric 
complex with PI3K, and disrupts the ability of p85β to control p110 function. 
 
Biological studies revealed that a mutant influenza A virus (Udorn/72) expressing 
NS1 with phenylalanine substituted for tyrosine-89 (Y89F) exhibited a small-plaque 
phenotype, and grew more slowly in MDCK cells than wild-type virus. Unexpectedly, 
another mutant influenza A virus strain (WSN/33) expressing NS1-Y89F was not 
attenuated in MDCK cells, yet appeared to be less pathogenic than wild-type in vivo. 
 
Overall, these data indicate a role for NS1-mediated PI3K activation in efficient 
influenza A virus replication. The potential application of this work to the design of 
novel anti-influenza drugs and vaccine production is discussed. 
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Introduction 
1. Introduction 
(i) Influenza A viruses 
- 1 - 
1.1 Influenza A viruses. 
 
1.1.1 Influenza and the influenza A virus. 
In humans, influenza is usually an acute, yet highly contagious, respiratory illness that 
mainly affects the upper respiratory tract (i.e. the nose, throat and bronchi) [reviewed 
in (WHO, 2003, Wright & Webster, 2001)]. Infection is often characterised by the 
sudden onset of fever, muscle pain, headache, and severe malaise, together with a non-
productive cough, sore throat, and nasal inflammation [reviewed in (Wright & 
Webster, 2001)]. In temperate climates, annual epidemics (seasonal influenza; 
increased general incidence) occur mostly during the winter, and seriously affect an 
estimated 3-5 million people worldwide [reviewed in (Subbarao et al., 2006, WHO, 
2003)]. Although most people recover within 1-2 weeks without requiring medical 
treatment, infections in the young, elderly, or chronically ill can sometimes result in 
pneumonia, hospitalisation, and death [reviewed in (Wright & Webster, 2001)]. 
Indeed, seasonal influenza still accounts for 250,000-500,000 deaths every year around 
the world (WHO, 2003). 
 
Occasionally, influenza affects 20-40% of the world’s population in a single year 
(Subbarao et al., 2006, Taubenberger & Palese, 2006). Such unpredictable influenza 
“pandemics” (global increases in incidence) occurred three times in the 20th century: 
1918-1919, 1957-1958, and 1968 [reviewed in (Taubenberger & Palese, 2006, Wright 
& Webster, 2001)]. The 1918 ("Spanish flu") pandemic was the most severe, and is 
estimated to have clinically affected ~500 million people (approximately one-third of 
the world’s population), and caused >40 million deaths [reviewed in (Taubenberger & 
Palese, 2006)]. The pandemics of 1957 ("Asian flu") and 1968 ("Hong Kong flu") had 
much lower, yet still significant, mortality rates (Subbarao et al., 2006, Wright & 
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Webster, 2001). A characteristic of all these pandemics (although most dramatically 
with the "Spanish flu") is their association with severe disease progression even in 
young healthy adults [reviewed in (Taubenberger & Palese, 2006)]. Since 1997, human 
infections caused by highly-pathogenic avian influenza have lead many to believe that 
another global pandemic is inevitable in the near future [reviewed in (Webster, 2006)]. 
 
The major causative agent of influenza is the influenza A virus, which was first 
isolated from humans in 1933 by Wilson Smith, Sir Christopher Andrewes, and Sir 
Patrick Laidlaw, whilst working together at the National Institute for Medical Research 
(NIMR), London, U.K. (Smith et al., 1933) (Fig. 1.1). However, Richard Shope 
(U.S.A.) had previously shown that swine influenza could be transmitted by filtered 
mucus, giving the first indication that the causative agent might be a virus (Shope & 
Lewis, 1931). 
 
1.1.2 Nomenclature. 
The nomenclature given to individual influenza A virus strains usually includes 
reference to the host of origin (except in humans), geographic location of first 
isolation, strain number, and year of isolation. Additionally, the antigenic description 
(subtype) of the two viral surface glycoproteins (see below - haemagglutinin, HA; and 
neuraminidase, NA) is given in parentheses [reviewed in (Wright & Webster, 2001)]. 
For example, A/Duck/Ukraine/1/63 (H3N8) is a type A influenza virus strain first 
isolated from a duck in the Ukraine in 1963. Of the 16 antigenically distinct HA 
subtypes (H1-H16) and 9 antigenically distinct NA subtypes (N1-N9), this virus has 
H3 and N8. Similarly, the lack of a designated species in A/Singapore/1/57 (H2N2) 
indicates that this virus was isolated from a human in Singapore in 1957 (Wright & 
Webster, 2001). 
Fig. 1.1. Cartoon from the London Evening Standard (1934). Researchers from the Na-
tional Institute for Medical Research (NIMR) are depicted on horseback “hunting down” the 
newly isolated human inﬂuenza A virus. The pack-dogs are represented by ferrets, which 
were used as the animal model for research. Courtesy of Prof. Willie Russell, University of 
St. Andrews, U.K.
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1.1.3 Virion structure. 
Influenza A viruses are classified as members of the Orthomyxoviridae family, which 
also includes the influenza B virus, influenza C virus, and thogotovirus genera (Klenk 
et al., 2004, Lamb & Krug, 2001). The Orthomyxoviridae are enveloped viruses 
containing a segmented, single-stranded, negative-sense RNA genome (i.e. the genome 
is complementary to mRNA, which by convention is termed positive-sense) (Klenk et 
al., 2004). Influenza A viruses can be distinguished from influenza B and C viruses by 
antigenic differences, morphological features, protein-encoding mechanisms, number 
of RNA segments, and sequence variability in their surface glycoproteins [reviewed in 
(Lamb & Krug, 2001)]. Additionally, influenza A viruses naturally infect a variety of 
animal species, including birds, humans, pigs, horses, seals, cats, and dogs (IDSA, 
2007, Wright & Webster, 2001), whilst influenza B and C viruses have so far been 
isolated predominantly (but not exclusively) from humans [reviewed in (Wright & 
Webster, 2001)]. 
 
Influenza A virus particles (virions) have a typical diameter of 80-160 nm, and are 
pleomorphic in shape, a characteristic dependent upon the viral strain, as well as the 
cell-type used for propagation (Lamb & Krug, 2001). Virions consist of a lipid 
envelope (derived from the host plasma membrane) out of which protrude two surface 
glycoproteins: haemagglutinin (HA) and neuraminidase (NA). Embedded within the 
lipid envelope bi-layer is the viral integral membrane protein, M2, whilst the viral 
matrix protein (M1) lies underneath the envelope and structurally supports the particle. 
Contained within this matrix shell is the segmented viral RNA genome, which (for 
influenza A virus) consists of eight strands. Each strand is wrapped-up in multiple 
copies of the nucleocapsid protein (NP), and is associated with three proteins 
responsible for transcription and replication: PB1, PB2, and PA (the viral polymerase 
1. Introduction 
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complex). Each NP-encapsidated RNA segment, together with its heterotrimeric 
polymerase, constitutes a viral ribonucleoprotein complex (RNP) (Fig. 1.4A). A 
schematic representation of the influenza A virus particle, together with its RNA 
segments and encoded proteins, is shown in Fig. 1.2. 
 
Although the influenza A virus genome consists of only 8 single-stranded, negative-
sense RNA segments, up to 11 viral proteins are produced during infection [reviewed 
in (Garcia-Sastre, 2005, Lamb & Krug, 2001)]: segment 1, PB2; segment 2, PB1 and 
PB1-F2; segment 3, PA; segment 4, HA; segment 5, NP; segment 6, NA; segment 7, 
M1 and M2; segment 8, NS1 and NEP). The varied roles of these proteins are briefly 
outlined below in the context of the virus replication cycle (summarised in Fig. 1.3). 
Interestingly, a putative additional ORF in the positive-sense of segment 8 has recently 
been identified (Zhirnov et al., 2007). This ORF could encode a hypothetical negative-
sense protein (NSP) of ~25 kDa, and might share some homology with a mitochondrial 
transmembrane proton channel (Zhirnov et al., 2007). However, the actual expression 
of NSP in influenza A virus-infected cells has yet to be demonstrated. 
 
1.1.4 Replication cycle – virus entry. 
Virus particles bind to the apical surfaces of polarized epithelial cells via an interaction 
between the viral HA spike glycoprotein and sialic acid residues linked to the cell 
membrane [reviewed in (Skehel & Wiley, 2000, Whittaker & Digard, 2006)]. 
Receptor-mediated endocytosis causes internalisation of the whole virus particle into 
intracellular pre-lysosomal, low pH vesicles [reviewed in (Whittaker & Digard, 2006)]. 
Such internalisation at the cell periphery requires the host GTPase dynamin (Roy et al., 
2000), and involves actin rearrangements (Lakadamyali et al., 2003). The virus particle 
is then rapidly trafficked through both early- and late- endosomes (of increasingly 
Fig. 1.2. Schematic representation of the inﬂuenza A virus particle. The 8 single-stranded 
negative-sense RNA segments are encapsidated by nucleoprotein (NP) and are each associ-
ated with a single polymerase complex (consisting PB1, PB2, and PA). These ribonucleopro-
teins (RNPs) interact with the M1 protein (which forms a matrix underneath the host-derived 
lipid bi-layer), and probably the NEP (NS2) protein. The haemagglutinin (HA) and neurami-
nidase (NA) glycoproteins, together with the M2 ion channel, span the membrane and likely 
form structural contacts with M1. NS1 and PB1-F2 are only found in infected cells, therefore 
they are not represented on the diagram. The proteins encoded by each genomic segment are 
indicated. Diagram modiﬁed from Lamb & Krug, 2001.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
Fig. 1.3. Schematic representation of the inﬂuenza A virus replication cycle. See text for 
details. Diagram reproduced from Lamb & Krug, 2001.   
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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acidic pH, regulated by endosomal proton pumps) in a dynein-dependent manner to the 
perinuclear region (Lakadamyali et al., 2003, Lamb & Krug, 2001, Whittaker & 
Digard, 2006). A number of cellular kinases have also been implicated in this process, 
including protein kinase C (Sieczkarski et al., 2003), and phosphoinositide 3-kinase 
(Ehrhardt et al., 2006). 
 
In order to release the viral genomic segments into the host-cell cytoplasm, the viral 
membrane and that of the late-endosome must first fuse. Fusion is mediated by a low-
pH-induced conformational change in the viral HA protein, which usually requires an 
optimum pH of ~5.0-5.5, but can be temperature dependent [reviewed in (Skehel & 
Wiley, 2000)]. Mature endosomal compartments have an acidic pH of between 4.5 and 
5.5, therefore localisation of influenza A virus particles into these specific vesicles is 
the physiological trigger for membrane fusion, and acts to direct virion release to the 
perinuclear region [reviewed in (Lamb & Krug, 2001, Whittaker & Digard, 2006)]. 
This sorting event alone is insufficient to deliver the individual viral genomic segments 
into the cytoplasm. However, the low-pH-activated ion channel activity of the viral M2 
protein permits the flow of protons from the lumen of the endosomal compartment into 
the virion (Pinto et al., 1992), thus acidifying the virion interior and consequently 
disrupting protein:protein interactions between the viral RNPs and M1, as well as HA 
and M1 (Bui et al., 1996, Lamb & Pinto, 2006). Dissociation of these interactions 
allows full egress of viral RNPs from the disassembled virion into the cytoplasm 
subsequent to membrane fusion [reviewed in (Lamb & Pinto, 2006)]. Regulation of 
virus uncoating/RNP release by ensuring prior translocation to low-pH endosomes near 
the perinuclear region efficiently targets RNPs to the site of transcription and 
replication (i.e. the cell nucleus, see below). This mechanism also potentially 
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minimises the contact time of “naked” RNPs with the cytoplasm, which may be 
beneficial to the virus for evading some host-cell viral sensors. 
 
1.1.5 Replication cycle – RNP nuclear import. 
Unlike most RNA viruses, transcription and replication of the influenza A virus 
genome occurs in the nucleus of the infected cell (Herz et al., 1981, Jackson et al., 
1982). It is not entirely clear why this should occur, although specific transcriptional 
requirements of the virus have been postulated to be determinants: initiation of viral 
mRNA synthesis requires the capped 5' ends of host mRNAs to act as primers (Plotch 
et al., 1981), and two viral mRNAs require splicing [reviewed in (Lamb & Krug, 
2001)]. Thus, it has been suggested that localising within the nucleus may allow close 
contact between viral replication centres and high concentrations of essential host 
factors, such as cellular mRNAs (their export is blocked by the viral NS1 protein, see 
below), and the cellular splicing machinery (Boulo et al., 2007, Lamb & Krug, 2001). 
However, viruses within the Bunyaviridae and Arenaviridae families (which possess 
segmented, negative-sense, RNA genomes) also require host-derived 5' cap structures 
to initiate mRNA transcription, yet these viruses replicate in the cytoplasm [reviewed 
in (Buchmeier et al., 2001, Schmaljohn & Hooper, 2001)]. Thus, as mRNA splicing is 
a common protein-encoding mechanism among all members of the Orthomyxoviridae 
family, it seems likely that the nuclear localisation of their replication is due to the 
requirement for splicing. In this regard, it is interesting to note that viruses of the 
Bunyaviridae and the Arenaviridae do not produce spliced mRNAs (and undergo 
cytoplasmic replication), whilst Borna disease virus (BDV; Bornaviridae), which 
possesses a non-segmented, negative-sense RNA genome, does produce spliced 
mRNAs and replicates in the cell nucleus (Carlos de la Torre, 2001).  
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After uncoating, all viral RNPs are actively transported into the nucleus [reviewed in 
(Whittaker & Digard, 2006)]. NP and the three polymerase subunits all contain nuclear 
localisation signals (NLSs) (Davey et al., 1985, Mukaigawa & Nayak, 1991, Nath & 
Nayak, 1990, Nieto et al., 1992). NP has multiple NLSs, and is both necessary and 
sufficient for mediating the nuclear import of each viral RNP segment, probably via its 
interaction with the cellular importin-α/β family (O'Neill et al., 1995, O'Neill & 
Palese, 1995, Whittaker & Digard, 2006). Within the nucleus, RNPs strongly associate 
with insoluble “nuclear matrix” or chromatin components (Bui et al., 2000, Whittaker 
& Digard, 2006). 
 
1.1.6 Replication cycle – viral mRNA synthesis. 
Influenza A virus RNA synthesis requires four proteins, which together with viral 
RNA, make up the functional RNP: NP, PA, PB1, and PB2 (Huang et al., 1990, 
Portela & Digard, 2002) (Fig. 1.4A). Genomic viral RNA (vRNA) has conserved 
sequences at the 5' and 3' termini that share some sequence complementarity 
(Desselberger et al., 1980, Robertson, 1979, Skehel & Hay, 1978), and thus cause 
base-pairing leading to the proposed formation of RNA structures, such as panhandles 
(Hsu et al., 1987), forks (Fodor et al., 1995), or corkscrews (Flick et al., 1996). Each 
vRNA is encapsidated by NP, and is associated with a single heterotrimeric 
polymerase complex [reviewed in (Elton et al., 2006)]. The incoming RNP (i.e. from 
the virion) is all that is required to transcribe mRNA, as long as an appropriate 5' host-
derived capped RNA (to act as a primer, see below) is available (Bouloy et al., 1978, 
Krug et al., 1979, Plotch & Krug, 1977). 
 
During mRNA synthesis (Fig. 1.4B), the polymerase (via PB1) binds to the 5' end of 
the vRNA segment and thereby stimulates the cap-binding activity of PB2, which 
Fig. 1.4. Structure and function of the inﬂuenza A virus RNP. (A) Cartoon model of a 
single RNP. The single-stranded vRNA (black line) is coiled into a panhandle due to comple-
mentary base-pairing between the 5` and 3` ends, and is encapsidated by nucleoprotein (NP; 
blue spheres). The heterotrimeric polymerase complex (PB1, PB2, and PA) binds to the RNP 
at the site of RNA duplexing. (B) Model of mRNA synthesis. Interaction of the polymerase 
complex with the 5` end of vRNA stimulates binding to host-cell mRNAs. Endonuclease 
activity is stimulated by binding of the 3` end of vRNA to the polymerase, such that a short, 
capped, host-derived RNA primer (blue line) is generated, which acts to initiate transcrip-
tion and viral mRNA synthesis (green line). Termination of transcription (and addition of the 
poly(A) tail) occurs via a steric block to polymerase progression and a “stuttering” mecha-
nism. (C) Possible mechanisms of cRNA synthesis (primer-independent transcription). 
(i) Initiation is promoted by NP “modifying the polymerase” by a protein:protein interaction. 
(ii) Initiation is promoted by NP disrupting the panhandle structure. For cRNA (and subse-
quent vRNA) synthesis, soluble NP is required in order to encapsidate newly transcribed 
RNA. The polymerase must “read-through” the poly(A) signal so as to produce a full-length 
genome copy. Diagrams modiﬁed from Portela & Digard, 2002. 
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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allows the polymerase to bind host-cell mRNAs produced as RNA polymerase II 
transcripts (Elton et al., 2006, Fodor et al., 1994, Lamb & Krug, 2001, Li et al., 
1998b). Subsequent interaction of the 3' end of the vRNA template with the viral 
polymerase triggers cleavage of the host-cell mRNA by PB1, thus retaining the 5'-
methylated host cap structure together with 9-15 cellular mRNA nucleotides (Cianci et 
al., 1995, Hagen et al., 1994, Li et al., 2001, Plotch et al., 1981). Interestingly, viral 
capped mRNAs are protected from cleavage when they interact with the viral 
polymerase (Shih & Krug, 1996b). The cleaved host cap structure acts as a primer for 
viral transcription initiation by PB1 (Elton et al., 2006, Lamb & Krug, 2001, Shaw & 
Lamb, 1984), which is enhanced by the physical interaction of PB2 with the cap 
structure (Penn & Mahy, 1984). Addition of ribonucleotides (elongation) occurs 
according to the viral template (vRNA), and at some point PB2 dissociates from the 
cap (Elton et al., 2006, Portela & Digard, 2002). 
 
Synthesis of viral mRNA terminates at a stretch of uridine (U) residues ~15-22 
nucleotides from the 5' end of the vRNA, where steric hindrance of the viral 
polymerase probably causes it to reiteratively copy the poly(U) tract (“stutter”) 
resulting in the generation of a poly(A) tail (Elton et al., 2006, Fodor et al., 1994, 
Lamb & Krug, 2001, Portela & Digard, 2002) (Fig. 1.4B). It is unclear what role, if 
any, is played by the PA polymerase subunit in viral mRNA synthesis, although it may 
contribute to the nuclear localisation of PB1, as well as efficient endonuclease activity 
and/or elongation (Fodor et al., 2002, Fodor et al., 2003, Fodor & Smith, 2004). 
 
Although pre-mRNAs of most eukaryotic cells are fully spliced (i.e. introns removed) 
in order to generate functionally mature mRNAs, only two influenza A virus mRNAs 
require splicing: NS1 and M1 (Inglis et al., 1979, Inglis & Brown, 1981, Lamb & 
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Krug, 2001). Additionally, unlike complete cellular mRNA splicing, the splicing of 
viral NS1 and M1 mRNAs (to produce NEP and M2 mRNAs, respectively) appears to 
be regulated such that spliced mRNA is only ~10% that of unspliced mRNA (Lamb et 
al., 1980, Lamb & Lai, 1981). M1 mRNA splicing is controlled by both the viral 
polymerase and cellular splicing factors, such as the serine/arginine-rich splicing factor 
SF2/ASF (Shih & Krug, 1996a, Shih et al., 1995). Splicing of NS1 mRNA to produce 
NEP mRNA can be regulated by the NS1 protein itself (Garaigorta & Ortin, 2007). It 
is not exactly clear how viral mRNAs (both spliced and un-spliced) can specifically 
leave the nucleus to be translated into protein, particularly as NS1 has been reported to 
block the nucleo-cytoplasmic transport of cellular mRNAs (Fortes et al., 1994, Qiu & 
Krug, 1994, Satterly et al., 2007). 
 
1.1.7 Replication cycle – genome replication. 
The replication of genomic virion RNA (vRNA) occurs in two stages: the initial 
synthesis of “template” RNA that is complementary to full-length vRNA (i.e. a 
positive-sense strand: cRNA), and the subsequent copying of cRNA into new vRNAs 
[reviewed in (Elton et al., 2006, Lamb & Krug, 2001, Portela & Digard, 2002)] (Fig. 
1.4C). Although viral mRNAs and cRNAs are both positive-sense, mRNA cannot act 
as a replicative intermediate in the formation of new vRNAs as it has a 5' host-derived 
cap and is truncated relative to the full-length genomic segments. Thus, the viral 
polymerase initiates cRNA synthesis in a cap-independent manner, and must “read-
through” the polyadenylation signal at the 5' end of vRNA (Elton et al., 2006). 
Additionally, cRNA (but not mRNA) is encapsidated by NP. Unlike mRNA 
transcription, the incoming viral RNP alone is insufficient to stimulate cRNA synthesis 
(Plotch & Krug, 1977, Skorko et al., 1991), and evidence suggests that an initial round 
of mRNA and protein synthesis is necessary prior to initiation of cRNA synthesis 
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(Beaton & Krug, 1984, del Rio et al., 1985, Hay et al., 1977, Nagata et al., 1989, 
Shapiro & Krug, 1988, Takeuchi et al., 1987). 
 
It is not clear what viral components constitute the replication polymerase complex. 
Soluble viral NP appears to be a major factor regulating replication, and its 
involvement would correlate with the requirement for de novo protein synthesis. 
Soluble NP may simply act in a concentration-dependent manner (i.e. stabilising 
cRNA transcripts when high enough levels of NP protein are available) (Beaton & 
Krug, 1984, Shapiro & Krug, 1988), by modifying the transcription template (Fodor et 
al., 1994, Hsu et al., 1987), or by directly modifying polymerase function (i.e. 
“switching” protein:protein interactions between NP and PB1/PB2 in order to favour a 
replication polymerase over a transcription polymerase) (Elton et al., 2006, Medcalf et 
al., 1999, Poole et al., 2004). Additionally, all three polymerase subunits (PA, PB1, 
PB2) are required for efficient cRNA synthesis (Nakagawa et al., 1996, Perales & 
Ortin, 1997, Perales et al., 2000), and it is possible (although uncertain) that PA acts in 
a proteolytic manner to clip components of the transcription polymerase, and thus 
convert it into a replication polymerase (Naffakh et al., 2001, Perales et al., 2000). 
Possible roles of numerous host-cell proteins (including hCLE, HSP90 and 
UAP56/BAT1; a DEAD-box ATP-dependent RNA helicase) in viral RNA synthesis 
have not been fully clarified (Huarte et al., 2001, Mayer et al., 2007, Momose et al., 
2001, Momose et al., 2002). 
 
Both PA and soluble NP are important for the synthesis of vRNA from cRNA (Elton et 
al., 2006, Shapiro & Krug, 1988). NP is probably required for encapsidation of the 
nascent RNA (Shapiro & Krug, 1988). NS1 protein has also been suggested to be an 
additional cofactor that directly interacts with the viral replication polymerase complex 
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and affects accumulation of vRNA, but not cRNA (Falcon et al., 2004, Marion et al., 
1997b). Intriguingly, vRNA only appears to be synthesised at sites of insoluble 
“nuclear matrix” within the nucleus, whilst both mRNA and cRNA synthesis is 
detectable in both soluble and insoluble nuclear fractions (Lopez-Turiso et al., 1990). 
 
1.1.8 Replication cycle –virion assembly and budding. 
Nuclear export of newly synthesised negative-sense vRNPs to the cytoplasm is an 
active and regulated process [reviewed in (Whittaker & Digard, 2006)]. Early in 
infection these RNPs act as templates for mRNA transcription, therefore their 
premature exit from the nucleus is likely to be detrimental. NEP (nuclear export 
protein (O'Neill et al., 1998); formerly designated non-structural protein 2 (NS2) 
(Lamb et al., 1978)) is a ~14 kDa protein found in both virions and virus-infected cells, 
and is essential for vRNP nuclear export (Boulo et al., 2007, Neumann et al., 2000, 
Richardson & Akkina, 1991, Yasuda et al., 1993). 
 
NEP binds directly to the viral M1 protein (Ward et al., 1995, Yasuda et al., 1993), 
and can also form complexes with members of the cellular nucleoporin family (i.e. 
Rab/hRIP1, yRIP1, yNup100 and yNup116 (O'Neill et al., 1998)), as well as hCRM1 
and Ran-GTP (Akarsu et al., 2003, Neumann et al., 2000, Paragas et al., 2001). At late 
times in the infection cycle, a nuclear fraction of M1 binds and inhibits the 
transcriptional activity of vRNPs (Perez & Donis, 1998, Zvonarjev & Ghendon, 1980). 
The interaction between M1 and NEP then links vRNPs to the cellular nucleo-
cytoplasmic transport machinery, which contributes to the nuclear export of vRNPs 
prior to virion formation at the plasma membrane (Akarsu et al., 2003, Neumann et al., 
2000, O'Neill et al., 1998). However, NP [which can also bind hCRM1 (Akarsu et al., 
2003, Elton et al., 2001)] appears to have a direct (and possibly NEP-independent) role 
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in regulating vRNP nuclear export (Bui et al., 2000, Elton et al., 2001), suggesting that 
additional (and possibly overlapping) vRNP nuclear export mechanisms exist. 
Furthermore, mitogen-activated protein kinase and caspase cascades may play some 
role in mediating the exit signal (Pleschka et al., 2001, Wurzer et al., 2003). Once in 
the cytoplasm, newly synthesised RNPs are directed to the cell surface, either via 
interaction with the M1 protein (which associates with membranes), or directly via 
cytoskeletal elements (Digard et al., 1999, Simpson-Holley et al., 2002, Whittaker & 
Digard, 2006). 
 
In infected epithelial cells, virion assembly is polarised and only occurs at the apical 
side of the cell (Boulan & Sabatini, 1978). Such polarity is directed by the independent 
targeting of the viral HA, NA, and M2 proteins to the apical plasma membrane 
(Hughey et al., 1992, Kundu et al., 1996, Roth et al., 1983, Whittaker & Digard, 
2006). NA, M2, and the precursor HA (HA0) are synthesised on membrane-bound 
ribosomes and translocated across the membrane into the lumen of the endoplasmic 
reticulum (ER). In the ER, these proteins are all individually and correctly folded 
(Lamb & Krug, 2001), and (in some cell-types) HA0 molecules with a "multi-basic" 
cleavage site are cleaved by the intra-cellular protease furin to produce the disulphide-
linked, fusion-ready, HA1 and HA2 (Stieneke-Grober et al., 1992). In this case, activity 
of the viral M2 ion channel is required in the ER/trans-Golgi network to regulate the 
intra-compartmental pH, thus preventing the conformational change in HA that is 
associated with fusion (Grambas & Hay, 1992, Sakaguchi et al., 1996, Takeuchi & 
Lamb, 1994, Takeuchi et al., 1994). However, for HA0 molecules with only a single 
arginine residue at this cleavage site (most influenza A virus strains), HA0 cleavage 
can only occur in response to extra-cellular proteases, thus ensuring that full 
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maturation of the virion (and infectivity) is achieved subsequent to viral exit from the 
cell [reviewed in (Lamb & Krug, 2001)].  
 
Evidence indicates that the HA and NA glycoproteins are specifically sorted to 
sphingolipid- and cholesterol- enriched lipid raft domains within the apical plasma 
membrane (Nayak & Barman, 2002, Scheiffele et al., 1997). Such domains are 
dynamic platforms where signal transduction events can be initiated, and from where a 
number of enveloped viruses bud [reviewed in (Suomalainen, 2002)]. Indeed, 
accumulation of viral HA within these surfaces appears to trigger a protein kinase Cα 
(PKCα)-dependent Raf/MEK/ERK signalling cascade that initiates nuclear export of 
vRNPs ready for virus assembly (Marjuki et al., 2006). Budding from these rafts also 
means that influenza A virus particles contain high concentrations of HA and NA 
surface glycoproteins, and subsequently have increased infectivity (Scheiffele et al., 
1999, Takeda et al., 2003, Zhang et al., 2000b). 
 
The mechanics of influenza A virus budding from the infected cell likely requires host-
cell “pinching machinery”, as well as interactions between the cytoplasmic tails of the 
viral integral membrane proteins (HA, NA, and M2) and the internal proteins/vRNPs 
(Chen et al., 2007, Iwatsuki-Horimoto et al., 2006, Jin et al., 1997, Lamb & Krug, 
2001, McCown & Pekosz, 2005, Zhang et al., 2000a, Zhang et al., 2000b). M1 can 
associate with the sites of budding (lipid rafts) via the cytoplasmic tails of HA and/or 
NA (Barman et al., 2001, Zhang et al., 2000b), and this could aid in the localisation of 
vRNPs into the assembly sites [reviewed in (Lamb & Krug, 2001)]. The vRNP 
segments are selectively (rather than randomly) incorporated into each budding virus 
particle, as efficient infectious virion formation appears to require all 8 segments 
(Duhaut & McCauley, 1996, Fujii et al., 2003, Muramoto et al., 2006, Noda et al., 
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2006, Odagiri & Tashiro, 1997). The mechanism of vRNP selection is unclear, but 
may be hierarchical and involve unique segment-specific packaging 
sequences/structures, similar to those already determined in the coding and non-coding 
regions of the HA, NA, PB1, PB2, PA, and NS segments (Fujii et al., 2003, Fujii et al., 
2005, Gog et al., 2007, Marsh et al., 2007, Muramoto et al., 2006). The functional role 
of neuraminidase (NA) activity during viral budding is to catalyse the removal of sialic 
acid from the surface of infected cells (and from HA and NA molecules), thus allowing 
efficient virus egress, and preventing self-aggregation of progeny virions (Lamb & 
Krug, 2001, Palese et al., 1974). Additionally, NA activity may permit transport of 
virions through the mucin layer of the respiratory tract (Lamb & Krug, 2001). 
 
1.1.9 “Accessory” proteins of influenza A virus. 
During infection, two viral proteins are expressed that are not packaged into budding 
virions: NS1 and PB1-F2. NS1 is described in detail in the following section (1.2). 
PB1-F2 is a 87 amino-acid protein encoded by an alternate (+1) reading frame within 
the PB1 gene (segment 2) (Chen et al., 2001). It is likely that both PB1 and PB1-F2 are 
translated from the same bicistronic mRNA by ribosomal scanning (Chen et al., 2001). 
PB1-F2 is maximally expressed at ~5h post-infection, and localizes to mitochondrial 
membranes (Chen et al., 2001, Gibbs et al., 2003, Yamada et al., 2004). 
 
PB1-F2 expression alone can induce the formation of non-specific pores within 
membranes (Chanturiya et al., 2004), and PB1-F2 interacts with the mitochondrial 
apoptotic mediators ANT3 and VDAC1 (Zamarin et al., 2005), thus sensitising some 
cell-types (mainly monocyte-derived) to apoptotic cell-death (Chanturiya et al., 2004, 
Chen et al., 2001, Gibbs et al., 2003, Lamb & Takeda, 2001, Zamarin et al., 2005). 
However, the PB1-F2 ORF is not conserved in all influenza A virus genomes (Lamb & 
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Takeda, 2001, Obenauer et al., 2006, Zell et al., 2007), and can be “knocked-out” 
without seriously attenuating virus replication (or virus-induced cell-death) in a 
number of tissue-culture cell-lines (e.g. MDCK, MBCK, A549, HeLa) (Chen et al., 
2001, Zamarin et al., 2006), and in an in vivo mouse model (Zamarin et al., 2006). 
Despite this, given the pro-apoptotic effect of PB1-F2 is most pronounced in 
“immune” monocyte/macrophage cells (Chen et al., 2001), and data from reassortment 
viruses indicate that PB1-F2 might contribute towards viral pathogenesis (Zamarin et 
al., 2006), it has been suggested that PB1-F2 acts to limit efficient immune-cell 
mediated virus clearance in vivo (Zamarin et al., 2006). 
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1.2 The non-structural (NS1) protein. 
 
NS1 protein is widely regarded as a multifunctional virulence factor, and is expressed 
at high levels in virus-infected cells [reviewed in (Garcia-Sastre, 2005, Kochs et al., 
2007b, Li et al., 2006b, Noah & Krug, 2005)]. It is not a structural component of the 
virion (Krug & Etkind, 1973, Lazarowitz et al., 1971). During infection, NS1 
performs a plethora of activities that each contribute to efficient virus replication: 
temporal regulation of viral RNA synthesis (Min et al., 2007), enhancement of viral 
mRNA translation (Burgui et al., 2003), regulation of virus particle morphogenesis 
(Garaigorta et al., 2005), and suppression of the host immune/apoptotic responses 
(Garcia-Sastre, 2005, Lowy, 2003, Nemeroff et al., 1998, Satterly et al., 2007). The 
protein:protein and protein:RNA interactions that mediate these functions are detailed 
below. 
 
1.2.1 Synthesis of the NS1 protein. 
The smallest genomic segment of influenza A virus (segment 8) is transcribed into 
two separate mRNAs, which encode the non-structural (NS1) and nuclear export 
(NEP) viral polypeptides (Inglis et al., 1979, Lamb & Choppin, 1979, Lamb & Krug, 
2001). A co-linear mRNA transcript directly codes for NS1, whilst NEP is translated 
from spliced mRNA (Lamb & Lai, 1980). Both mRNA species share a 56-nucleotide 
viral leader sequence, which contains the AUG initiation codon and encodes 9 N-
terminal amino acid residues common to NS1 and NEP (Lamb & Lai, 1980). 
Removal of the 473-nucleotide intron in order to form NEP mRNA means that after 
the 9 shared residues, translation of NEP continues in the +1 ORF relative to NS1 
(Lamb & Lai, 1980). Thus, after the splicing site, the NS1 and NEP ORFs overlap by 
the equivalent of ~70 residues (Lamb & Lai, 1980). In infected cells, the steady-state 
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amount of spliced NEP mRNA is only ~10% that of unspliced NS1 mRNA (Lamb et 
al., 1980). Regulation of this splicing is thought to be controlled, in part, by the viral 
NS1 protein itself (Garaigorta & Ortin, 2007). 
 
1.2.2 Biochemistry of NS1 protein. 
NS1 is a ~26 kDa protein, and has a strain specific length of 230-237 amino acids 
(Lamb & Krug, 2001). A proportion of the NS1 protein population appears to be 
phosphorylated within infected cells (Petri & Dimmock, 1981, Petri et al., 1982, 
Privalsky & Penhoet, 1978, Privalsky & Penhoet, 1981). Comparison of NS1 proteins 
derived from a range of human and animal influenza A viruses has revealed 
considerable differences in charge and phosphorylation between strains (Petri et al., 
1982). NS1 proteins derived from “avian” influenza A viruses are predominantly 
acidic, whereas “human” NS1 proteins are generally basic (Petri et al., 1982). This is 
due primarily to sequence differences, but is intriguing given the high degree of 
reported charge homogeneity among other viral proteins (PA, PB1, PB2, NP, M1, 
HA, NA) (Petri et al., 1982). 
 
Phosphorylation of NS1 is also highly virus-specific, and some NS1 proteins (almost 
exclusively the acidic “avian” ones) were not found to be phosphorylated in tissue 
culture studies (Petri et al., 1982). For NS1 proteins that can be phosphorylated, there 
are at least two distinct sites of modification (Privalsky & Penhoet, 1981), and these 
have recently been speculated to be serine-195 and threonine-197 (Bornholdt & 
Prasad, 2006). Mono- or di- phosphorylation of NS1 sub-populations occurs rapidly 
after translation, and appears to occur in the cell nucleus (Privalsky & Penhoet, 1981). 
This is compatible with evidence that indicates NS1 can be phosphorylated in vitro by 
a kinase activity associated with purified virion RNPs, which would normally be 
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located within the nucleus of infected cells (Skorko et al., 1991). It is still largely 
unknown if any physiological role for NS1 phosphorylation exists. 
 
NS1 contains two distinct structural/functional domains: an N-terminal RNA-binding 
domain (residues 1-73), which binds with low affinity to double-stranded RNA 
(dsRNA) in a sequence independent manner (Chien et al., 2004, Qian et al., 1995); 
and a C-terminal “effector” domain (residues 74-237), which mediates interactions 
with a number of host-cell proteins (Krug et al., 2003, Qian et al., 1994) (see below). 
In vitro and in vivo studies show that NS1 exists as a homodimer, and both the RNA-
binding domain and effector domain contribute to functional multimerisation 
(Nemeroff et al., 1995, Wang et al., 2002). Evidence to support this also comes from 
individual x-ray crystallographic and nuclear magnetic resonance structures of both 
NS1 domains (Bornholdt & Prasad, 2006b, Chien et al., 1997, Liu et al., 1997). 
 
The RNA-binding domain alone is a symmetrical homodimer, and each monomer 
consists of three α-helices (Chien et al., 1997, Liu et al., 1997) (Fig. 1.5). 
Dimerisation is essential for binding dsRNA (Wang et al., 1999), and the 
stoichiometry of dimer:dsRNA is 1:1 (Chien et al., 2004). Further studies have also 
shown that the structure and position of all six α-helices in the dimer do not alter 
upon dsRNA binding (Chien et al., 2004, Yin et al., 2007). Two identical helices 
from each NS1 monomer contribute significantly to dsRNA binding (termed α1/α1' 
and α2/α2') (Yin et al., 2007) (Fig. 1.5). The α2/α2' helices form antiparallel “tracks” 
on either side of a deep cleft that is bounded at its base by the α1/α1' helices (Liu et 
al., 1997, Yin et al., 2007). The “tracks” are made up of highly conserved basic and 
hydrophilic residues that likely form complementary contacts with the polyphosphate 
backbone of dsRNA (Yin et al., 2007). Residues in NS1 that mediate this interaction 
Fig. 1.5. Structure of the inﬂuenza A virus NS1 protein (RNA-binding domain). The 
N-terminal 73 amino-acids of NS1 form the functional RNA-binding domain. Cartoon (A), 
and surface (B-E) representations of the RNA-binding domain homodimer. The two mono-
mers are coloured green and blue. The 3 helices of each monomer are labelled a1, a2, and 
a3 (or a1`, a2`, and a3`). Views are arbitrarily designated front (A & B), side (C), bottom 
(D), and top (E). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 1NS1). 
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(either directly, or via improving complex stability), include: threonine-5, proline-31, 
aspartic acid-34, arginine-35, arginine-38, lysine-41, glycine-45, arginine-46, and 
threonine-49 (Wang et al., 1999, Yin et al., 2007) (Fig. 1.6). 
 
The C-terminal effector domain of NS1 is also a homodimer, and each monomer 
consists of seven β-strands and three α-helices (Bornholdt & Prasad, 2006b) (Fig. 
1.7). The structure/function relationship of this domain with cellular proteins is 
discussed further in the following sections (see also Fig. 1.8). 
 
1.2.3 Sub-cellular localisation of NS1 protein. 
The sub-cellular localisation of NS1 protein appears to be dependent on several 
factors, including: virus strain, expression level of NS1, cell-type used, state of cell-
polarity, and time post-infection (Newby et al., 2007). Experimental detection of NS1 
within cells is also determined by the fixation procedure used, as some fixatives (such 
as acetone) have been suggested to preferentially extract small proteins like NS1 from 
the cytoplasm (Li et al., 1998c). Nevertheless, in infected tissue-culture cells, most 
NS1 protein localises predominantly to the nucleus, but a significant proportion can 
also be found in the cytoplasm (Greenspan et al., 1988, Krug et al., 2003, Newby et 
al., 2007). Indeed, early work identified the NS1 protein in crystalline cytoplasmic 
inclusions that could be isolated from cells late in infection (Morrongiello & Dales, 
1977, Shaw & Compans, 1978). 
 
NS1 proteins contain one or two nuclear localisation sequences (NLSs; NLS1 and 
NLS2) (Greenspan et al., 1988), which mediate their active nuclear import via 
binding to cellular importin-α molecules (Melen et al., 2007). As such, translocation 
of NS1 from cytoplasmic ribosomes to the nucleus is thought to be extremely rapid 
(Privalsky & Penhoet, 1981). NLS1 in NS1 is monopartite, and involves arginine-35, 
Fig. 1.6. Residues of the NS1 protein important for RNA-binding. Cartoon/stick 
(A & B), and surface (C & D) representations of the RNA-binding domain homodimer. 
The two monomers are coloured green and blue. All residues implicated in RNA-bind-
ing are coloured red. The two most important residues (arginine-38 (R-38) and lysine-41 
(K-41)) are labelled (A & B).  Views are arbitrarily designated front (A & C), and bot-
tom (B & D). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 1NS1). 
(E) Model of the NS1 RNA-binding domain homodimer (bottom view) in complex with 
16-bp dsRNA (green). Both monomers are coloured silver, and the basic residues of NS1 
involved in contacting dsRNA are coloured blue. Image modiﬁed from Yin et al., 2007.  
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Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
Fig. 1.7. Structure of the inﬂuenza A virus NS1 protein (C-terminal effector domain). 
Cartoon (A), and surface (B-E) representations of the C-terminal effector domain homodimer. 
The two monomers are coloured green and blue. The N-terminal and C-terminal ends of one 
monomer are labelled (A). Views are arbitrarily designated front (A & B), side (C), bottom 
(D), and top (E). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 2GX9). 
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Fig. 1.8. Schematic representation of the inﬂuenza A virus NS1 protein, together with its 
known interactors. The inﬂuenza A virus NS1 protein is 230-237 amino-acids long depend-
ing upon the strain. The N-terminal 73 amino-acids form a functional RNA-binding domain 
(RBD), whilst the C-terminal effector domain mediates interactions with host-cell proteins. 
NS1 contains two nuclear localisation sequences (black circles), and a nuclear export se-
quence (white circle). Residues involved in RNA-binding (arginine-38 [R38] and lysine-41 
[K41]) are also implicated in the inhibition of cellular 2`-5`-oligo (A) synthetase/RNase L, 
the inhibition of Jun N-terminal kinase, and the interaction with/inhibition of RIG-I. Ad-
ditionally, NS1 contains binding sites for: poly (A)-binding protein I (PABI), nucleolin, 
eIF4GI, hStaufen, protein kinase R (PKR), 30 kDa subunit of cleavage and polyadenylation 
speciﬁcity factor (CPSF30), poly (A)-binding protein II (PABII), PDZ domain-containing 
proteins, and the viral polymerase. For diagrammatic clarity, the following interactors have 
not been included: NS1-BP, NS1-I, and components of the mRNA nuclear export machinery. 
See text for references.
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arginine-38, and lysine-41, residues also involved in dsRNA-binding (Melen et al., 
2007) (Fig. 1.6). This NLS is well-conserved among all known influenza A virus NS1 
proteins (Melen et al., 2007). In contrast, the bipartite NLS2 comprises specific 
amino-acids at the C-terminus of only some NS1 proteins (lysine-219, arginine-220, 
arginine-231, and arginine-232) (Melen et al., 2007). 
 
Concurrent with NLS2 is a functional nucleolar localisation signal (NoLS), which 
requires additional basic residues (usually arginine and lysine, respectively) at 
positions 224 and 229 (Melen et al., 2007). Thus, although the NS1 proteins of most 
strains appear predominantly nuclear during virus infection, only a subset that contain 
a functional NoLS localise into nucleoli (Melen et al., 2007). The nucleolar function 
of NS1 is unknown, however a mutant influenza A virus (A/Udorn/72 strain) 
expressing a truncated NS1 protein unable to localise into nucleoli was not attenuated 
for replication under tissue-culture conditions (Melen et al., 2007). Therefore, it has 
been suggested that any nucleolar function of NS1 may only be necessary for the in 
vivo pathogenesis of some viruses (Melen et al., 2007). As NLS2 is absent from the 
majority of pathogenic and non-pathogenic influenza A virus strains, it is difficult to 
ascribe a critical function to this sequence with regards viral replication/pathogenesis. 
 
In infected cells, the cytoplasmic localisation of a sub-population of NS1 is probably 
regulated by two mechanisms. Some newly synthesised NS1 may be sequestered by a 
cellular/viral binding partner, thus masking the NLSs and retaining NS1 in the 
cytoplasm. Alternatively, a latent nuclear export signal (NES) in NS1 may cause the 
nucleo-cytoplasmic transport of nuclear NS1 back into the cytoplasm (Li et al., 
1998c). The NS1 NES lies within residues 138-147, and requires leucines at positions 
144 and 146 (Li et al., 1998c) (Figs. 1.9A & 1.9B). In the full-length molecule, the 
Fig. 1.9. The nuclear export signal (NES) of NS1. Surface representations of the C-terminal 
effector domain homodimer (monomers coloured green and blue) (A-C). Residues compris-
ing the NES are highlighted in red (A & B). Residues comprising the NES “mask” are high-
lighted in black (C). Views are arbitrarily designated as for Fig. 1.7: angled front (A), top 
(B), and front (C). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 2GX9). 
A B
C
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NES is functionally “masked” by residues spatially adjacent to it: 148-161 
(particularly arginine-148, glutamic acid-152, and glutamic aid-153) (Li et al., 1998c) 
(Fig. 1.9C). Thus, for NS1 to be re-localised back into the cytoplasm of infected cells, 
it has been postulated that the NES must be “unmasked”, possibly by interaction of 
residues 148-161 in NS1 with another virus protein (Li et al., 1998c). This would 
potentially allow spatial control of NS1 to be regulated temporally by the relative 
expression levels of other viral proteins. However, host-cell factors also clearly play 
an important role in determining the sub-cellular localisation of NS1. For example, in 
infected murine tracheal epithelial cell cultures, the NS1 protein of A/WSN/33 
localises mainly to the cytoplasm, a striking contrast to the nuclear distribution of the 
same protein observed in MDCK cells (Newby et al., 2007). 
 
Thus, many regulatory signals are responsible for the varied distribution of NS1 
during infection (i.e. nuclear, nucleolar, or cytoplasmic). Such varied localisations 
presumably contribute to the reported ability of NS1 to perform a number of different 
functions, as detailed below. 
 
1.2.4 NS1 and viral RNA synthesis. 
Gene expression in influenza A virus-infected cells can be divided into “early” and 
“late” phases [reviewed in (Elton et al., 2006, Lamb & Krug, 2001)]. Immediately 
after nuclear import, all the viral segments appear to be equally transcribed into 
mRNA (Barrett et al., 1979, Hay et al., 1977). However, the NS and NP vRNA 
segments become preferentially synthesised, and there is a consequent increase in 
NS1 and NP mRNA transcription leading to high levels of NS1 and NP proteins 
(Barrett et al., 1979, Inglis et al., 1979, Lamb & Krug, 2001, Shapiro et al., 1987, 
Smith & Hay, 1982). In contrast, at “late” phases of infection all the viral segments 
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are efficiently replicated, and there is a high rate of transcription/translation for all the 
viral genes, particularly HA and M1 (Hay et al., 1977, Inglis et al., 1979, Shapiro et 
al., 1987, Skehel, 1973). 
 
The NS1 protein has been reported to control the temporal synthesis of both viral 
mRNAs and vRNAs (Falcon et al., 2004, Min et al., 2007, Wolstenholme et al., 
1980). The highly conserved (>95%) isoleucine-123 and methionine-124 residues in 
the C-terminal effector domain of NS1 have been implicated in this activity (Fig. 
1.10), as the substitution of these two residues for alanine resulted in the increased 
synthesis of all viral mRNAs and vRNAs early in infection (Min et al., 2007). In 
particular, both HA and M1 (usually only synthesised in the “late” phase of infection) 
were synthesised “early” in the context of a mutant virus encoding NS1 with amino-
acid substitutions at isoleucine-123 and methionine-124 (Min et al., 2007). The 
mechanism by which NS1 might regulate switches in viral vRNA, mRNA, and 
protein synthesis is unclear, but is not thought to involve PKR, a cellular protein 
bound by NS1 that can regulate translation (see below) (Min et al., 2007). One 
possibility is that NS1 functionally interacts with the viral polymerase complex to 
affect these processes (Marion et al., 1997b). 
 
1.2.5 NS1 and viral mRNA translation. 
As an RNA-binding protein, NS1 has been shown to interact in vitro with a variety of 
RNA species: dsRNA (Hatada & Fukuda, 1992, Wang et al., 1999), viral genomic 
RNA (Hatada et al., 1997), viral mRNA (Marion et al., 1997a, Park & Katze, 1995), 
poly(A)-containing RNAs (Qiu & Krug, 1994), and snRNAs (small nuclear RNAs) 
derived from the U6 promoter (Qiu et al., 1995). As described below, the interactions 
of NS1 with putative viral dsRNA, viral genomic RNA, and cellular poly(A)-
Fig. 1.10. Residues of NS1 involved in controlling RNA synthesis. Surface representations of 
the C-terminal effector domain homodimer (monomers coloured green and blue) (A-C).  Resi-
dues of NS1 that contribute to the regulation of viral RNA synthesis (isoleucine-123 and methio-
nine-124) are highlighted in red. Views are arbitrarily designated as for Fig. 1.7:  front (A ), side 
(B), and bottom (C). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 2GX9). 
A B
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containing RNAs (as well as the cellular proteins that may bind these ligands) likely 
play predominant roles in countering the host antiviral response (Kochs et al., 2007a, 
Min & Krug, 2006, Nemeroff et al., 1998, Pichlmair et al., 2006). Moreover, the 
possible interaction of NS1 with the 5’UTR (untranslated region) of viral mRNAs 
(Garfinkel & Katze, 1993, Park & Katze, 1995) has been linked to the ability of NS1 
to directly enhance the translation initiation of viral mRNAs (de la Luna et al., 1995, 
Enami et al., 1994, Marion et al., 1997b). 
 
Other than possibly binding the 5’UTR of viral mRNAs, NS1-mediated enhancement 
of viral protein synthesis may also require its interaction with host-cell proteins: NS1 
can form an RNA-protein complex consisting of the eukaryotic translation initiation 
factor eIF4GI, poly(A)-binding protein I (PABI), and viral mRNAs (Aragon et al., 
2000, Burgui et al., 2003). The RNA-independent binding of NS1 to eIF4GI requires 
the N-terminal 113 residues of NS1 (Aragon et al., 2000), whilst the RNA-
independent interaction with PABI requires residues in the N-terminal 81 amino acids 
of NS1 (Burgui et al., 2003) (Fig. 1.8). Thus, mutant NS1 proteins unable to bind 
eIF4GI are also defective in enhancing viral mRNA translation (Marion et al., 1997a). 
 
In addition, NS1 interacts with hStaufen, a dsRNA- and tubulin- binding protein that 
is related to PKR (Falcon et al., 1999). The interaction is independent of RNA, and 
appears to be mediated by the C-terminal effector domain of NS1 and the dsRNA-
binding domains of hStaufen (Falcon et al., 1999) (Fig. 1.8). hStaufen is normally a 
cytoplasmic protein, but a sub-population can be relocalised to the nucleus upon co-
expression with NS1 (Falcon et al., 1999). As hStaufen contributes to the 
microtubular transport of cellular mRNAs to sites of enhanced translation (such as 
cytoplasmic polysomes – collections of ribosomes translating the same mRNA), it has 
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been speculated that the interaction between NS1 and hStaufen may also promote 
efficient protein synthesis from viral mRNAs (Falcon et al., 1999). Indeed, a 
proportion of both NS1 and hStaufen has been found to co-fractionate with 
cytoplasmic polysomes in influenza A virus-infected cells (Compans, 1973, Falcon et 
al., 1999, Krug & Etkind, 1973, Marion et al., 1999). Thus, in order to promote 
efficient viral protein synthesis, NS1 may interact with cellular hStaufen, eIF4GI and 
PABI to specifically recruit viral mRNAs to multi-protein translation-initiation 
complexes. The additional contribution of NS1 to viral protein synthesis by inhibiting 
PKR is discussed below. 
 
1.2.6 NS1 and the host immune response. 
The innate interferon (IFN) response of the host-cell is a potent antiviral mechanism 
that can limit the replication and spread of viruses [reviewed in (Goodbourn et al., 
2000, Haller et al., 2006)]. IFNs (such as IFNα or IFNβ) are soluble cytokines 
synthesised by cells in response to viral infection [reviewed in (Goodbourn et al., 
2000)]. Secreted IFNs act in both an autocrine and paracrine fashion to upregulate 
>300 genes (Der et al., 1998), and thereby induce an “antiviral state” within target 
host cells [reviewed in (Goodbourn et al., 2000)]. 
 
Studies using modified influenza A viruses (strain A/Puerto Rico/8/34; PR8) that are 
either unable to express NS1 (termed PR8delNS1), or express truncated NS1 proteins, 
have revealed that a major role for NS1 during infection is to counter the innate 
immune response (Egorov et al., 1998, Fernandez-Sesma et al., 2006, Garcia-Sastre et 
al., 1998, Kochs et al., 2007b). PR8delNS1 replicates to titres ~1000-fold lower than 
wild-type (WT) PR8 in “IFN-competent” MDCK cells (Garcia-Sastre et al., 1998). 
However, in Vero cells (which have the genes encoding both IFNα and IFNβ deleted 
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(Diaz et al., 1988, Mosca & Pitha, 1986)), PR8delNS1 replicates to titres only ~10-
fold lower than WT PR8 (Garcia-Sastre et al., 1998). Additionally, PR8delNS1 virus 
is only pathogenic in mice with a homozygous deletion in STAT1 (an essential 
molecule that mediates the cellular response to exogenous IFN), and PR8delNS1 (but 
not WT PR8) causes high transactivation of an IFN-stimulated reporter gene (Garcia-
Sastre et al., 1998). Together, these data indicate that NS1 normally functions to limit 
the host innate IFN-mediated antiviral response. However, given that viruses 
completely lacking NS1 still replicate to titres ~10-100-fold lower than WT in Vero 
cells (Garcia-Sastre et al., 1998, Kochs et al., 2007b), it is clear that NS1 has 
functions that are independent of its IFN-antagonistic abilities (see above sections). 
 
A number of studies have demonstrated, at the molecular level, how NS1 functions to 
limit both the production and downstream effects of IFN. As described below, it is 
becoming increasingly apparent that the mechanisms by which NS1 achieves this are 
likely to be strain and/or cell-type specific (Geiss et al., 2002, Hayman et al., 2006, 
Kochs et al., 2007a). 
 
1.2.6.1 Limitation of IFN production by NS1. 
The H1N1 influenza virus A/Puerto Rico/8/34 (PR8) is a commonly used laboratory 
strain that has been extensively passaged in tissue culture and eggs. Unusually, it is 
highly mouse-adapted, and is attenuated in humans. Studies on the PR8/NS1 protein 
show that it can specifically prevent dsRNA- and virus- mediated activation of the 
transcription factors interferon regulatory factor-3 (IRF-3), NFκB, and c-Jun/ATF-2, 
and thus limit induction of IFNβ (Ludwig et al., 2002, Talon et al., 2000a, Wang et 
al., 2000). This inhibition appears to occur pre-transcriptionally, and has been 
attributed to two residues in the dimerised RNA-binding domain of PR8/NS1: 
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arginine-38 and lysine-41 – both of which mediate efficient RNA-binding (Talon et 
al., 2000a, Wang et al., 1999, Wang et al., 2002) (Fig. 1.6). 
 
Although it was postulated that PR8/NS1 might sequester aberrant dsRNA produced 
during virus infection (and thus limit the activation of transcription factors necessary 
for IFNβ gene transcription), dsRNA has not been detected in influenza A virus 
infected cells (Pichlmair et al., 2006, Weber et al., 2006), and recent work indicates 
that the mechanism of IFN inhibition may actually involve PR8/NS1 forming a 
complex with retinoic acid-inducible gene product I (RIG-I) (Guo et al., 2007, 
Mibayashi et al., 2007, Opitz et al., 2006, Pichlmair et al., 2006). 
 
RIG-I is a cytoplasmic RNA helicase that acts as a cellular sensor of RNA virus 
infection, and can lead to the induction of IFNβ synthesis (Yoneyama et al., 2004). 
The co-precipitation of RIG-I with PR8/NS1 is largely dependent upon arginine-38 
and lysine-41 in PR8/NS1 (Pichlmair et al., 2006), suggesting that these two residues 
are involved in the protein:protein interaction, or that RNA acts as an intermediary 
component (Fig. 1.6). Indeed, studies to date have failed to confirm direct binding of 
PR8/NS1 to RIG-I (Mibayashi et al., 2007), and the presence of 5'-phosphorylated 
ssRNA clearly enhances the stability of a PR8/NS1:RIG-I complex (Pichlmair et al., 
2006). However, it is intriguing to note that PR8/NS1 has also been shown to block 
the function of a constitutively active RIG-I construct lacking its RNA-binding 
helicase domain (Mibayashi et al., 2007), indicating that inhibition of RIG-I mediated 
IFNβ induction is complex, and could involve multiple mechanisms. 
 
Studies using the human H3N2 virus A/Udorn/72 (Ud) have revealed that Ud/NS1 
can limit IFNβ induction by preventing the global post-transcriptional processing of 
cellular pre-mRNAs (Lu et al., 1994). For this, the C-terminal effector domain of 
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Ud/NS1 binds directly to two zinc-finger regions in the 30 kDa subunit of cleavage 
and polyadenylation specificity factor (CPSF30), and also binds poly(A)-binding 
protein II (PABII) (Chen et al., 1999, Nemeroff et al., 1998, Noah et al., 2003, Twu et 
al., 2006). NS1 binding to CPSF30 prevents the cellular protein from binding pre-
mRNAs, thus inhibiting the correct cleavage and polyadenylation of host mRNAs 
(Nemeroff et al., 1998). NS1 binding to PABII is thought to block the nuclear export 
of mRNAs that might partially escape from the inhibition of 3'-end formation (Chen 
et al., 1999). Retention of cellular pre-mRNAs within the nucleus of infected cells 
usually leads to their rapid degradation (Katze & Krug, 1984). 
 
The CPSF30-binding site on Ud/NS1 includes residues 184-188 (glycine-leucine-
glutamic acid-tryptophan-asparagine) (Noah et al., 2003), as well as leucine-144 
(Twu et al., 2006). Binding is also stabilised by either phenylalanine-103 and 
methionine-106, or by an NS1-mediated interaction with the cognate viral polymerase 
complex (Kochs et al., 2007a, Twu et al., 2007) (Fig. 1.11). The PABII interaction 
site requires Ud/NS1 residues 223-237 (Noah et al., 2003) (Fig. 1.8). Recombinant 
Ud viruses expressing NS1 with a mutated CPSF30-binding site are highly attenuated 
under tissue culture conditions, and induce the synthesis of large amounts of IFNβ 
mRNA, as well as other antiviral mRNAs (such as ISG15, p56, and 2'-5'-
oligoadenylate synthetase mRNAs) (Noah et al., 2003). 
 
Despite the discrepancy in proposed “modes of action” for the IFN-antagonistic 
properties of NS1, recent comparative studies suggest that influenza A viruses may 
have evolved two strategies to circumvent the host immune response, and these 
strategies might normally synergise to mediate efficient evasion of the IFN system 
(Hayman et al., 2006, Kochs et al., 2007a). For example, PR8/NS1 cannot bind 
Fig. 1.11. Residues of NS1 that mediate the interaction with CPSF30. Surface representa-
tions of the C-terminal effector domain homodimer. The two monomers are coloured green and 
blue. Residues involved in mediating the stable interaction between NS1 and CPSF30 are shown 
in red (amino-acids 103, 106, 144, and 184-188). Views are arbitrarily designated front (A), 
side (B), and top (C). Images were prepared using MacPyMol (Protein Data Bank ﬁle: 2GX9). 
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directly to CPSF30, and is therefore unable to block the activation of gene reporter 
constructs (Hayman et al., 2006, Kochs et al., 2007a). For comparison, the NS1 
proteins of other influenza A virus strains, including Ud, A/Brevig Mission/1/18 
(BM), A/Texas/36/91 (Tx) and A/Victoria/3/75 (Vic), can efficiently limit host-cell 
gene transcription (and specifically RNA polymerase II transcripts (Kochs et al., 
2007a)), a property shown for Tx/NS1 to be dependent upon its binding to CPSF30 
(Hayman et al., 2006, Kochs et al., 2007a). However, during infection PR8/NS1 
efficiently limits IFNβ synthesis by a pre-transcriptional block on IRF-3 activation, 
which probably involves its interaction with RIG-I (Kochs et al., 2007a). In contrast, 
Tx/NS1 (which interacts poorly with RIG-I) only partially limits IRF-3 activation in 
response to virus infection, yet completely blocks IFNβ mRNA synthesis (Kochs et 
al., 2007a). Furthermore, during virus infection Vic/NS1 limits both IRF-3 
translocation to the nucleus and host-cell gene transcription (Hayman et al., 2006), 
suggesting that this NS1 protein might functionally interact with both RIG-I and 
CPSF30. It is of interest to note that PR8/NS1 (unlike other NS1 proteins) has been 
reported to enhance the translation of cellular mRNAs (Salvatore et al., 2002), which 
may be due in part to its inability to suppress the 3'-end processing of cellular pre-
mRNAs prior to translation. 
 
Thus, evidence indicates that different NS1 proteins may limit the synthesis of IFNβ 
by both pre-transcriptional and/or post-transcriptional processes. The existence and 
evolution of two mechanisms may increase the capacity of influenza A viruses to 
adapt to new environments and hosts (Kochs et al., 2007a). However, it is also 
possible that the laboratory adaptation of some strains of influenza A virus has lead to 
the loss of one or other of these mechanisms, resulting in viruses that inhibit IFNβ 
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pathways by distinct means. Either way, there is clearly a potential problem in 
interpreting data from studies using only a single virus strain. 
 
1.2.6.2 Inhibition of host-cell mRNA processing by NS1. 
Given that most NS1 proteins cause the bulk nuclear retention of host mRNAs, but 
not viral mRNAs (Fortes et al., 1994, Qiu & Krug, 1994), it should be noted that NS1 
can also form a complex with components of the mRNA nuclear export machinery: 
NXF1, p15, Rae1, E1B-AP5, and to some extent Nup98 (Satterly et al., 2007). 
Interestingly, within influenza A virus infected cells, Nup98 protein appears to be 
actively degraded (Satterly et al., 2007). 
 
Complex formation between NS1 and NXF1, Rae1, and E1B-AP5 requires residues in 
both the RNA-binding and C-terminal effector domains of NS1, whilst the interaction 
with p15 appears to be mediated solely by the C-terminal effector domain (Satterly et 
al., 2007) (Fig. 1.8). Although the RNA-binding domain of NS1 is implicated in the 
interaction with NXF1, Rae1, and E1B-AP5, treatment with RNase A only affects the 
co-precipitation of E1B-AP5 with NS1 (Satterly et al., 2007). Overexpression of these 
mRNA nuclear export factors is able to overcome the NS1-mediated block on mRNA 
nucleo-cytoplasmic transport, suggesting that the inhibitory effect of NS1 can be 
titrated out by functional NXF1, Rae1, p15, and E1B-AP5 (Satterly et al., 2007). 
Thus, in addition to inhibiting the 3'-end processing of host-cell pre-mRNAs (and 
thereby mRNA export) by binding CPSF30 and PABII, NS1 can act directly at the 
level of nuclear mRNA export transporters in order to prevent host protein synthesis. 
 
Yeast two-hybrid studies also identified a novel ~70 kDa NS1-binding protein 
(subsequently termed NS1-BP) (Wolff et al., 1998). NS1-BP predominantly co-
localises with the spliceosome assembly factor SC35 into nuclear “speckle” domains, 
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suggesting that NS1-BP is involved in the cellular mRNA splicing machinery (Wolff 
et al., 1998). During influenza A virus infections, the cytoplasmic fraction of NS1-BP 
redistributes into the nucleus, and thus colocalises with NS1 (Wolff et al., 1998). In 
addition, NS1 also induces a change in the nuclear localisation of other cellular 
splicing factors (Fortes et al., 1995), and the “speckle domains” appear to change 
dramatically in size, shape and composition (Fortes et al., 1995, Wolff et al., 1998). It 
has been proposed that the interaction between NS1 and NS1-BP may contribute 
towards the inhibition of host-cell mRNA processing, although a role for the 
interaction in regulating viral mRNA splicing cannot be ruled out (Garaigorta & 
Ortin, 2007, Wolff et al., 1998). 
 
It should be noted that, in contrast to the effect of NS1 on host-cell mRNAs, NS1 
does not inhibit the nuclear export of most viral mRNAs, with the apparent exception 
of its own NS1 mRNA (Garaigorta & Ortin, 2007, Satterly et al., 2007). The 
mechanism by which NS1 achieves this specificity is unknown, but suggests that viral 
mRNAs leave the nucleus by a means independent of nuclear pore complexes 
containing NXF1, Rae1, p15, and E1B-AP5. 
 
1.2.6.3 Inhibition of IFN-inducible enzymes by NS1. 
The ability of some NS1 proteins to efficiently limit IFN and tumour necrosis factor α 
(TNFα)-stimulated gene expression (thereby conferring resistance to their antiviral 
effects), has a beneficial effect on virus replication and pathogenicity (Geiss et al., 
2002, Hayman et al., 2006, Kobasa et al., 2007, Kochs et al., 2007a, Seo et al., 2002). 
However, NS1 also specifically blocks the activation of two cytoplasmic IFN-
inducible anti-viral proteins: 2'-5'-oligoadenylate synthetase (2'-5'-OAS), and the 
dsRNA-dependent serine/threonine protein kinase R (PKR). 
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dsRNA (a putative by-product of RNA virus replication) acts as co-factor to activate 
2'-5'-OAS, which is then able to polymerize adenosine triphosphate (ATP) into 2'-5' 
oligoadenylate (2'-5' oligo(A)) chains [reviewed in (Sen, 2000)]. These 2'-5' oligo(A) 
chains in turn cause dimerisation and activation of the latent ribonuclease, RNaseL 
that inhibits viral replication (translation) by degrading single-stranded RNAs, such as 
mRNAs and ribosomal RNAs [reviewed in (Sen, 2000)]. 
 
dsRNA also activates PKR - it binds to specific motifs within the N-terminal domain 
of PKR, and thereby releases its conformationally-induced autoinhibition (Nanduri et 
al., 2000). Activated PKR phosphorylates the α-subunit of eIF2 (eukaryotic 
translation initiation factor 2), a process which causes the inhibition of both cellular 
and viral protein synthesis [reviewed in (Samuel, 1993)]. PKR also has roles in 
upregulating gene expression (IFNβ) from IRF-3 and NFκB responsive promoters 
[reviewed in (Goodbourn et al., 2000, Sen, 2000)], and is involved in initiating the 
apoptotic response (Balachandran et al., 1998). Thus, both 2'-5'-OAS and PKR play 
important roles in limiting virus replication, and their effects are dramatically 
increased by a functional IFN system. 
 
A study using a recombinant influenza A virus (strain A/Udorn/72) that expresses an 
RNA-binding deficient NS1 (single amino-acid substitution at arginine-38) revealed 
that RNA-binding by NS1 plays a major role in circumventing the host IFN-induced 
antiviral state (Min & Krug, 2006). Pretreatment of A549 cells with IFNβ resulted in 
~1000-fold decrease in the yield of this virus (rUd NS1-R38A) as compared with WT 
rUd (Min & Krug, 2006). This effect was mediated mostly (but not exclusively) by 
RNaseL, as short-interfering RNA (siRNA) targeting this latent ribonuclease restored 
the yield of rUd NS1-R38A by ~100-200-fold (Min & Krug, 2006). Given that 
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RNaseL is activated solely by 2'-5'-OAS, and NS1 likely has a higher binding affinity 
for dsRNA than 2'-5'-OAS, it has been postulated that the primary function of the 
NS1 RNA-binding domain is to out-compete 2'-5'-OAS for binding dsRNA, thus 
preventing the activation of this antiviral enzyme (Min & Krug, 2006). The cytokine 
sensitivity of influenza A viruses expressing NS1 proteins with a single amino-acid 
substitution at arginine-38 has also been confirmed in an in vivo (mouse) model, and 
in primary murine tracheal epithelial cells (Newby et al., 2007). In addition, it is 
interesting to note that in vivo such a mutant virus induces large amounts of TNFα, 
interleukin-6 (IL-6), and IFNβ (Newby et al., 2007). [As RNaseL has recently been 
shown to augment the actual induction of IFNβ in a 2'-5' oligo(A)-dependent manner 
(Malathi et al., 2007), it is possible that inhibition of 2'-5'-OAS activity by NS1 may 
also contribute to limiting IFNβ induction.] 
 
Influenza A viruses have developed two direct mechanisms by which to counteract 
the powerful antiviral activity of PKR (Katze et al., 1988). Firstly, influenza A virus 
upregulates the activity of the normal cellular inhibitor of PKR, p58IPK (Lee et al., 
1990). The mechanism by which this upregulation occurs is not entirely clear, 
although there is no increase in the total amount of p58IPK protein (Lee et al., 1992). 
Rather, evidence suggests that influenza A virus infection may cause the dissociation 
of p58IPK from its own cellular inhibitor, HSP40 (Melville et al., 1997, Melville et al., 
1999). The influenza A virus NS1 protein can also directly negatively regulate PKR 
activity (Bergmann et al., 2000). Although in vitro data indicate that NS1 effectively 
blocks PKR activation by competing with PKR for dsRNA (Hatada et al., 1999, Lu et 
al., 1995), the relatively low affinity of NS1 for dsRNA (Chien et al., 2004) means it 
is unlikely to successfully achieve this block during an in vivo infection (Li et al., 
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2006a). It has since been shown that NS1 can bind directly to PKR (Tan & Katze, 
1998) in a dsRNA-independent manner (Li et al., 2006a, Min et al., 2007). 
 
The binding of NS1 to PKR requires amino acids 123-127 in the C-terminal effector 
domain of NS1, and these amino acids are essential for the NS1-mediated inhibition 
of PKR during virus infection (Min et al., 2007). Thus, NS1 has been proposed to 
interact with a linker region in the PKR molecule and mechanically prevent the 
autoinhibitory relief conferred upon PKR when dsRNA binds to its N-terminal 
domain (Li et al., 2006a). NS1-mediated inhibition of PKR therefore allows efficient 
viral protein synthesis to occur during infection (Salvatore et al., 2002). [Given that 
PKR may also contribute to IFN induction [reviewed in (Goodbourn et al., 2000, Sen, 
2000)], its inhibition by NS1 could play an additional role in the antagonism of IFN 
production by influenza A viruses.] 
 
1.2.6.4 NS1 and host RNAi pathways. 
In eukaryotic organisms, RNA silencing (RNA interference; RNAi) is a unique RNA-
guided mechanism for suppressing the expression of specific genes [reviewed in 
(Denli & Hannon, 2003)]. The host endoribonuclease, Dicer, produces small ~22 
nucleotide RNAs from dsRNA, which act individually in a homology-dependent 
manner to form a ribonucleoprotein complex – the RNA-induced silencing complex 
(RISC) [reviewed in (Cullen, 2006)]. RISC acts on the homologous target mRNA in 
two ways: translational inhibition requires only partial homology between the “guide” 
RNA and the target mRNA, whilst degradation of the mRNA requires extensive 
homology between the two RNA species [reviewed in (Bartel, 2004)]. The possible 
role of endogenous host RNAi pathways in the anti-viral response to RNA viruses in 
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mammalian cells is controversial and unclear [reviewed in (Cullen, 2006, Gitlin & 
Andino, 2003)]. 
 
In the case of influenza A virus, artificially introduced RNAi responses can protect 
mammalian cells from infection, both in tissue-culture cells and in in vivo mouse 
models (Ge et al., 2004a, Ge et al., 2004b, Ge et al., 2003, Hui et al., 2004, Tompkins 
et al., 2004, Zhou et al., 2004). Despite this, only recent data have suggested that 
mammalian cells may potentially mount an innate RNAi-associated anti-influenza 
virus response (Matskevich & Moelling, 2007). Studies on Vero cells showed that 
siRNA-mediated knock-down of Dicer increased the replication of influenza A virus, 
and enhanced virus-induced apoptosis (Matskevich & Moelling, 2007). However, as 
knock-down of Dicer also causes the modest upregulation of several hundred host-cell 
gene transcripts (Schmitter et al., 2006), it is possible that this effect is unrelated to 
RNAi-degradation of viral RNAs. Nevertheless, Dicer mRNA and protein appear to 
be preferentially downregulated during normal influenza A virus infections 
(Matskevich & Moelling, 2007), suggesting that this host-cell protein may be 
specifically targeted by the virus to suppress an anti-viral function. 
 
Although involvement of RNA silencing in the anti-viral response of mammalian 
cells to viruses is yet to be fully resolved, the influenza A virus NS1 protein has 
already been proposed to antagonize such a host defence (Li et al., 2004). In this 
regard, overexpression of NS1 can demonstrably inhibit the induction of RNAi 
pathways in heterologous Drosophila (insect) and plant cell systems (Bucher et al., 
2004, Delgadillo et al., 2004, Li et al., 2004). However, this may simply be due to the 
non-specific sequestration of dsRNA, as arginine-38 and lysine-41 in NS1 
significantly contribute to this suppression (Cullen, 2006, Li et al., 2004) (Fig. 1.6). 
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Evidence indicates that NS1 is unable to exert the same inhibitory effect in 
mammalian cells (Kok & Jin, 2006), thus the role of mammalian RNAi pathways 
during virus infection (and their antagonism by viral factors), still needs to be fully 
determined. 
 
1.2.6.5 NS1 and the adaptive immune response. 
During viral/bacterial infections in vivo, dendritic cells (DCs) act as sentinels to 
survey infected tissues (Mellman & Steinman, 2001). Upon contact with a pathogen, 
DCs mature, leading to the upregulation of major histocompatibility complex (MHC) 
class II molecules and the release of pro-inflammatory cytokines/chemokines 
(including IFNα/IFNβ) (Fernandez-Sesma et al., 2006). Mature DCs migrate to 
lymph nodes and present pathogen-specific antigens on their surface to both cytotoxic 
and helper T-cells, thus stimulating initiation of adaptive immune responses specific 
for the infecting pathogen (Mellman & Steinman, 2001). Activated cytotoxic (CD8+) 
T-cells are able to directly kill (virus)-infected cells, whilst helper (CD4+) T-cells 
produce cytokines such as IFNγ and TNFβ, which further activate the killing capacity 
of macrophages and CD8+ T-cells (Mellman & Steinman, 2001). 
 
Studies on human-derived primary DCs have revealed that the influenza A virus NS1 
protein is able to prevent the correct maturation of DCs in response to virus infection, 
and thereby limits host T-cell activation (Fernandez-Sesma et al., 2006). Specifically, 
infection of DCs with PR8delNS1 virus (lacking the ability to express full-length 
NS1) lead to the secretion of higher amounts of IFNα, IFNβ, TNFα, and IL-6, as 
compared to the WT virus (Fernandez-Sesma et al., 2006). This is in agreement with 
in vivo mouse studies done using a mutant influenza A virus (WSN strain) expressing 
NS1 with a single amino-acid substitution at arginine-38, and which is thus unable to 
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bind RNA (Newby et al., 2007). Expression of WT NS1 also specifically limited the 
virus-induced expression of several genes involved in DC maturation and migration, 
including: MHC, IL-8, IL-12 p35, IL-23 p19, IRF-7, RANTES, TRIF, MIP-1β, and 
CCR7 (Fernandez-Sesma et al., 2006). Thus, DCs infected with influenza A viruses 
expressing WT NS1 are unable to mature, and thereby fail to stimulate the secretion 
of IFNγ from T-cells (Fernandez-Sesma et al., 2006). This effect of NS1 would 
clearly have a profound inhibitory effect on the adaptive immune response to 
infection. 
 
1.2.7 Effect of NS1 on other cell signalling pathways. 
A number of studies have reported and attempted to characterise novel cellular 
binding partners for NS1 [most recently nucleolin (Murayama et al., 2007)]. The NS1 
proteins from five different human and avian influenza A virus strains can associate 
with NS1-I, a human protein highly homologous to the porcine 17β-estradiol 
dehydrogenase precursor protein, which may mediate steroid hormone levels (Wolff 
et al., 1996). Although the function of this interaction is not well understood, 
overexpression of NS1-I in 293 cells specifically reduces the expression of influenza 
A virus proteins, suggesting that NS1-I has antiviral activity that may be inhibited by 
NS1 (Wolff et al., 1996). 
 
Large-scale sequence analyses of avian influenza A viruses have also revealed two 
other putative protein-binding motifs within NS1: a Src-homology 3 (SH3) binding 
motif (residues 212-216) (Finkelstein et al., 2007), and a PDZ (postsynaptic density, 
PSD-95; discs large, Dlg; zonula occludens-1, ZO-1) domain ligand (final four 
residues at the C-terminus) (Obenauer et al., 2006) (Fig. 1.8). Cellular proteins 
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containing SH3 or PDZ domains often coordinate the assembly of a diverse array of 
localized signalling complexes. 
 
No host-cell proteins have, to date, been identified as interacting with the putative 
SH3 binding motif in NS1 (though Crk and CrkL are strong possibilities (Heikkinen 
et al., 2007)). However, in vitro studies have shown that the PDZ domain ligand of 
highly pathogenic avian influenza virus NS1s (including those from H5N1 and 1918 
strains) can bind (and therefore potentially disrupt the activity of) over 30 different 
human PDZ-proteins (Obenauer et al., 2006). 
 
1.2.8 NS1 and the host apoptotic response. 
During infection, influenza A viruses induce cell death by both apoptosis (Fesq et al., 
1994, Hinshaw et al., 1994, Lowy, 2003, Takizawa et al., 1993), and (in certain cell 
types) necrosis (Arndt et al., 2002, Seo et al., 2004). Most infected cells undergo 
apoptosis by intrinsic mechanisms, however influenza A virus can induce apoptosis in 
neighbouring, uninfected cells by triggering the release of extracellular cytokines that 
act in a paracrine fashion (Zhirnov & Klenk, 2007). 
 
The role of apoptosis during infection is somewhat controversial. For example, 
cellular pro-apoptotic factors, such as caspase-3 or the NFκB/FasL/TRAIL (TNF-
related apoptosis-inducing ligand) pathway, have been reported to promote the 
efficient propagation of influenza A viruses (Wurzer et al., 2004, Wurzer et al., 
2003). Alternatively, apoptosis can be regarded as a host antiviral defence mechanism 
that is activated in response to infection and limits virus replication (Barber, 2001, 
Kurokawa et al., 1999). As such, cell-death induction is probably dependent upon the 
temporal balance between pro- and anti-apoptotic functions of several viral proteins, 
as well as the rate of production of other viral apoptosis “inducers”, such as dsRNA 
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(Morris et al., 2005). The kinetics of apoptosis induction throughout each stage of 
infection are likely to be important for virus propagation. “Early” apoptosis may be 
severely detrimental to virus replication, packaging, and spread, whilst “late” 
apoptosis may benefit the virus by clearing infected cells that might otherwise 
stimulate cell-mediated cytotoxic responses and/or the adaptive immune system.  
 
Several influenza A virus proteins have been shown to directly modulate apoptosis: 
NS1 can have both pro- and anti- apoptotic functions (Morris et al., 2002, Schultz-
Cherry et al., 2001, Zhirnov et al., 2002a); NA activates transforming growth factor β 
(TGFβ), a known inducer of apoptosis in epithelial cells (Morris et al., 1999, Schultz-
Cherry & Hinshaw, 1996); PB1-F2 promotes the formation of ion channels in the 
inner mitochondrial membrane (see section 1.1), either by itself or through 
interactions with ANT3 and VDAC (Chanturiya et al., 2004, Chen et al., 2001, Gibbs 
et al., 2003, Zamarin et al., 2005); and M1 may enhance apoptosis by interacting with 
caspase-8 (Zhirnov et al., 2002b). 
 
The exact function of NS1 with regard to virus-induced apoptosis/cell-death is 
unclear, and may be dependent upon specific host-cell factors or virus strain – for 
example, Ud/NS1 on its own appears to be extremely toxic to MDCK cells, but not 
HeLa cells (Schultz-Cherry et al., 2001); and Ud/NS1 (but not PR8/NS1) inhibits the 
processing of cellular pre-mRNAs, a process likely to be toxic to the cell (Kochs et 
al., 2007a, Noah et al., 2003). Indeed, experiments using transiently expressed 
Ud/NS1 have demonstrated that residues in the RNA-binding domain of NS1 can 
augment NS1-induced apoptosis in MDCK cells independently of other virus-derived 
factors (Schultz-Cherry et al., 2001). However, in the context of virus infection, NS1 
appears to have anti-apoptotic functions, which have been linked largely to its ability 
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to limit the production and/or downstream effects of IFN (Zhirnov et al., 2002a). As 
such, catalytically active PKR is reported to play an important role in influenza A 
virus-mediated induction of apoptosis (Takizawa et al., 1996), thus the direct binding 
and inhibition of PKR by NS1 may contribute to cell-death suppression (Li et al., 
2006a). The same may be true for the pro-apoptotic functions of 2'-5' OAS/RNaseL 
(Diaz-Guerra et al., 1997, Min & Krug, 2006, Zhou et al., 1997). In addition, by 
limiting the production of IFN and other cytokines, NS1 might reduce paracrine-
mediated (extrinsic) apoptosis induction in neighbouring uninfected cells (Zhirnov & 
Klenk, 2007, Zhirnov et al., 2002a). Overall, there may be a temporal role for NS1 in 
contributing to both “early” (active) suppression of apoptosis, and “late” (toxic) 
induction cell-death during infection. 
 
As part of this thesis, a functional interaction between NS1 and the phosphoinositide 
3-kinase (PI3K) signalling pathway was identified (Hale et al., 2006). This was 
subsequently confirmed by several other groups (Shin et al., 2007a, Ehrhardt et al., 
2007a, Zhirnov & Klenk, 2007), and a possible role for the interaction in delaying 
virus-induced apoptosis was inferred (Ehrhardt et al., 2007a, Zhirnov & Klenk, 2007). 
The remainder of this introduction is therefore concerned with detailing the molecular 
details of PI3K signalling (section 1.3), and reviewing how different viruses hijack 
this pathway in order to benefit their replication (section 1.4). 
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1.3 Phosphoinositide 3-kinase (PI3K) signalling. 
 
1.3.1 Membrane lipids as signalling molecules. 
Phosphatidylinositol (PtdIns) is a component of eukaryotic cell membranes [reviewed 
in (Fruman et al., 1998)]. Despite its relatively low abundance, PtdIns plays a crucial 
role in many cell signalling events as a metabolic precursor of several second 
messenger molecules [reviewed in (Cantley, 2002, Cantrell, 2001, Fruman et al., 
1998, Hawkins et al., 2006, Vanhaesebroeck et al., 2005)]. As a phospholipid, PtdIns 
is unique in that its inositol head group can become phosphorylated at multiple free 
hydroxyl positions [reviewed in (Fruman et al., 1998, Hawkins et al., 2006)]. Thus, 
within cells seven different phosphorylated PtdIns species (phosphoinositides) have 
been detected, each presumably with unique signalling functions [reviewed in 
(Hawkins et al., 2006)] (Fig. 1.12). The generation and regulation of 
phosphoinositides is controlled by a variety of lipid kinases and phosphatases that act 
directly on PtdIns or its phosphoinositide derivatives (see below). An alternative 
mechanism involves phospholipase C, which hydrolyses phosphatidylinositol (4,5) 
biphosphate (PtdIns(4,5)P2) to produce soluble inositol (1,4,5) triphosphate 
(Ins(1,4,5)P3), and membrane-associated diacylglycerol (DAG). Ins(1,4,5)P3 acts via 
receptors in the endoplasmic reticulum to increase intracellular Ca2+ levels, whilst 
DAG can activate pathways downstream of the serine/threonine protein kinase C 
family [reviewed in (Cantrell, 2001, Vanhaesebroeck et al., 1997a)]. However, the 
events concerning this PtdIns metabolism are not considered further here. 
 
Phosphoinositide kinases are enzymes that catalyse the transfer of phosphate to a 
particular position on the inositol ring of PtdIns or one of its phosphorylated forms 
[reviewed in (Fruman et al., 1998)]. They are highly conserved (at the amino acid 
Fig. 1.12. Structure of phosphatidylinositol and its seven phosphorylated derivatives. 
Phosphatidylinositol (PtdIns; top left) found in mammalian cells comprises fatty acid chains 
(which are inserted into the plasma membrane), and a cytosolic head-group (inositol). The in-
ositol head-group can become phosphorylated at multiple hydroxyl (-OH) positions to form 
various PtdIns derivatives (as shown). Each derivative is named for the position of phospho-
rylation - consensus numbering is indicated on the PtdIns (top left) diagram.  PtdIns(3,4,5)P
3 
(the product of class I PI3K) is shown top right. The regulation of PtdIns phosphorylation is 
controlled by lipid kinases and phosphatases (see text). Schematic modiﬁed from Hawkins et 
al., 2006.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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level) amongst eukaryotic organisms (including yeasts) [reviewed in 
(Vanhaesebroeck et al., 1997a)], and are classified with respect to the position on the 
inositol ring that they phosphorylate (note: although PtdIns has free hydroxyls at 
positions 2-6, only positions 3-5 are known to be phosphorylated in vivo [reviewed in 
(Hawkins et al., 2006)]): phosphoinositide 3-kinases (PI3Ks) phosphorylate the 3'-OH 
position of PtdIns; phosphoinositide 4-kinases (PI4Ks) phosphorylate the 4'-OH 
position of PtdIns; and phosphoinositide (P) 5-kinases (PIP5Ks) phosphorylate the 5'-
OH position of PtdInsP [reviewed in (Fruman et al., 1998)]. PI3Ks have been the 
most intensively studied phosphoinositide kinases, and are the subjects of the 
following sections. 
 
1.3.2 PI3K enzymes, substrates, and products. 
Lipid second messengers generated by PI3Ks regulate an array of protein kinase 
signalling cascades which, in turn, control diverse cellular processes such as cell 
survival, metabolism, proliferation, and inflammation/immunity [reviewed in 
(Cantley, 2002, Hawkins et al., 2006, Vanhaesebroeck et al., 2005)]. Several PI3K 
enzymes (which specifically catalyse the reactions shown in Fig. 1.13), have been 
characterised, and are grouped into four classes (IA, IB, II, and III) based upon their 
structural and functional homologies [reviewed in (Fruman et al., 1998, Hawkins et 
al., 2006)] (Fig. 1.14A). Class IA PI3Ks (the subject of this thesis) and class IB 
PI3Ks preferentially generate PtdIns(3,4,5)P3 from PtdIns(4,5)P2, whilst class II and 
class III PI3Ks are primarily responsible for the synthesis of PtdIns3P (how 
PtdIns(3,4)P2 is made from PtdIns4P is not yet clear) (Hawkins et al., 2006). Class I 
PI3K-generated PtdIns(3,4,5)P3 is part of a major signal transduction pathway 
downstream of cell-surface receptors [reviewed in (Cantley, 2002, Hawkins et al., 
Fig. 1.13. Phosphorylation of PtdIns derivatives by various PI3K classes. Each PI3K 
activity transfers phosphate from ATP to the 3`-OH position of the inositol head-group of 
a speciﬁc PtdIns derivative. Class II and class III PI3Ks phosphorylate PtdIns to produce 
PtdIns(3)P, whilst class I PI3K phosphorylates PtdIns(4,5)P
2
 to produce PtdIns(3,4,5)P
3
. The 
kinase responsible for producing PtdIns(3,4)P
2
 from PtdIns(4)P is unknown. For clarity, only 
the inositol head-groups are shown, although it should be noted that the fatty-acid chains 
would normally extend from the 1` position. Schematic modiﬁed from Hawkins et al., 2006.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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2006)], and class III PI3K-generated PtdIns3P regulates endocytosis, vesicle transport 
and lysosome formation [reviewed in (Cantrell, 2001, Hawkins et al., 2006)]. 
 
1.3.3 Regulation of class IA PI3K activity. 
Class IA PI3Ks are dimeric enzymes consisting of a p110 catalytic subunit (p110α, 
p110β, or p110δ) tethered to a smaller non-catalytic (“p85”) regulatory subunit 
(typically p85α, p85β, p55α, p50α, or p55γ) (Fig. 1.14A). p85α, p85β, and p55γ are 
all encoded by separate genes, but p55α and p50α are splice variants from the p85α 
gene (and thus lack the SH3 and BH domain sequences of full-length p85α.) 
[reviewed in (Vanhaesebroeck et al., 2005)]. All regulatory subunits (with the 
exception of p55γ) exhibit a wide tissue distribution (Vanhaesebroeck et al., 2005). 
The interaction of “p85” with p110 functions to both stabilize heat-labile p110, and 
suppress its enzymatic activity (Yu et al., 1998). Thus, within cells, “p85” and p110 
exist as obligate heterodimers (Geering et al., 2007, Yu et al., 1998), and subsequent 
activation of PI3K must occur via inter- or intra- molecular allosteric changes. “p85s” 
are also essential for recruiting p110 subunits to the plasma membrane, where the 
necessary lipid substrates for PI3K reside (Vanhaesebroeck et al., 2005). 
 
The p85 regulatory subunits contain an N-terminal SH3 (Src homology 3) domain, a 
BH (B-cell receptor homology) domain flanked by proline-rich sequences, and two 
SH2 (Src homology 2) domains, which are on either side of the p110-binding inter-
SH2 (iSH2) domain (Fig. 1.14B) (Dhand et al., 1994, Vanhaesebroeck et al., 2005). 
All the domains of p85 contribute to the regulation of p110, and stimulatory signals 
(such as growth factors, hormones, neurotransmitters, and many inflammatory stimuli 
including IFNs) act through multiple mechanisms in order to modulate the basal 
inhibition of PI3K (Hawkins et al., 2006, Kaur et al., 2005). For example, tyrosine 
Fig. 1.14. Classiﬁcation and organisation of the four PI3K classes. (A) Schematic domain 
structures for the regulatory and catalytic subunits comprising each class of PI3K. After each 
structure is the protein and gene name. Classes are determined by the homology between the 
relevant catalytic subunits. Class IA PI3Ks are heterodimers of a p85/p55/p50 regulatory 
subunit complexed to a p110 subunit. Class IB PI3Ks are heterodimers of a p84/p101 regula-
tory subunit complexed to a speciﬁc p110 subunit. Class II PI3Ks consist of only a catalytic 
subunit. Class III PI3K is a heterodimer of a p150 protein kinase in complex with the human 
homologue of VPS34. The kinase speciﬁcity of each PI3K class is detailed further in Fig. 
1.13. (B) Larger schematic representation of the p85 regulatory subunit of class IA PI3K 
(724 amino-acids long). p85 consists of an N-terminal SH3 (Src homology 3) domain, a BH 
(B-cell receptor homology) domain, and two SH2 (Src homology 2) domains (N-terminal: 
nSH2, and C-terminal: cSH2), which ﬂank the inter-SH2 (iSH2) domain. The iSH2 domain 
binds the p110 catalytic subunit of PI3K. Asterisks denote two proline-rich regions within the 
p85 protein. Schematic modiﬁed from Hawkins et al., 2006.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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phosphorylation of consensus YXXM motifs in activated growth factor receptors (or 
their specific adaptor substrates, including the insulin receptor substrates: IRS1-IRS-
4), provides docking sites for the two p85 SH2 domains and relieves the effect of p85 
on p110 (Carpenter et al., 1993a, Rordorf-Nikolic et al., 1995). Binding to the BH 
domain of p85 by GTPases such as Cdc42 or Rac have also been shown to increase 
the activity of the p85:p110 heterodimer (Tolias et al., 1995, Zheng et al., 1994). In 
contrast, a novel adapter protein, Ruk, can interact with the N-terminal SH3 domain 
of p85 and negatively regulate PI3K (Gout et al., 2000). Additional direct 
phosphorylations of p85 also determine p110 activity: Src kinase-mediated 
phosphorylation of tyrosine-688 alleviates p110 inhibition (Cuevas et al., 2001), 
whilst autophosphorylation of serine-608 restores inhibition (Foukas et al., 2004). 
Thus, docking of adapter proteins to particular domains, or phosphorylation of key 
residues, probably induces conformational changes in p85 that are transmitted to p110 
and affect its catalytic activity (Fig. 1.15). It should be noted that p110 itself can also 
be directly regulated by other host-cell proteins, such as activated Ras (Rodriguez-
Viciana et al., 1994, Rodriguez-Viciana et al., 1996). 
 
The generation of PtdIns(3,4,5)P3 is countered by the lipid phosphatases PTEN 
(phosphatase and tensin homologue deleted on chromosome ten), and SHIP1/SHIP2 
(SH2 domain-containing inositol 5'-phosphatases). PTEN acts to convert 
PtdIns(3,4,5)P3 to PtdIns(4,5)P2, whilst SHIP1/SHIP2 dephosphorylate the 5'-OH of 
PtdIns(3,4,5)P3 to produce PtdIns(3,4)P2 [reviewed in (Cantley, 2002, 
Vanhaesebroeck et al., 2005)]. PTEN is a tumour suppressor protein that is often 
mutated or deleted in a variety of different human cancers (Cantrell, 2001). Cells 
lacking functional PTEN have increased levels of PtdIns(3,4,5)P3 and PtdIns(3,4)P2, 
which leads to the constitutive activation of signalling pathways downstream of class 
Fig. 1.15.  Model for class IA p85-p110 lipid kinase (PI3K) regulation. The interaction of 
p85 with p110 functions to stabilise the heat-labile p110 subunit, as well as inhibit its cata-
lytic activity. p85 interacts with the N-terminus of p110 via the coiled-coil inter-SH2 domain 
of p85, but another interaction (via a putative leucine zipper region) has been postulated. The 
PtdIns inositol ring is represented by a hexagon that contacts the C-terminus of p110 and 
possibly the inter-SH2 domain of p85. As p85 and p110 are obligate heterodimers, release of 
p85-mediated inhibition of p110 occurs via inter- and intra- molecular steric changes: bind-
ing of the two SH2 domains of p85 to phospho-tyrosines (pY) in activated cell surface recep-
tors, Src kinase-mediated phosphorylation of tyrosine-688 in p85, or binding of GTPases to 
the p85 BH domain. Ras can also directly activate p110 lipid kinase activity. PI3K catalytic 
activity is negatively regulated by Ruk binding to the SH3 domain of p85, as well as the au-
tophosphorylations of serine-608 in p85, and/or serine-1039 in p110. Legend as for Fig. 1.14. 
Diagram reproduced from Vanhaesebroeck et al., 1999.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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I PI3K (see below). Members of the SHIP phosphatase family mediate an important 
inhibitory role in lymphocytes, and loss of SHIP1/SHIP2 can lead to unbalanced 
immune responses and/or autoimmune problems [reviewed in (Cantrell, 2001, 
Vanhaesebroeck et al., 2005)]. 
 
1.3.4 Signalling downstream of PI3K. 
Membrane-associated PtdIns(3,4,5)P3 (generated by active PI3Ks) causes the specific 
recruitment of proteins containing pleckstrin homology (PH) domains [reviewed in 
(Hawkins et al., 2006)] (Fig. 1.16). Thus, PI3K activity is “interpreted” by multiple 
primary effectors, which will have a large influence on a variety of signalling 
cascades. Indeed, upwards of ~20 different PtdIns(3,4,5)P3-binding proteins (with PH 
domains) have been identified from a single cell-type (Krugmann et al., 2002). The 
serine/threonine protein kinase Akt (also known as protein kinase B; PKB) is perhaps 
one of the best understood (and arguably most important) PH-domain containing 
PI3K effectors (Fig. 1.16), and is ubiquitously expressed in all cell-types [reviewed in 
(Manning & Cantley, 2007)]. Although the remainder of this section (and thesis) will 
focus on the activation and downstream effects of Akt, it should be kept in mind that 
other effectors exist. Indeed, there are at least three different Akt isoforms (Manning 
& Cantley, 2007). Thus, the functional consequences of PI3K activation are likely to 
extend well beyond Akt signalling, and may display cell-type, temporal, or spatial 
specificity. As such, the differential metabolism of phosphoinositides may act as a 
“regulatable scaffold”, which influences the protein composition (and subsequent 
signalling) in a particular membrane location (Hawkins et al., 2006). 
 
Akt is activated by phosphorylation at two sites: Thr308 and Ser473. 
PtdIns(3,4,5)P3/PH domain-dependent membrane recruitment of PDK1 
Fig. 1.16.  Downstream of PI3K: Akt. Model for PI3K-dependent Akt activation. The serine/
threonine protein kinase Akt (also known as PKB; protein kinase B), is a major downstream 
effector of  class IA PI3K signalling. In response to increased PtdIns(3,4,5)P
3
, both PDK1 
(phosphoinositide-dependent kinase-1) and Akt are recruited to the plasma membrane via 
PtdIns(3,4,5)P
3
-binding PH (pleckstrin homology) domains. The constitutively active PDK1 
is therefore brought into close proximity with Akt, and phosphorylates Akt at Thr308 (T308) 
in its activation loop. Ser473 (S473) is then further phosphorylated by the mTORC2 protein 
complex in a PI3K-dependent, PDK1-independent, manner. Phosphorylation of Ser473 may 
act to regulate the degree of Akt activation once Thr308 has been phosphorylated by PDK1, 
although both phosphorylations are necessary for the full activation of Akt. Diagram modi-
ﬁed from Hawkins et al., 2006.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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(phosphoinositide-dependent kinase-1) brings this kinase into close proximity with 
Akt, which is also recruited to the plasma membrane in a PtdIns(3,4,5)P3/PH domain-
dependent fashion [reviewed in (Hawkins et al., 2006, Manning & Cantley, 2007)]. 
The increase in “effective concentration” of these two enzymes allows the 
constitutively active PDK1 to phosphorylate Akt at Thr308 in its activation loop (Fig. 
1.16). PI3K also stimulates the function of the multi-protein mTORC2 complex, 
which contains mTOR, Rictor, SIN1, and mLST8 (Bayascas & Alessi, 2005, Brazil et 
al., 2004, Manning & Cantley, 2007). The exact upstream mechanism of this 
regulation is unclear, but mTORC2 is responsible for phosphorylating Akt at Ser473 
in its hydrophobic motif, thus causing full PI3K-dependent activation of Akt 
(Manning & Cantley, 2007). There are over 100 reported protein substrates 
immediately regulated by Akt phosphorylation, and some Akt substrates control more 
than one cellular function, which often varies in a cell- and signal- dependent manner 
[reviewed in (Manning & Cantley, 2007)]. It is impossible to describe all of these 
targets/activities, however a number of common (and sometimes overlapping) themes 
relating to Akt activity can be inferred, particularly with respect to cell survival, 
growth, and proliferation (Fig. 1.17). 
 
1.3.4.1 PI3K-Akt and anti-apoptosis. 
A major and critical role for Akt is to promote cell survival downstream of growth 
factors, oncogenes, and cell stress. The Bcl-2 homology domain 3 (BH3)-only family 
of proteins normally exert a pro-apoptotic effect by binding to and inactivating the 
pro-survival Bcl-2 proteins at the mitochondrial membrane (Manning & Cantley, 
2007). Active Akt blocks the function of these BH3-only proteins at several levels. 
Firstly, Akt can directly phosphorylate some BH3-only proteins (i.e. BAD), causing 
their cytosolic sequestration and inactivation by 14-3-3 proteins (Cooray, 2004, Datta 
Fig. 1.17. Akt/PKB substrates and physiological functions. Activated Akt/PKB can phos-
phorylate >100 different proteins (10 examples shown), which regulates various cellular 
processes (e.g. survival, growth, proliferation, glucose uptake, metabolism, and angiogen-
esis). Akt/PKB-mediated phosphorylation of its substrates leads to their activation (arrows) 
or inactivation (blocked arrows). Diagram reproduced from Manning & Cantley, 2007.
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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et al., 1997, Datta et al., 2000, del Peso et al., 1997). The 14-3-3 cytosolic regulatory 
proteins generally act to cause conformational changes in proteins they bind to, and 
thus mask/reveal functional motifs that control the localisation, activity, 
phosphorylation status and/or stability of the target protein [reviewed in (Dougherty 
& Morrison, 2004)]. Akt can also directly limit the expression of several BH3-only 
proteins by phosphorylating and inactivating FOXO (also known as Forkhead; 
FKHR) transcription factors, which may additionally be sequestered and inactivated 
by 14-3-3 proteins (Tran et al., 2003) [it should be noted that phosphorylation of 
FOXO/FKHR transcription factors also reduces the expression of the pro-apoptotic 
cytokine, Fas ligand (FasL) (Brunet et al., 1999)]. Further, the expression of some 
pro-apoptotic BH3-only proteins (specifically Puma and Noxa) is reduced by Akt-
mediated phosphorylation of the E3 ubiquitin ligase, MDM2 (also known as HDM2 
in humans), which is translocated into the nucleus and negatively regulates the 
transcriptional activity of p53 (Manning & Cantley, 2007, Mayo & Donner, 2001, 
Zhou et al., 2001b). 
 
Active Akt can also phosphorylate and inactivate the serine/threonine protein kinase, 
glycogen synthase kinase-3 (both GSK-3α and GSK-3β isoforms) [reviewed in 
(Manning & Cantley, 2007)]. Inhibition of GSK-3β function leads to increased 
activity of the pro-survival Bcl-2 protein, MCL-1 (Maurer et al., 2006), which 
together with other Bcl-2 proteins (see above) acts to limit the release of cytochrome 
c from mitochondria [reviewed in (Manning & Cantley, 2007)]. This prevents the 
proteolytic cleavage of procaspase-9, thus blocking the “initiator” effect of mature 
caspase-9 on the pro-apoptotic caspase cascade. In addition, Akt has been reported to 
directly phosphorylate procaspase-9, thus rendering it less proteolytically active 
(Cardone et al., 1998). 
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1.3.4.2 PI3K-Akt and cell growth. 
Akt-mediated activation of a Raptor-containing mTOR complex (mTORC1: 
consisting mTOR, mLST8, and Raptor) plays an essential function in increasing cell 
growth (protein and membrane synthesis) in response to nutrients and growth factor 
signalling [reviewed in (Manning & Cantley, 2007)]. Akt directly phosphorylates and 
inactivates the tuberous sclerosis complex 2 (TSC2), and thereby indirectly activates 
mTORC1 (Manning et al., 2002, Potter et al., 2002). Additionally, phosphorylation of 
the mTORC1 inhibitor, PRAS40, by Akt causes it to dissociate from mTORC1 and be 
sequestered by 14-3-3 proteins, thus releasing the PRAS40-mediated inhibition of 
mTORC1 (Kovacina et al., 2003, Sancak et al., 2007). mTORC1 enhances protein 
synthesis by modulating the activities of both p70S6K and 4E-BP1 (eukaryotic 
initiation factor 4E (eIF4E)-binding protein 1), which act to regulate ribosome 
biogenesis and translation initiation (Manning & Cantley, 2007). Inhibition of 4E-
BP1 by mTORC1 phosphorylation leads to the activation of eIF4E, and thus promotes 
the cap-dependent translation of numerous target mRNAs (Mamane et al., 2004). In 
addition, lipid membrane synthesis (an essential requirement for cell growth) may be 
enhanced by the Akt-mediated phosphorylation and activation of ATP-citrate lyase 
(Berwick et al., 2002). 
 
1.3.4.3 PI3K-Akt and cell proliferation. 
Akt-dependent phosphorylation of the cyclin-dependent kinase inhibitors p21Cip1/WAF1 
and p27Kip1 causes their cytosolic sequestration by 14-3-3 proteins, and leads to cell-
cycle progression (Liang et al., 2002, Sekimoto et al., 2004, Shin et al., 2002, 
Viglietto et al., 2002, Zhou et al., 2001a, Zhou et al., 2001b). Akt also regulates 
p21Cip1/WAF1 and p27Kip1 protein levels by decreasing the activity of p53 and 
FKHR/FOXO transcription factors (see above) (Collado et al., 2000, Dijkers et al., 
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2000, Mayo & Donner, 2001, Medema et al., 2000, Zhou et al., 2001b). GSK-3β may 
also contribute to driving cell proliferation. Akt-mediated phosphorylation (and thus 
inactivation) of GSK-3β prevents GSK-3β from targeting β-catenin for proteasome-
mediated degradation. This leads to the accumulation of β-catenin protein, and an 
increase in the transcription of genes such as cyclin D1 and c-myc, the encoded 
proteins of which are involved in cell-cycle entry or phase transition (Manning & 
Cantley, 2007). The Akt-mediated phosphorylation/inactivation of GSK-3β also 
directly stabilises the protein levels of cyclin D, cyclin E, c-jun, and c-myc by 
preventing their proteasome-mediated degradation (Diehl et al., 1998, Manning & 
Cantley, 2007, Welcker et al., 2003) . In addition, it is likely that translational effects 
downstream of mTORC1/4E-BP1 (see above) contribute significantly to cell 
proliferation [reviewed in (Manning & Cantley, 2007)]. 
 
1.3.4.4 PI3K-Akt and cytokine production/signalling. 
Recent work has uncovered an important role for the PI3K-Akt signalling pathway in 
regulating the host innate immune response downstream of cell-surface Toll-like 
receptors (TLRs). TLRs recognise a number of microbial products (often termed 
pathogen-associated molecular patterns (PAMPs)), and can trigger the production of 
various immunomodulatory cytokines, including IFNα/IFNβ, TNFα, and interleukin-
12 (IL-12) (Fukao & Koyasu, 2003). IL-12 is a key regulator of host innate and 
adaptive immune responses during infection: it enhances the cytolytic activity of 
natural killer (NK) cells and CD8+ T-cells, and contributes to the optimal production 
of IFN-γ (Trinchieri, 1995). In dendritic cells (DCs), the synthesis of IL-12 is 
negatively regulated by active PI3K-Akt signalling (Fukao et al., 2002). Interestingly, 
the PI3K pathway is also implicated in limiting TNFα induction (Guha & Mackman, 
2002). 
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The role of PI3K in IFNβ production is somewhat controversial and confusing, and 
may be cell-type specific. Studies done in 293 cells have shown PI3K and Akt to be 
essential for TLR3-mediated IFNβ induction (Sarkar et al., 2004). Such PI3K-
mediated activation is not required for the nuclear localisation or dimerisation of the 
IRF-3 transcription factor, but appears to regulate the full activation of IRF-3 by 
hyperphosphorylation (Sarkar et al., 2004). However, similar to the situation with IL-
12 synthesis, recent work using DCs has proposed a role for active PI3K in the 
negative regulation of IFNβ production in response to extracellular TLR 
(TLR3/TLR4) ligands (such as the dsRNA analogue, poly I:C), a mechanism likely to 
involve a limitation of NFκB transcriptional activity (Aksoy et al., 2005). It is not 
known if PI3K is also involved in the regulation of IFNα/IFNβ production 
downstream of the intracellular viral PAMP receptors, RIG-I and mda-5. However, 
tissue-culture studies on two types of viruses that can induce IFN via RIG-I (namely, 
influenza A viruses and flaviviruses) have shown PI3K inhibitors and/or dominant 
negative constructs dramatically prevent virus-induced IFNβ promoter activity 
(Chang et al., 2005, Ehrhardt et al., 2006). 
 
The PI3K pathway is also implicated in IFN-mediated signalling, independent of 
classical JaK-STATs (Janus kinase; signal transducer and activator of transcription) 
[reviewed in (Kaur et al., 2005)]. Receptor binding of IFNα/IFNβ induces the 
tyrosine phosphorylation of IRS1/IRS2 adapter proteins, and the IFN-dependent 
recruitment and activation of p85:p110 heterodimers (Platanias et al., 1996, Uddin et 
al., 1995). IFNα/β-induced, IRS-mediated, and STAT-independent PI3K stimulation 
increases both the lipid kinase and serine kinase activities of PI3K, although the 
functional consequences of these events are unclear (Platanias, 2005, Platanias et al., 
1996). As STAT-dependent anti-viral effects of IFNs can be partly attributed to the 
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PKR-mediated inhibition of viral mRNA translation (see section 1.2), one hypothesis 
is that IFN-induced PI3K activation may contribute to the selective regulation of 
cellular mRNA translation initiation, thus ensuring the production of other IFN-
induced anti-viral proteins (Platanias, 2005). To this end, IFN has been shown to 
activate a PI3K-dependent, STAT-independent, mTOR-p70S6K/4E-BP1 pathway 
(Lekmine et al., 2003), although how cellular versus viral mRNA translation might 
possibly be selected for is not known. 
 
Specific PI3K activation by IFNγ has an important role in IFNγ-induced 
transcriptional regulation [reviewed in (Platanias, 2005)]. PI3K causes the IFNγ-
dependent phosphorylation of STAT1 at Ser727, which although not essential for the 
dimerisation or nuclear translocation of STAT1, contributes significantly to STAT1-
driven transcription (Nguyen et al., 2001). Mechanistically, this involves the PI3K-
dependent activation of PKCδ (protein kinase C, δ isoform) that directly 
phosphorylates STAT1 at Ser727 (Deb et al., 2003), and leads to the induction of pro-
apoptotic genes (DeVries et al., 2004). Although IFNs are widely implicated in 
contributing to apoptosis, it seems surprising that PI3K is involved given its well-
documented anti-apoptotic roles. However, in response to IFNs, the PI3K signalling 
pathway can mediate either pro- or anti- apoptotic signals, which probably depends 
upon the cellular context and the simultaneous activation of other cytokine-induced 
signalling pathways (e.g. by TNFα) (Platanias, 2005, Yang et al., 2001). 
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1.4 PI3K signalling and virus infections. 
Given the diverse array of cellular processes regulated by signalling downstream of 
PI3K, it is not surprising that viruses hijack this pathway in order to support their own 
replication. In particular, activating PI3K is a popular means of delaying virus-
induced cell-death and/or apoptosis. During acute virus infections, increased short-
term cell viability is likely to increase efficient replication, whilst for more chronic 
infections PI3K signalling can modify the cell cycle, and may contribute towards 
latency or transformation. However, viral activation of this pathway is clearly 
important for functions independent of cell survival, including virus entry, 
RNA/protein synthesis, persistence, and immunomodulation. Additionally, some 
DNA and RNA viruses actually down-regulate PI3K signalling during infection. 
Thus, it is possible that the requirement and/or consequences of PI3K signalling for 
virus replication may depend upon a range of factors, including the host species, cell-
type, or stage of infection.  
 
It should be stressed that although many viruses have been reported to affect the PI3K 
signalling pathway, it is often unclear whether this kinase is actively stimulated by the 
pathogen, or if activation is simply a cellular response to infection (for examples see 
section 1.3). Furthermore, it has yet to be determined if PI3K activation globally 
stimulates all substrates downstream of it, or if additional (spatial/temporal) 
regulation at distinct levels of the pathway ensure the mediation of particular signals. 
Thus, although many investigations report upon specific virus-modulated PI3K-
dependent pathways, it may be that virus-activated PI3K does not discriminate with 
regards its normal cellular targets. With this in mind, viral strategies to modulate 
components of the PI3K pathway are detailed (as they have been reported) in the text 
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below. DNA virus families are dealt with first, followed by RNA virus families 
(indicated within parentheses). 
 
1.4.1 PI3K and the Adenoviridae family (DNA). 
Binding of the adenovirus (AdV) capsid penton to cell-surface integrins not only 
initiates the PI3K-dependent uptake (endocytosis) of virions (Li et al., 1998a), but has 
been shown to stimulate the PI3K-dependent induction of TNFα and the maturation 
of dendritic cells (Philpott et al., 2004). Additionally, the E4-ORF1 oncoproteins of 
some AdV subtypes bind directly to PDZ domain-containing proteins and directly 
stimulate PI3K activity, thereby inducing the phosphorylations of Akt and p70S6K 
(Frese et al., 2003). This also causes GSK-3β phosphorylation, stabilizes β-catenin 
levels, and decreases the activity of the FKHR transcription factor (Frese et al., 2003, 
Zhang et al., 2004). These signalling events have been associated with AdV-mediated 
mammary tumourigenesis (Frese et al., 2003), selective endothelial cell survival 
(Rajala et al., 2005, Zhang et al., 2004), gap junction expression, and vascular 
angiogenesis (Zhang et al., 2004, Zhang et al., 2005). In contrast to the stimulation of 
PI3K by virus binding or E4-ORF1 activity, the AdV E1A protein can down-regulate 
the basal level of Akt phosphorylation in some human cell-types (probably by acting 
upstream of PI3K), and can thus potentiate apoptosis and tumour suppression 
(Viniegra et al., 2002). This function of E1A is remarkable, given that E1A was 
originally described as a transforming oncoprotein in rodent cells [reviewed in (Frisch 
& Mymryk, 2002)].  
 
1.4.2 PI3K and the Hepadnoviridae family (DNA). 
Hepatitis B virus (HBV; Hepadnoviridae) causes acute liver disease, although ~10% 
of infections become chronic and may subsequently result in the development of 
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hepatocellular carcinoma (Cooray, 2004). The HBV X protein is multifunctional, and 
regulates a variety of host-cell processes which may contribute to HBV-induced 
transformation [reviewed in (Murakami, 1999)]. In particular, HBV X activates a Src 
(and possibly Ras)-mediated, PI3K-dependent signalling cascade involving the 
phosphorylation and activation of Akt, the phosphorylation of BAD, and the down-
regulation of caspase-3 (Klein & Schneider, 1997, Lee et al., 2001, Shih et al., 2003). 
These processes have been linked to increased cell viability during HBV infections 
(Lee et al., 2001), and it has been noted that the X protein can specifically prevent 
apoptosis induced by transforming growth factor β (TGFβ) (Shih et al., 2000). In 
addition, the PI3K activating function of HBV X leads to the overexpression of 
matrix metalloproteinase-9, the secretion of which causes breakdown of the extra-
cellular matrix, and may be responsible for the increased likelihood of HBV-infected 
tumour cells spreading (Chung et al., 2004). 
 
1.4.3 PI3K and the Herpesviridae family (DNA). 
Epstein-Barr virus (EBV; Herpesviridae) is associated with the development of both 
lymphoid (B-cell) and epithelial tumours [reviewed in (Rickinson & Kieff, 2001). 
Transformation of B-cells is linked to the expression of a limited set of latent viral 
genes, including the integral membrane proteins LMP1 and LMP2A [reviewed in 
(Rickinson & Kieff, 2001)]. LMP1 is the major transforming protein of EBV 
(Dawson et al., 2003), and can act as a constitutively activate viral homologue of the 
cellular TNF receptor (TNFR) superfamily (Gires et al., 1997). The cytoplasmic tail 
of LMP1 recruits a number of signalling adapter proteins, and upregulates many host-
cell pathways [reviewed in (Rickinson & Kieff, 2001)]. Oligomerised LMP1 can also 
interact with the PI3K p85 subunit, potentially bringing it into contact with other 
activating signals at the plasma membrane, and causing constitutive PI3K-Akt activity 
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(Dawson et al., 2003).  This not only provides a cell survival signal, but also induces 
actin remodelling associated with cell migration, both factors which could contribute 
to B-cell transformation and/or EBV persistence (Dawson et al., 2003). 
 
The other latency-associated EBV integral membrane protein, LMP2A, also causes 
the PI3K-dependent phosphorylations of Akt, GSK-3β, and FKHR (Morrison et al., 
2003, Swart et al., 2000). However, as LMP2A is not associated with B-cell survival 
(Speck et al., 1999), this activity may regulate another function in lymphoid tissues, 
such as cell-cycle progression (Swart et al., 2000). In epithelial cells (often the first 
cell-type infected by EBV), LMP2A-mediated PI3K activation likely contributes to 
anchorage-independent cell growth and survival (Scholle et al., 2000). Thus, LMP2A 
may play an important role in early virus spread, and ultimately in epithelial cell 
tumour development. In addition to the contribution of LMP1- and LMP2A- mediated 
PI3K activation in EBV-induced lymphoid and epithelial cell survival, PI3K-Akt 
signalling is also necessary for EBV reactivation from latency (Darr et al., 2001). 
Indeed, the viral BRLF1 protein activates PI3K and disrupts EBV latency, thereby 
inducing the lytic form of EBV (Darr et al., 2001). As EBV expresses several proteins 
that modulate PI3K signalling at different stages of its latent/lytic replication cycle, it 
is clear that the overall regulation of this pathway during infection is complex. 
 
A number of other herpesviruses modulate the activity of PI3K pathway components 
by various means, and for various reasons: Kaposi's sarcoma-associated herpesvirus 
(KSHV) latency-associated nuclear antigen (LANA), and the herpesvirus saimiri 
homologue ORF73, both bind to GSK-3β and sequester it in the nucleus, thus 
stabilising β-catenin levels and stimulating β-catenin-dependent transcription 
(Fujimuro & Hayward, 2003, Fujimuro et al., 2003); Varicella-Zoster virus (VZV) 
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activates a PI3K-Akt-GSK-3β pathway to enhance virus replication, a process 
dependent upon expression of two VZV kinases: ORF47 and ORF66 (Rahaus et al., 
2007); Herpes simplex virus type-1 (HSV-1) infection induces the early (anti-
apoptotic) PI3K-dependent phosphorylation of Akt at Ser473, which is then down-
regulated by the late expression of the HSV-1 U(S)3 serine/threonine protein kinase 
via an unknown mechanism (Benetti & Roizman, 2006); and human cytomegalovirus 
(hCMV) activates a PI3K-Akt-p70S6K-NFκB response in order to upregulate cellular 
gene expression and promote the transcription/translation of hCMV immediate-early 
genes, which may promote hCMV DNA replication (Johnson et al., 2001). 
 
1.4.4 PI3K and the Papillomaviridae family (DNA). 
Human papillomavirus (HPV) usually causes benign epithelial warts, but some high-
risk sub-types (such as HPV-16) are associated with severe cervical and urogenital 
cancers [reviewed in (zur Hausen, 2002)]. HPV-16 E5 protein associates with the 
cellular epidermal growth factor (EGF) receptor, and can augment the EGF-induced 
stimulation of PI3K-Akt-BAD, resulting in reduced sensitivity of cells to apoptosis 
(Zhang et al., 2002). Intriguingly, the HPV-16 E7 protein (a major oncoprotein), also 
contributes to this phenotype (Pim et al., 2005). E7 binds to the two subunits of 
protein phosphatase 2A (PP2A), and prevents PP2A from dephosphorylating Akt, 
thus maintaining activation of cell survival signalling (Pim et al., 2005). 
 
1.4.5 PI3K and the Polyomaviridae family (DNA). 
 
The polyomavirus “tumour” (or “T”) antigens are produced early during infection, 
and stimulate cellular DNA replication leading to the re-entry of resting cells into the 
cell cycle (Cooray, 2004). The middle “T” antigen (MT) of murine polyomavirus can 
be tyrosine-phosphorylated by cellular Src-kinases, and the resulting phospho-motifs 
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in MT provide consensus docking sites for the SH2 domains of p85 subunits 
(Courtneidge & Heber, 1987, Kaplan et al., 1987, Talmage et al., 1989, Yoakim et 
al., 1992). In this way, phosphorylated MT is associated with increased anti-apoptotic 
PI3K-Akt activity (Dahl et al., 1998, Whitman et al., 1985), a process likely to 
contribute to MT-induced transformation (Dahl et al., 1998, Whitman et al., 1985). In 
addition, the large “T” antigen (LT) of some human neurotropic polyomaviruses can 
bind directly to β-catenin, inducing its nuclear accumulation, and increasing 
transcription of β-catenin-dependent genes (Gan & Khalili, 2004). Thus, 
polyomaviruses can act via different mechanisms (and at different levels) in order to 
activate unique, virus-specific components of the PI3K pathway.  
 
1.4.6 PI3K and the Coronaviridae family (RNA). 
 
The severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV; 
Coronaviridae) was identified as an emerging and important infectious disease agent 
in 2003 (Ksiazek et al., 2003, Rota et al., 2003). SARS-CoV infection of Vero-E6 
cells has been demonstrated to cause the transient phosphorylation (Ser473) of Akt 
(Mizutani et al., 2004), which may delay virus-induced apoptosis and contribute 
towards the establishment of persistent tissue-culture infections (Mizutani et al., 2004, 
Mizutani et al., 2005). The mechanism of Akt phosphorylation during SARS-CoV 
infection is controversial, but appears to require active replication and PI3K function 
(Mizutani et al., 2004). Additionally, one study has demonstrated that vaccinia virus-
mediated expression of the SARS-CoV N (nucleocapsid) protein (but not Green 
Fluorescent Protein; GFP) is sufficient to cause Akt phosphorylation (Ser473) in 
Vero-E6 cells (Mizutani et al., 2006). However, work in COS-1 cells previously 
showed that N expression actually induces a host apoptotic response, and no striking 
differences in Akt phosphorylation (Thr308) were observed (Surjit et al., 2004). The 
1. Introduction 
(iv) Viruses and PI3K 
- 57 - 
situation is also complicated by possible roles for the SARS-CoV S (spike) and M 
(membrane) proteins in de-regulating Akt signalling (Chan et al., 2007, Liu et al., 
2007). Indeed, expression of M protein in Drosophila cells has been shown to cause 
the de-phosphorylation of Akt, and is pro-apoptotic (Chan et al., 2007). Clearly, more 
work is needed to clarify the temporal activity and functions of PI3K-Akt signalling 
during SARS-CoV infections. 
 
1.4.7 PI3K and the Flaviviridae family (RNA). 
Viruses of the Flaviviridae family are enveloped, with a single-stranded positive 
sense RNA genome. They are perhaps within one of the most characterised RNA 
virus families with regards viral interaction with host-cell PI3K. Hepatitis C virus 
(HCV; Flaviviridae; hepacivirus) is a major public health concern, and commonly 
establishes long-term infections culminating in chronic inflammation, cirrhosis, and 
hepatocellular carcinoma [reviewed in (Cooray, 2004, Street et al., 2005)]. The HCV 
NS5A protein interacts with the p85:p110 heterodimer by binding directly to the SH3 
domain of p85 (He et al., 2002b, Street et al., 2004). Although NS5A clearly 
increases the lipid kinase activity of PI3K (Street et al., 2004), the mechanism of 
activation is unclear. For example, the interaction between NS5A and p85 appears to 
be enhanced in vivo by EGF stimulation, and NS5A has been suggested to form a 
heterotrimeric complex consisting NS5A, p85, and Gab1 (an EGF receptor docking 
protein) (He et al., 2002b). Thus, NS5A may promote the interaction of p85:p110 
heterodimers with active Gab1:EGFRs, thereby increasing EGF-induced PI3K 
activity (Cooray, 2004, He et al., 2002b). This would be consistent with the 
observation that expression of NS5A in mammalian cells only significantly increases 
p85 tyrosine phosphorylation (a marker of active PI3K) in response to EGF 
stimulation (He et al., 2002b). However, in vitro experiments have shown that 
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baculovirus- (but not E. coli-) expressed and purified NS5A can directly increase the 
lipid kinase activity associated with p85 immunoprecipitates (M. Harris, personal 
communication), suggesting that membrane and/or receptor recruitment of p85:p110 
is not essential for NS5A-mediated PI3K activation (Street et al., 2004), and that 
eukaryotic post-translational modification of NS5A (such as phosphorylation 
[reviewed in (Macdonald & Harris, 2004)]) may be necessary. 
 
The effect of NS5A on PI3K causes an increase in the Ser473 phosphorylation (and 
kinase activity) of Akt (He et al., 2002b, Street et al., 2004, Street et al., 2005). 
Downstream of Akt, BAD and GSK-3β have been identified as phosphorylation 
substrates of NS5A-activated PI3K (He et al., 2002b, Street et al., 2004, Street et al., 
2005). As consequences of these phosphorylation events, NS5A has been reported to 
stimulate β-catenin dependent transcription, as well as reduce the transcriptional 
activity of FOXO/FKHR (Street et al., 2005). Additionally, HCV can stimulate 
mTOR activity downstream of Akt, and thus induces the activation of p70S6K and 
the inactivation of 4E-BP1, thus leading to overall translational enhancement 
(Mannova & Beretta, 2005). 
 
The biological consequences of NS5A activating the PI3K signalling pathway are not 
entirely known, although anti-apoptotic and some translational effects have clearly 
been demonstrated (Mannova & Beretta, 2005, Street et al., 2004). Thus, by limiting 
cell-death, NS5A-activated PI3K may augment the persistence of HCV infections, a 
factor which could contribute to the development of infection-associated chronic liver 
disease and carcinoma (He et al., 2002b, Street et al., 2004, Street et al., 2005). 
 
Two flavivirus members of the Flaviviridae family (namely, DEN and JEV) have also 
been reported to activate PI3K-Akt signalling in order to counter virus-induced 
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apoptosis (Lee et al., 2005). Intriguingly, activation occurs at an early stage of 
infection (possibly virus binding), and appears to require intact lipid-rafts (Lee et al., 
2005). DEN- and JEV- induced Akt phosphorylation peaks during the first few hours 
of infection and then subsides, although the mechanism behind this negative-
regulation is unknown (Lee et al., 2005). Despite the anti-apoptotic function of this 
pathway during infection, PI3K inhibitors have little effect on DEN and JEV RNA 
synthesis or protein levels, suggesting that these viruses [unlike HCV (Mannova & 
Beretta, 2005)] do not absolutely require host PI3K-mediated translational functions 
(Lee et al., 2005). However, the absolute role of PI3K during flavivirus infections is 
complicated by the report implicating PI3K as an essential mediator of JEV- and 
DEN- induced IFNβ production (Chang et al., 2005). Similarly, although some 
biotypes of Bovine Viral Diarrhoea Virus (BVDV; Flaviviridae; pestivirus) can 
induce Akt phosphorylation during infection (Bendfeldt et al., 2007), it is unclear 
whether this is functionally virus-mediated, or if it is part of the cellular anti-viral 
response. 
 
1.4.8 PI3K and the Paramyxoviridae family (RNA). 
Human respiratory syncytial virus (hRSV; Paramyxoviridae; pneumovirus) is a 
globally important cause of lower respiratory tract disease in young children 
[reviewed in (Collins et al., 2001)]. hRSV infection of tissue-culture cells induces the 
lipid kinase activity of PI3K, and the subsequent PI3K-dependent phosphorylations of 
Akt and GSK-3β (Thomas et al., 2002). PI3K activation during hRSV infection 
appears to be transient – phosphorylation of Akt is first detectable ~30 mins after 
infection, and is maintained until at least 6h post-infection (Thomas et al., 2002). 
Interestingly, phospho-Akt/phospho-GSK-3β is undetectable at ~24h post-infection, 
although total levels of Akt/GSK-3β are unaffected (Thomas et al., 2002). hRSV-
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induced PI3K-dependent phosphorylation of Akt causes the activation of the E3-
ubiquitin ligase, MDM2, which targets the pro-apoptotic tumour suppressor, p53, for 
proteasome-mediated degradation (Groskreutz et al., 2007). Although, the mechanism 
of hRSV-induced PI3K activation is unclear, specific siRNA-mediated knock-down 
of either NS1 or NS2 mRNAs during infection has been shown to completely 
abrogate the phosphorylation of Akt (Bitko et al., 2007). Similarly, viruses unable to 
express either NS1, NS2 (or both NS1 and NS2) are unable to cause Akt 
phosphorylation (Bitko et al., 2007). Thus, studies using such NS1/NS2-deleted 
viruses (as well as work done with inhibitors of PI3K) have lead to the proposition 
that PI3K activation during hRSV infection induces the Akt-MDM2 pathway to 
reduce levels of p53, and thereby limit virus-induced apoptosis (Bitko et al., 2007, 
Groskreutz et al., 2007, Thomas et al., 2002). 
 
Suppression of immune functions is a major contributory factor associated with infant 
deaths during acute measles virus (MV; Paramyxoviridae; paramyxovirus) infections 
(Avota et al., 2001). This immunosuppression is thought to be caused by the co-
interaction of both MV fusion (F) and haemagglutinin (H) glycoproteins with the 
lipid-raft surfaces of T-cells (Avota et al., 2004), which has been shown to reduce T-
cell proliferation in vitro (Avota et al., 2001, Schlender et al., 1996). This cell-surface 
contact event appears to specifically prevent IL-2-induced phosphorylation of Akt 
(Ser473), as (surprisingly) it does not affect BAD phosphorylation (Avota et al., 
2001, Avota et al., 2004). Thus, MV modulates T-cell immune function without 
sensitizing the cell to apoptosis (Avota et al., 2001). Mechanistically, contact of MV 
with T-cell lipid rafts induces the nuclear translocation of splicing proteins, which 
specifically upregulate expression of the lipid phosphatase, SIP110 (Avota et al., 
2006). SIP110 can dephosphorylate PtdIns(3,4,5)P3, and thus depletes the cellular 
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reservoir of this second messenger that would otherwise cause sustained Akt 
phosphorylation (Avota et al., 2006). Additionally, contact of MV glycoproteins with 
T-cell lipid rafts may stabilize the levels of Cbl-b, a cellular protein that can 
chaperone the PI3K p85 subunit away from lipid raft signalling hubs (Avota et al., 
2004), thereby attenuating PtdIns(3,4,5)P3 generation. 
 
1.4.9 PI3K and the Picornaviridae family (RNA). 
 
Studies on human rhinovirus type-2 (hRV2; Picornaviridae) and enterovirus-71 
(EV71; Picornaviridae) have demonstrated a role for PI3K in the transport of 
internalized virion particles from early vesicles to late (low pH) endosomes (Brabec et 
al., 2006, Wong et al., 2005). Indeed, an early receptor (integrin) binding event 
mediated by the VP-1 capsid protein has been shown to induce Akt phosphorylation 
during Foot-and-Mouth disease virus (FMDV) infections (Peng et al., 2004). 
 
In addition to viral entry into the cytoplasm, PI3K may also be important at later 
times during the picornavirus replication cycle. Coxsackievirus B3 (CVB3) infection 
stimulates the PI3K-dependent phosphorylations of Akt (both Ser473 and Thr308) 
and GSK-3β at ~6h post-infection (Esfandiarei et al., 2004). Such stimulation is 
dependent upon CVB3 genome replication, and appears to delay apoptosis, augment 
viral RNA synthesis, increase protein expression, and (ultimately) increase progeny 
virus production (Esfandiarei et al., 2004, Zhang et al., 2003). Intriguingly, the delay 
in apoptosis is not responsible for increasing viral protein expression (Esfandiarei et 
al., 2004), suggesting that CVB3-mediated activation of PI3K-Akt regulates viral 
protein expression directly and independently. 
 
The mechanism of PI3K activation during CVB3 infection is unclear, but it is 
interesting to note that RasGAP (a cellular negative-regulator of the PI3K-activating 
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protein, Ras) is cleaved in CVB3-infected cells (Huber et al., 1999). Thus, as the 
kinetics of this cleavage event correlate well with the observed phosphorylations of 
Akt (Huber et al., 1999), it has been speculated that this may contribute to PI3K 
activation (Esfandiarei et al., 2004). Such a mechanism may be common to many 
picornaviruses, as echovirus-11 and echovirus-12 also induce the cleavage of 
RasGAP during infection (Huber et al., 1999). Additionally, IFNγ inducible GTPase 
[IGTPase; the expression of which is up-regulated during CVB3 infections (Yang et 
al., 1999)], can also stimulate PI3K activity, and this protein may therefore also play a 
role in CVB3-mediated PI3K-Akt activation (Zhang et al., 2003). However, 
overexpression of IGTPase actually causes a reduction in CVB3 replication (Zhang et 
al., 2003), indicating a potential anti-viral function for this IFN-inducible enzyme. 
Thus (as stated previously), it is often difficult to distinguish between possible virus- 
and/or cell- instigated PI3K activities, which are likely to direct opposing effects. 
 
1.4.10 PI3K and the Retroviridae family (RNA). 
Many retroviruses activate the PI3K pathway during infection. Indeed, Akt was 
originally identified as a cellular homologue of an oncoprotein encoded by the acutely 
transforming retrovirus, AKT-8 (Bellacosa et al., 1991, Staal, 1987). The human T-
cell leukaemia virus type-1 (HTLV-1) Tax protein stimulates the PI3K-Akt signalling 
pathway to increase the accumulation and transcriptional activity of β-catenin and 
HIF-1α transcription factors (Liu et al., 2001, Tomita et al., 2006, Tomita et al., 
2007). Such activity may contribute towards the survival of infected T-cells, and 
likely plays a crucial role in transformation (Liu et al., 2001, Tomita et al., 2006). 
 
For human immunodeficiency virus type-1 (HIV-1), binding of the virion gp120 
glycoprotein to the CD4 surface molecule of T-cells results in the G-protein and Lck-
1. Introduction 
(iv) Viruses and PI3K 
- 63 - 
mediated activation of class IB PI3K (Briand et al., 1997, Francois & Klotman, 
2003). gp120 binding to CD4 stimulates phosphorylation of both Akt and the 
downstream p70S6K, and appears to be required for a function prior to HIV-1 
genome integration (Francois & Klotman, 2003). In addition to gp120, soluble (and 
secreted) HIV-1 Tat protein also causes the PI3K-dependent phosphorylation and 
activation of Akt (Borgatti et al., 1997, Deregibus et al., 2002, Zauli et al., 2001). 
Such Tat-mediated PI3K activation is biphasic, with initial stimulation probably 
occurring by the binding of soluble Tat to the cell-surface receptor VEGFR-2, and the 
later stimulation requiring internalised Tat-mediated synthesis of IGF-1 and IL-3 
(Deregibus et al., 2002). Thus, a suggested role for the multifunctional Tat protein 
with regards PI3K may be to regulate cell proliferation or apoptosis (Borgatti et al., 
1997, Deregibus et al., 2002, Zauli et al., 2001). 
 
HIV-1 proteins can also directly stimulate components of the PI3K pathway. For 
example, the HIV-1 Vpu protein blocks the ubiquitination and proteasomal 
degradation of β-catenin by binding and inactivating the βTrCP E3-ligase (Besnard-
Guerin et al., 2004). In addition, expression of HIV-1 Nef protein can increase PI3K 
activity (Schibeci et al., 2000), and Nef has been reported to bind directly to the C-
terminal half of p85 (Linnemann et al., 2002). Such an interaction between Nef and 
PI3K has been proposed to contribute towards the Nef-mediated stimulation of IL-2 
production (Schibeci et al., 2000), the downregulation of surface MHC class I 
molecules (Blagoveshchenskaya et al., 2002, Larsen et al., 2004, Swann et al., 2001), 
and the anti-apoptotic phosphorylation of BAD (Wolf et al., 2001). 
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2.1 Mammalian cells and tissue culture. 
 
2.1.1 Cell types used in this study. 
293T:  human embryonic kidney cells. 
HEp2:   human larynx carcinoma epithelial cell-line. 
1321N1:  human brain astrocytoma cell-line (from Prof. C. Peter Downes). 
MDCK: derived from the kidney of an adult cocker spaniel. 
Vero:   fibroblast-like cells originating from the kidney of an African Green 
  monkey (from ICN Pharmaceuticals Ltd., U.K.). 
 
In addition to the basic cell-lines mentioned above, the following permanent cell-lines 
(generated by others) were also used: 
 
HEp2-PR8/NS1: HEp2 cells stably expressing the influenza A virus NS1 protein 
   (PR8; produced by Dr. Yun-Hsiang Chen, Hale et al., 2006). 
HEp2-SeV/V:  HEp2 cells stably expressing the V protein of Sendai virus  
   (produced by Dr. Yun-Hsiang Chen, Hale et al., 2006). 
HEp2-SeV/C:  HEp2 cells stably expressing the C protein of Sendai virus  
   (produced by Dr. Yun-Hsiang Chen, manuscript in prep). 
MDCKΔPTEN: MDCK cells stably expressing GFP and shRNA targeting  
   PTEN (provided by Dr. Nick Leslie; Lackey et al., 2007). 
MDCK-PIV5/V: MDCK cells stably expressing the V protein of PIV5 (Precious 
   et al., 2005). 
A549-NFκBLuc: A549 cell-line (human lung epithelial) stably expressing the 
   Firefly luciferase gene under the control of the NFκB promoter 
   (provided by Prof. Ron Hay, University of Dundee, U.K.).  
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The following stable cell-lines were also generated and used as part of this study: 
 
1321N1-NS1:  1321N1 cells stably expressing the wild-type influenza A virus 
   NS1 protein (PR8; Hale et al., 2006). 
1321N1-NS1(Y89F): 1321N1 cells stably expressing the PR8/NS1 protein with a 
   Y89F amino-acid substitution (Hale et al., 2006). 
MDCK-iSH2:  MDCK cell-line constitutively expressing the C-terminally V5-
   tagged iSH2 domain of bovine p85β. 
MDCK-NLS-iSH2: MDCK cell-line constitutively expressing the C-terminally V5-
   tagged iSH2 domain of bovine p85β with an N-terminal NLS 
   derived from the SV40 T antigen (MPKKKRKV). 
 
2.1.2 Cell maintenance. 
Cell monolayers were generally maintained in 25cm2 or 75cm2 tissue culture flasks 
(Greiner, U.K.) in DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen, U.K.) 
supplemented with 10% (v/v) heat-inactivated FBS (foetal bovine serum; Biowest) 
and incubated at 37oC/5% CO2. Cells were routinely trypsinised (Trypsin, EDTA; 
Becton Dickinson Ltd., U.K.), and diluted every 4-7 days as appropriate. 
 
2.1.3 Cell stock freezing and resuscitation. 
Adherent cells were trypsinised, resuspended in the relevant growth medium, and 
pelleted at ~500xg for 5mins. Cells were then resuspended in “freezing medium” 
(DMEM supplemented with 20% FBS and 10% DMSO), aliquoted into cryovials, and 
(slowly) frozen at -70oC before long-term storage in liquid N2. For resuscitation of 
cells, cryovials were rapidly thawed at 37oC before centrifugation at ~500xg. Cells 
were then resuspended and grown in normal growth medium (tissue culture flasks) at 
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37oC/5% CO2 overnight. Medium was replaced after 24h in order to remove traces of 
DMSO. 
 
2.1.4 Treatment of cells. 
As required, cells were treated with media supplemented with recombinant human 
IFNαΑ/D (PBL Biomedical Labs) or recombinant human TNFα (Dr. Rachel Evans, 
University of Dundee, U.K.). For stimulation of IFN-responsive promoters, cells were 
incubated overnight with 103 units/ml IFNα. For stimulation of NFκB-responsive 
promoters, cells were incubated with TNFα at a concentration of 50ng/ml for ~6h. 
LY294002 (Calbiochem, U.S.A), LY303511 (Alexis, U.S.A.), and wortmannin 
(Sigma-Aldrich, U.K.) were dissolved in DMSO and used as directed by the 
respective manufacturer. Transfection of cells by plasmids (and synthetic dsRNA; 
poly I:C) was carried out using the FuGENE 6 transfection reagent (Roche 
Diagnostics, U.K.), according to the manufacturer’s instructions. As required, cells 
were metabolically labelled for 1h with [35S]methionine (25 µCi/25cm2 flask; 
Amersham International Ltd., U.K.) in methionine-free tissue-culture medium.
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2.2 Mammalian viruses and infection of cells. 
 
2.2.1 Main replicating viruses used in this study. 
PIV5 (W3):  wild-type laboratory strain of PIV5. 
CPI-:   canine isolate of PIV5 unable to block IFN signalling. Is also 
   reported to induce the synthesis of IFN (Poole et al., 2002). 
PR8:   influenza virus strain A/Puerto Rico/8/34 (stock provided by 
   Dr. A. Douglas, National Institute for Medical Research, U.K.). 
rUd WT:  recombinant wild-type influenza A virus (A/Udorn/72)  
   generated and provided by Dr. Dave Jackson, Northwestern 
   University, U.S.A. (Hale et al., 2006). 
rUd NS1-Y89F: recombinant influenza A virus (A/Udorn/72) expressing NS1 
   with the Y89F amino-acid substitution. Generated and provided 
   by Dr. Dave Jackson, Northwestern University, U.S.A. (Hale et 
   al., 2006). 
rWSN WT:  recombinant wild-type influenza A virus (A/WSN/33)  
   generated and provided by Dr. Dave Jackson, Northwestern 
   University, U.S.A. (Hale et al., 2006). 
rWSN NS1-Y89F: recombinant influenza A virus (A/WSN/33) expressing NS1 
   with the Y89F amino-acid substitution. Generated and provided 
   by Dr. Dave Jackson, Northwestern University, U.S.A. (Hale et 
   al., 2006). 
 
As required, UV-inactivation of viruses was performed as described by others 
(Hayman et al., 2006). Efficiency of UV-inactivation was assessed using virus 
titration by plaque assay (see below). 
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2.2.2 Infection of cells. 
For infections where determination of infectious virus was not required, no trypsin 
was added to the medium. Monolayers of cells were infected with virus diluted in 
serum-free DMEM at an appropriate multiplicity of infection (MOI). Monolayers 
were washed prior to infection in PBS to remove all traces of serum. After an 
adsorption period of 1-2h on a rocking platform at 37°C, the virus inoculum (or 
DMEM only for mock infections) was removed and replaced with serum-free 
DMEM. Cells were incubated at 37°C/5% CO2 until harvested. 
 
2.2.3 Virus yield assays. 
To determine infectious titres over multiple replication cycles, 90% confluent MDCK 
cell monolayers were infected at a MOI of 0.001 PFU/cell in serum-free DMEM for 
1h on a rocking platform at 37°C. Monolayers were washed twice in sterile PBS prior 
to infection in order to remove all traces of serum. After the adsorption period, the 
virus inoculum was removed by washing twice in PBS, and the cultures were 
subsequently incubated in serum-free DMEM (supplemented with 0.2% BSA and 
2µg/ml TPCK- [L-1-tosylamido-2-phenylethylchloromethylketone] treated trypsin) at 
37°C/5% CO2. As required, chemical compounds under test were also included in this 
medium. Samples of the culture supernatants were removed at 24h, 48h, 72h, and 96h 
p.i., and virus titres were determined by plaque assay on Vero cells (PIV5), or MDCK 
cells (influenza A virus). as described below. 
 
2.2.4 Preparation of virus stocks. 
Stocks of the paramyxoviruses, PIV5(W3) and CPI-, were kindly maintained and 
provided as required by Mr. Dan Young (University of St. Andrews, U.K.). For stocks 
of the influenza A viruses, 90% confluent MDCK cells (2x75cm2 flasks) were washed 
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twice in sterile PBS in order to remove traces of serum, and then infected in serum-
free DMEM at an MOI of ~ 0.001 PFU/cell. After ~2h rocking at 37°C, the inoculum 
was removed and monolayers were washed with ~5mls serum-free DMEM. 12mls 
(per 75cm2 flask) of serum-free DMEM supplemented with 2µg/ml TPCK-treated 
trypsin (Sigma-Aldrich, U.K.) was added to the monolayers. Cells were incubated at 
37°C/5% CO2 for ~36-48h, and supernatants were harvested when 50-70% CPE 
(cytopathic effect) was observed. Debris was removed by centrifugation (~3000xg for 
10mins), and aliquots were frozen at -70°C. Titres were determined by plaque assay. 
 
2.2.5 Titration of viruses. 
For titrations of PIV5, monolayers of Vero cells were grown in 6-well plates (Greiner, 
U.K.) until 80-90% confluent. Virus preparations were serially diluted 10-fold in 
DMEM supplemented with 2% FBS, and cells were inoculated with 1ml of each virus 
dilution per well. After adsorption for ~2h on a rocking platform at 37°C/5% CO2, the 
virus inoculum was removed, and ~6mls of overlay (DMEM supplemented with 2% 
FBS and 0.5% carboxy methyl cellulose [Methocel MC; Sigma-Aldrich, U.K.]) was 
added to each well. Cells were incubated at 37°C/5% CO2 for 8-10 days (without 
agitation) until distinct plaques had formed. The overlay was then removed, and 
monolayers were fixed for 1h with 5% formaldehyde in PBS. Areas of cell lysis 
(plaques) were visualised by staining with crystal violet (0.1% crystal violet, 3.6% 
formaldehyde, 1% methanol, 20% ethanol in H2O) for 20mins, followed by rinsing in 
H2O. Plaques were counted, and titres estimated as plaque-forming-units per ml of 
virus preparation; PFU/ml), taking into account the original dilutions made. 
 
For titrations of influenza A viruses, monolayers of MDCK cells were grown in 6-
well plates (Greiner, U.K.) until 80-90% confluent, and washed twice in serum-free 
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DMEM in order to remove all traces of serum. Virus preparations were serially 
diluted 10-fold in serum-free DMEM, and cells were inoculated with 1ml of each 
virus dilution per well. After adsorption for ~2h on a rocking platform at 37°C/5% 
CO2, the virus inoculum was removed, and ~6mls of molten overlay (serum-free 
DMEM supplemented with 0.2% BSA, 2µg/ml TPCK-trypsin, and 0.9% agarose 
[NuSeive GTG; Cambrex, U.K.]) was added to each well. After the overlay had set, 
monolayers were incubated at 37°C/5% CO2 for 3-4 days (without agitation) until 
distinct plaques had formed. 5% formaldehyde in PBS was then added on top of the 
agarose plugs, and the monolayers were left to fix overnight. Plaques were visualised 
by immunostaining as described below. Titres were estimated as plaque-forming-units 
per ml of virus preparation; PFU/ml), taking into account the original dilutions made. 
 
2.2.6 Visualisation of virus plaques by immunostaining. 
To visualise influenza A virus plaques, an immunostaining technique was used. Fixed 
MDCK monolayers (see above) were permeablised (5% NP-40, 10% sucrose in PBS) 
for 15 min, and then washed in PBS supplemented with 1% FBS. Areas of virus 
infection (plaques) were visualised by detecting viral structural proteins. Monolayers 
were incubated for 1h at room-temperature with 500µl/well of appropriately diluted 
primary antisera (rabbit antisera raised against whole X31 [H3N2] or PR8 [H1N1]; 
diluted in PBS/1% FBS). Cells were washed with PBS/1% FBS, and monolayers were 
incubated for 1h at room-temperature with 500µl/well of appropriately diluted 
secondary anti-rabbit IgG alkaline phosphatase (AP)-conjugated antibody. 
Monolayers were subsequently washed with PBS/1% FBS, and incubated for 
~30mins with 500µl/well of alkaline phosphatase substrate (as per manufacturer's 
instructions; Sigma-Aldrich. U.K.), or until sites of virus infection were easily 
visualised. The reaction was stopped by rinsing with water. 
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2.3 Molecular biology. 
 
2.3.1 Polymerase chain reaction (PCR). 
Polymerase chain reaction (PCR) was used to amplify DNA fragments required for 
cloning. Products were obtained by PCR amplification using either Taq or PfuI 
polymerases (Promega Ltd., U.K.) according to the manufacturer’s instructions. The 
50µl reaction mixture (made up in sterile water) consisted of enzyme buffer (at an 
appropriate dilution), 0.2mM of each dNTP, ~100-200ng of DNA template, ~0.1µM 
of each specific primer (forward and reverse), and ~3 units of DNA polymerase. PCR 
was generally performed using a GeneAmp PCR System 2400 (Applied Biosystems, 
U.K.) as follows: melting at 94°C for 30 secs, annealing at 55°C for 45 secs, and 
strand extension at 72°C (for Taq) or 68°C (for PfuI) for 45 secs. The PCR set 
(typically 30 cycles) was preceded by an initial step of melting at 94°C for 5 min 
followed by a final step of strand extension at 72°C (for Taq) or 68°C (for PfuI) for 7 
mins. 
 
2.3.2 Agarose gel electrophoresis. 
DNA was analysed by gel electrophoresis in horizontal mini-gels of 1% (w/v) agarose 
(Sigma-Aldrich, U.K.) in TBE buffer (45mM Tris-borate, 1mM EDTA). DNA 
samples were mixed with the appropriate volume of DNA loading buffer (Promega 
Ltd., U.K.), prior to electrophoresis. Samples were run at 90V in TBE buffer 
(containing 1 µg/ml ethidium bromide), until bands were clearly resolved.  Along 
with the samples, known DNA size markers were also run (1kb ladder; Promega Ltd., 
U.K.). Resolved DNA bands of interest were excised under UV light, and DNA was 
recovered using a QIAquick™ Gel Extraction Kit (following manufacturer’s 
instructions; QIAGEN® Ltd., U.K.). 
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2.3.3 Restriction enzyme digestion of DNA. 
Backbone vector DNA and purified PCR products were individually mixed with 2µl 
10X enzyme buffer, 0.5µl (5U) each of the desired restriction enzymes (New England 
Biolabs, U.K.), and 0.2µl 10mg/ml acetylated BSA, in a reaction mixture made up to 
20µl with de-ionised H2O. Reactions were incubated at 37oC (for the majority of 
enzymes) for 2-4h, or overnight as appropriate. 
 
2.3.4 Ligation of DNA fragments (vector/insert). 
Insert and vector DNA were prepared by enzyme digestion/gel purification as 
described above. 10µl insert was mixed with 1µl vector, 2µl 10X ligase buffer, 1µl T4 
DNA ligase and made up to 20µl with de-ionised H2O. Reactions were incubated 
overnight at 16oC and stored at –20oC until ready for use. Ligation reaction products 
were used for heat-shock transformation of competent E. coli DH5α cells as 
described below. 
 
2.3.5 Preparation of (heat-shock) competent bacterial cells. 
E. coli strain DH5α was used to propagate plasmids. E. coli strain BL21(DE3) was 
used exclusively for protein expression. Generally, bacteria were grown in liquid 
Luria-Bertani (LB) medium (10g/l bacto-tryptone, 5g/l yeast extract, 10mM NaCl, pH 
7.5), or plated on solid LB medium supplemented with 1.5% (w/v) agar and 10mM 
MgSO4. As appropriate, media were supplemented with ampicillin (100 µg/ml), or 
kanamycin (10 µg/ml). 
 
For competent cells, a fresh bacterial mini-culture (10mls LB broth without antibiotic) 
was diluted 1/100 into 100mls of the same medium and incubated in a 37oC shaking 
incubator until OD600nm reached ~0.6 (approx. 2h). The culture was then chilled on ice 
(15mins), before being pelleted by centrifugation at ~4000xg for 15mins. After 
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removal of the supernatant, cells were resuspended in 20mls filter sterilised TFB1 
buffer (30mM potassium acetate, 10mM CaCl2, 50mM MnCl2, 100mM RbCl, 15% 
(v/v) glycerol, pH 5.8 – with 1M acetic acid). After 30mins on ice, cells were re-
pelleted at ~4000xg for 15mins and resuspended in 2mls filter sterilised TFB2 (10mM 
MOPS (pH 6.5), 75mM CaCl2, 10mM RbCl, 15% glycerol (v/v), pH 6.5 – with 1M 
KOH). Aliquots (100µl) were snap-frozen in liquid N2 and stored at –70oC until 
required. 
 
2.3.6 Heat-shock transformation of competent cells. 
10µl of ligated reaction mix (or ~1µg pre-purified plasmid) was added directly to 
100µl of thawed, competent cells. After incubation on ice for 1h, cells were heat-
shocked in a 42oC water bath for 2mins before being immediately transferred back to 
ice for a further 2mins. Cells were resuspended in 1ml LB broth and incubated at 
37oC for 1h (in order to assist cell recovery). The suspension was then plated out onto 
solid LB-agar plates supplemented with an appropriate antibiotic (90 mm-diameter 
Petri dishes; Scientific Laboratory Supplies Ltd., U.K.). Plates were inverted and 
incubated at 37oC overnight. Mini-cultures were prepared from selected colonies. 
 
2.3.7 Preparation of plasmid DNA. 
For small-scale preparations, bacterial cell cultures of 2-3 ml (in LB broth containing 
appropriate antibiotic) were grown overnight at 37°C in a shaking incubator. DNA 
was extracted from cells and purified on silica gel membrane columns using the 
QIAGEN® DNA mini-prep kit (QIAGEN® Ltd., U.K.), according to the 
manufacturer’s instructions. For large-scale preparations, bacterial cultures of 200-
250 ml were grown overnight at 37°C in a shaking incubator, and DNA was extracted 
from cells using the QIAfilter™ Plasmid Maxi Kit (following manufacturer’s 
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instructions; QIAGEN® Ltd., U.K.). The extraction of DNA using these QIAGEN® 
kits is based on the alkaline lysis of bacterial cells, followed by adsorption of DNA 
onto silica in the presence of high salt. 
 
2.3.8 Colony screening. 
Following heat-shock transformation of ligation reactions into competent cells, 
amplification of growing colonies, and mini-prep purification of DNA (see above), 
DNA samples were screened to find positive clones. 7.5µl of miniprep DNA was 
incubated with ~2U of the appropriate restriction enzyme(s), and 10X buffer in a 10µl 
reaction mix, and incubated at the appropriate temperature (37°C for the majority of 
enzymes) for 2-4h. DNA samples were analysed by agarose gel electrophoresis as 
described above. 
 
2.3.9 UV spectrophotometry. 
Appropriately diluted plasmid DNA was quantified by measuring Abs260 using a 
UVIKON 923 UV spectrophotometer (Bio-Tek Kontron Instruments Ltd., U.K.). An 
Abs260 of 1 was taken to correspond to a dsDNA concentration of 50 µg/ml. The 
purity of DNA preparation (i.e. protein contamination) was estimated by calculating 
the Abs260/Abs280 ratio (ratios greater then 1.8 were considered acceptable). 
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2.4 Plasmid DNAs. 
 
2.4.1 Plasmids used in this study. 
Several plasmids were used in this study, either directly, as backbone vectors for 
cloning, or to provide DNA sequences for the construction of new plasmids: 
 
pdl'MCS(C'V5): empty lentivirus vector for expressing proteins with a C-
terminal V5-tag. Expression is controlled by the constitutive SFFV (spleen focus 
forming virus) promoter, which produces a single bicistronic mRNA that encodes for 
the protein of interest together with a puromycin resistance product for mammalian 
cell selection (modified from the self-inactivating lentivirus vector pHR-SIN-CSGW 
by Dr. Yun-Hsiang Chen; see appendix A.1). 
 
pdl'PR8/NS1(C'V5):  lentivirus vector expressing C-terminally V5-tagged PR8/NS1; 
provided by Dr. Yun-Hsiang Chen (Hale et al., 2006). 
 
pdl'PR8/NS1(N'V5): lentivirus vector expressing N-terminally V5-tagged PR8/NS1; 
provided by Ms. Marian Killip (Hale et al., 2006). 
 
pdl'Vic/NS1(C'V5):  lentivirus vector expressing C-terminally V5-tagged Vic/NS1; 
provided by Dr. Yun-Hsiang Chen (Hale et al., 2006). 
 
pdl'SeV/V(C'V5):  lentivirus vector expressing C-terminally V5-tagged SeV/V; 
provided by Dr. Yun-Hsiang Chen (Hale et al., 2006). 
 
pCMVR8.91:  plasmid expressing the gag/pol, tat and rev genes of HIV-1 
(used in lentivirus production, provided by Dr. Yun-Hsiang Chen). 
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pMD-G:  plasmid expressing the vesicular stomatitis virus glycoprotein 
(VSV-G) gene (used in lentivirus production, provided by Dr. Yun-Hsiang Chen). 
 
pGEX-4T3:  used for bacterial expression of GST, and to generate vectors 
encoding GST-TEV-fusion proteins (Amersham Biosciences Ltd., U.K.). 
 
pHH21-Ud/NS: vector containing the entire NS segment of Ud virus (provided 
by Prof. Robert A. Lamb, Northwestern University, U.S.A.). Used to amplify Ud/NS1 
cDNA for other vectors, as well as to substitute nucleotides encoding the Y89F 
mutation prior to recombinant Ud virus rescue. 
 
pHH21-WSN/NS: vector containing the entire NS segment of WSN virus 
(provided by Prof. Robert A. Lamb, Northwestern University, U.S.A.). Used to 
amplify WSN/NS1 cDNA for other vectors, as well as to substitute nucleotides 
encoding the Y89F mutation prior to recombinant WSN virus rescue. 
 
pEF.mda-5'c-myc: mammalian expression vector encoding myc-tagged mda-5 
(Andrejeva et al., 2004). 
 
pGFP.RIG-I(Heli): mammalian expression vector encoding the GFP-tagged 
helicase domain of RIG-I (provided by Dr. Friedemann Weber, University of 
Freiburg, Germany). 
 
pGFP.RIG-I(CARD): mammalian expression vector encoding the GFP-tagged CARD 
domain of RIG-I (provided by Dr. Friedemann Weber, University of Freiburg, 
Germany). 
 
pEF'tag:  mammalian expression vector derived from pEF-plink2 
(provided by Dr. Jelena Andrejeva, University of St. Andrews, U.K.), and used to 
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express domains of bovine p85β with an N-terminal myc-tag. 
 
pMT2-bov.p85β: used as template to amplify fragments of bovine p85β 
(provided by Prof. Bart Vanhaesebroeck, Queen Mary, University of London, U.K.). 
 
pEHISTEV:  used to generate T7-driven 6His-tagged constructs where the 
6His-tag can be removed from the recombinant protein by digestion with TEV 
protease (provided by Dr. Huanting Lui, University of St. Andrews, U.K.). 
 
pGAD.p110α.ABD: T7-driven expression of the adapter-binding domain of human 
p110α (provided by Dr. Marie DeFrances, University of Pittsburgh, U.S.A.; Zu et al., 
2007). 
 
2.4.2 Plasmids generated in this study. 
Several novel plasmids were generated for transfections, the isolation of stable cell-
lines, or bacterial expression. The integrity of all new constructs was confirmed by 
sequencing prior to use (DNA Sequencing Service, Dundee, U.K.): 
 
pdl'WSN/NS1(C'V5): cDNA encoding for the NS1 protein of WSN was amplified by 
PCR from pHH21-WSN/NS using gene-specific primers. Silent splice acceptor 
mutations and a silent SmaI site were made by overlap PCR (i.e. pHH21-WSN/NS 
nucleotides 525-530 were changed from CCAGGA to CCCGGG without altering any 
amino acids). This prevents the production of NEP mRNA. The resulting PCR 
product was ligated between the SpeI and NdeI sites of pdl'MCS(C'V5). 
 
pGEX'TEV'PR8/NS1: cDNA encoding for the PR8/NS1 protein was amplified from 
pdl'PR8/NS1(C'V5) by PCR using gene-specific primers. The forward primer 
contained a coding region (GAAAACCTGTATTTTCAGGGCGCC) for the cleavage 
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sequence of tobacco etch virus (TEV) protease. The digested PCR product was ligated 
between the EcoRI and NotI sites of pGEX-4T3. 
 
pGEX'TEV'Ud/NS1, pGEX'TEV'Vic/NS1, pGEX'TEV'PR8/NS1Δ72: constructed as for 
pGEX'TEV'PR8/NS1 using specific templates. The template for Ud/NS1 was pHH21-
Ud/NS, therefore the same splice acceptor mutation was generated as for 
pdl'WSN'NS1(C'V5). The template for Vic/NS1 was pdl'Vic'NS1(C'V5). Primers for 
pGEX'TEV'PR8/NS1Δ72 were designed to amplify nucleotides encoding amino acid 
residues 73-230 of PR8/NS1. All forward primers used to construct these plasmids 
contained nucleotides encoding for the TEV protease cleavage sequence (see above). 
 
pdl'PR8/NS1Δ73(C'V5): nucleotides encoding amino acid residues 74-230 were 
amplified by PCR from pdl'PR8/NS1(C'V5) and ligated between the SpeI and NdeI 
sites of pdl'MCS(C'V5). 
 
pdl'β-iSH2(C'V5): nucleotides encoding amino acids 433-610 of bovine p85β were 
amplified by PCR from pMT2-bov.p85β and ligated between the SpeI and NdeI sites 
of pdl'MCS(C'V5). 
 
pdl'NLS'β-iSH2(C'V5): nucleotides encoding amino acids 433-610 of bovine p85β 
were amplified by PCR from pMT2-bov.p85β. The forward primer contained 
nucleotides encoding for the NLS of SV40 T antigen (namely, MPKKKRKV). The 
digested fragment was ligated between the SpeI and NdeI sites of pdl'MCS(C'V5). 
 
pHH21-Ud/NS (NS1-Y89F) and pHH21-WSN/NS (NS1-Y89F): A ~900bp fragment of 
the respective NS segment was amplified by PCR, and digested at the "internal" 
restriction sites: NcoI and ApaI. The gene-specific forward primer consisted of 
nucleotides encoding for the Y89F amino acid substitution, and NcoI/ApaI were 
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unique within the vector. Thus, after excision of the ~900bp NcoI/ApaI fragment from 
each wild-type vector, the "mutated" fragment was ligated in. Ligated constructs were 
screened by sequencing. The plasmids were sent to Prof. Robert Lamb (Northwestern 
University, U.S.A.) in order to rescue recombinant influenza A viruses.  
 
pEF-p85β'myc and pEHISTEV-p85β plasmids: For mammalian expression vectors 
encoding N-terminally myc-tagged domains of bovine p85β, cDNA fragments 
corresponding to each domain [SH3 (aa 1-100), nSH2 (aa 313-433), iSH2 (aa 433-
610), and cSH2 (aa 611-724)] were amplified by PCR from pMT2-bov.p85β and 
ligated between the NcoI and SpeI sites of pEF'tag. For T7-driven 6His-tagged β-
iSH2 (aa 433-610), nSH2-iSH2 (aa 313-610), β-iSH2’565 (aa 433-564), and nSH2-
iSH2’565 (aa 313-564), the relevant cDNAs were PCR amplified from pMT2-
bov.p85β and ligated between the NcoI and NotI sites of pEHISTEV. 
 
pGEX'TEV'β-iSH2(565-610): A cDNA fragment encoding the C-terminal 45 amino 
acids of the p85β iSH2 domain was amplified by PCR using gene-specific primers 
and ligated between the NcoI and NotI sites of digested pGEX'TEV'PR8/NS1. The 
resulting plasmid encodes β-iSH2(565-610) with a GST-tag fused to its N-terminus. 
The GST-tag can be removed from the fusion protein by digestion with TEV protease. 
 
pEHISTEV'PR8/NS1: 6His-tagged full-length PR8/NS1 was generated by partially 
digesting pGEX'TEV'PR8/NS1 with NcoI/NotI and ligating the ~700 bp fragment into 
the corresponding sites of linearised pEHISTEV. 
 
For all plasmids, 4-primer overlap PCR was used to introduce specific site-directed 
point mutations into a variety of constructs as required (e.g. NS1-Y89F, NS1-M93A, 
NS1-D92E, NS1-Y89E, NS1-R38AK41A). 
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2.5 Lentivirus-mediated generation of stable cell-lines. 
 
2.5.1 Lentivirus production. 
To generate recombinant lentiviral particles, 293T cells (70% confluent; 75 cm2 tissue 
culture flask) were co-transfected with three plasmids: 3µg pCMVR8.91, 3µg pMD-
G, and 5µg of the pdl vector containing the construct of interest. Supernatants were 
harvested at 48h and 72h post-transfection, and pooled. Cell debris was removed from 
supernatants by centrifugation at 3,000xg for 10mins, and filtering through 0.45µm 
Tuffryn membrane filters (Invitrogen, U.K.). Virus aliquots were frozen at -70°C until 
required. 
 
2.5.2 Transduction of target cells. 
30% confluent target cell monolayers (25cm2 flask) were transduced with the 
harvested lentivirus supernatant (estimated MOI of ~1PFU/cell) in the presence of 
Polybrene (Sigma-Aldrich, U.K.; 8µg/ml). 48h post-infection, pools of transformed 
cells were selected by resistance to puromycin (HEp2/1321N1 cells, 2µg/ml; MDCK 
cells, 5µg/ml). Puromycin-containing medium was replaced every four days until 
control naïve cells were dead. Stocks of stable cell-lines were frozen away, and 
working cell-lines were regularly subjected to re-selection with puromycin. 
Expression of the required protein was further confirmed by 
immunoblot/immunofluorescence analysis of cells using an anti-V5 antibody. 
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2.6 Immunoprecipitations. 
 
2.6.1 General immunoprecipitations. 
For most applications, cells were washed twice in ice-cold PBS and lysed for 10mins 
on ice with 500µl (per 4.5x106 cells) immunoprecipitation buffer (20 mM Tris-HCl 
(pH 7.8), 5 mM EDTA, 0.5% (v/v) NP-40, and 650mM NaCl, freshly supplemented 
with a protease inhibitor cocktail; Roche Diagnostics, Germany). Concentrations of 
NaCl were adjusted as required for each specific experiment. Lysates were further 
disrupted by sonication with an ultrasonic probe. Soluble antigen extract was prepared 
by centrifuging the cell lysate at 12,000xg for 50mins to pellet particulate matter. 
Large volume extracts were additionally clarified by filtration (pore size 0.1-0.2 µm). 
 
Immune complexes were formed by incubating 1ml samples of the supernatant 
(soluble antigen extract) with ~1-5µg of the desired antibody for 2h at 4°C.  The 
immune complexes were isolated by incubation with protein G-Sepharose 4B Fast 
Flow beads (Sigma-Aldrich Ltd., U.K.) for 1h at 4°C. Alternatively, immune 
complexes were formed by incubating the soluble antigen extracts with an excess of 
cross-linked anti-V5 mAb protein-G beads (see below). For some applications 
siliconised tubes (Sigma-Aldrich, U.K.) were used to minimize any non-specific 
protein binding. After extensive washing in immunoprecipitation buffer, proteins in 
the immune complexes were dissociated by heating in SDS-PAGE loading buffer at 
100°C for 5min. Proteins were analysed by SDS-PAGE as described below. 
 
2.6.2 Production of cross-linked anti-V5 mAb beads. 
The anti-V5 mAb is a high affinity antibody raised against a linear 14 amino-acid 
epitope (GKPIPNPLLGLDST) found on the paramyxovirus PIV5 P/V common N-
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terminal domain (produced from a mouse hybridoma cell-line as required by Mr. Dan 
Young). 
 
Protein G-Sepharose beads (binding capacity for IgG >20mg/mL) were pre-washed 
several times with ice-cold PBS. An appropriate amount of isolated beads was mixed 
with anti-V5 mAb tissue culture fluid (approx. 4mg of mAb per mL of beads), 
resuspended in binding buffer A (20mM Tris-HCl (pH 7.8); 650mM NaCl), and 
incubated at 4°C for 4h (“end over end” tumbler). 
 
Antibody-bead complexes were rescued and isolated after four repeated wash cycles 
of: low-speed centrifugation to pellet beads, removal of supernatant, resuspension of 
beads in binding buffer A. Antibody-bead complexes were then washed twice in 
buffer B (3M NaCl; 1.5M glycine [buffered to pH 8.9 with 3M NaOH]), and twice 
with buffer C (3M NaCl; 50mM Borate [buffered to pH 8.9 with 3M NaOH]). 
 
The antibody-bead complexes were then incubated with freshly prepared buffer D 
(40mM di-methyl-pimelimidate; 3M NaCl; 200mM Borate [buffered to pH 8.9 with 
3M NaOH]) for 1h at 4°C (“end over end” tumbler). The beads were pelleted by low-
speed centrifugation and incubated on ice (10mins) with buffer E (200mM 
ethanolamine [buffered to pH 8.0 with HCl]). Complexes were washed twice more 
with buffer E and then re-incubated for a further 2h at room temperature with buffer E 
(“end over end” tumbler).  
 
Finally, the cross-linked anti-V5 mAb beads were subjected to four wash cycles with 
buffer A. The efficiency of cross-linking was determined by analysing bead samples 
(SDS-PAGE) at various stages throughout the procedure. Cross-linked beads were 
produced as required and stored as a 50% (v/v) slurry in buffer A at 4°C. 
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2.7 Protein expression/purification from E. coli and insect cells. 
 
2.7.1 Protein purification from E. coli. 
GST- or 6His- tagged fusion proteins were expressed and purified from E. coli 
BL21(DE3) cells. Briefly, 10ml overnight mini-cultures (37°C) were diluted 1:100 
into 3 litres fresh LB liquid medium (containing antibiotic), and grown at 30°C in a 
shaking incubator. When OD600 reached 0.5-0.6 units, protein expression was induced 
by addition of 1mM IPTG (isopropyl-β-D-thiogalactopyranoside) for 4h. After 
centrifugation, the bacterial cells were resuspended in buffer [50mM Tris-HCl 
(pH 7·8), 200mM NaCl, together with appropriate protease-inhibitor tablets (Roche, 
Germany)], and lysed by sonication. Lysates were clarified by centrifugation at 
30,000 rpm for 30mins in a Beckman 42.1 rotor, and supernatants were filtered 
through a 0.45µm Tuffryn membrane filter (Invitrogen, U.K.). GST fusion proteins 
were purified by binding to glutathione-agarose beads (Sigma-Aldrich, U.K.), and (if 
required) eluted in buffer containing 10mM glutathione. 6His-tagged proteins were 
purified on Ni-NTA resin (GE Healthcare, Sweden), and eluted in buffer containing 
100mM imidazole. As necessary, cleavage by TEV protease (1:50 dilution; 
Invitrogen, U.K.) was carried out overnight at room temperature with accompanying 
dialysis in 50mM Tris-HCl (pH 7.8), 200mM NaCl, 1mM DTT. 
 
2.7.2 p85α  and p85β  expression in Sf9 (insect) cells. 
The Spodoptera frugiperda (Sf9) insect cell-line was maintained at 28°C as a 
suspension culture in TC-100 medium (Invitrogen, U.K.) supplemented with 7% FBS. 
Cells were routinely passaged and diluted every 3-5 days. 
 
Titrated recombinant baculoviruses expressing untagged bovine p85α and p85β were 
kindly provided by Prof. Bart Vanhaesebroeck (Queen Mary University of London, 
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U.K.) (Gout et al., 1992). For p85α or p85β expression, monolayers of approximately 
1x108 Sf9 cells in 300cm2 flasks (Helena Biosciences Ltd., U.K.) were infected with 
recombinant baculoviruses at an MOI of ~3 for 1h at 28°C with frequent rocking. 
After removal of inoculum, cells were incubated at 28°C for 72h in fresh medium. To 
harvest, the medium was removed and cells were scraped into 10mls PBS, centrifuged 
at 500xg for 5mins, and the cell pellet was resuspended in 5mls of a lysis buffer 
containing 50mM HEPES (pH 7.6), 10mM KCl, 1.5mM MgCl2, 1% NP40, 5mM 
DTT, and 10% glycerol [supplemented with protease inhibitors (Roche, U.K.)]. 
Samples were centrifuged at 35,000xg for 30min at 4°C in a Beckman SW50.1 rotor, 
and supernatants were frozen at –70°C until required. 
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2.8 Miscellaneous assays. 
 
2.8.1 EMCV-inhibition assays. 
The amount of IFN secreted by HEp2 cells was estimated by using a biological 
EMCV (Encephalomyocarditis virus)-inhibition assay in Vero cells. 50% confluent 
Vero cells in 96-well plates were pre-treated with UV-inactivated 2-fold serial 
dilutions of culture media containing IFN for 24h prior to infection with EMCV 
[which is sensitive to IFN]. The development of CPE was monitored 36h p.i. by 
crystal violet staining (see above). Units of IFN were estimated as the dilution of 
media required to reduced the CPE by ~50%. 
 
2.8.2 Luciferase assays. 
Following virus infection and TNFα treatment, A549-NFκBLuc cell monolayers (in 
6-well plates) were washed once in PBS and lysed for 2mins in 300µl (per well) 
luciferase buffer A (25mM Tris-phosphate (pH 7.8), 8mM MgCl2, 1mM DTT, 1mM 
EDTA, 1% TritonX-100). Following lysis, 300µl (per well) of luciferase buffer B 
(30% glycerol, 0.8mM ATP, 2% BSA in luciferase buffer A) was added to each 
sample. A portion of the soluble cell extract (300µl) was subsequently transferred to a 
luciferase cuvette into which 100µl of luciferase substrate (1.5mM luciferin in TE 
buffer) was injected. Substrate injection, as well as measurement of the light emitted 
over the first 10s following substrate addition (measured in relative light units; RLU), 
was performed using a Lumat LB9501 luminometer (Bertold, Germany). 
 
2.8.3 In vitro PI3K assays. 
Monolayers from 6-well plates were fixed and lysed by addition of ice-cold lysis 
buffer (1% (v/v) TritonX-100, 120mM NaCl, 50mM NaF, 1mM MgCl2, 1mM EGTA, 
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1mM EDTA, 5mM β-glycerophosphate, 25mM HEPES, pH 7.6 at 4°C, supplemented 
with 0.1 mM PMSF, 0.1mM benzamidine, 10µM leupeptin, 1mM Na3VO4, and 1mM 
DTT). Cell debris was centrifuged for 5min at 20,000xg (4°C), and lysate 
supernatants were frozen in liquid N2 before storage at -80°C. Analysis of NS1-
associated PI3K activity was performed by Dr. Ian Batty (University of Dundee. 
U.K.). Briefly, cell lysates were mixed for ~2h at 4°C with 10µg of anti-V5 antibody 
pre-coupled to protein G-Sepharose beads. Immunoprecipitates were collected by 
brief centrifugation, washed, and analysed for PI3K activity as described previously 
(Herbert et al., 2000, Tang & Downes, 1997). 
 
2.8.4 In vitro synthesis of [35S]methionine-labelled proteins. 
[35S]methionine-labelled proteins were synthesised individually from plasmid DNA 
via T7-dependent in vitro translations carried out using the TnT Quick Coupled 
Transcription/Translation system (Promega, U.S.A.) according to the manufacturer's 
instructions. For protein interaction experiments, lysates expressing different proteins 
were mixed on ice for 30mins prior to addition of antibody (1h). Mixtures were then 
diluted up to 0.5ml with immunoprecipitation buffer (see above), and incubated with 
protein G-Sepharose beads for 1h to precipitate immune complexes. Samples were 
washed and analysed as described in sections 2.6.1 and 2.9.1. 
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2.9 Protein analysis. 
 
2.9.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein samples were prepared in SDS-PAGE disruption buffer (6M Urea, 2M β-
mercaptoethanol, 4% (w/v) SDS, with bromophenol blue colouring) and heated at 
100°C for 2 mins prior to analysis. Polypeptides were separated through 4-12% 
NuPAGE polyacrylamide gradient gels (Invitrogen, U.K.) by electrophoresis at 180-
200V until maximum resolution of polypeptide bands was noted. MOPS [3-(N-
morpholino)propanesulphonic acid] or MES [2-(N-morpholino)ethanesulphonic acid] 
buffer was used as appropriate (Invitrogen, U.K.). Gels were stained (0.5% (w/v) 
R250 Coomassie Blue, 40% (v/v) methanol, 10% (v/v) acetic acid) and de-stained 
(20% (v/v) methanol, 10% (v/v) acetic acid) as necessary. If appropriate, gels were 
dried and exposed to an imaging plate (Fuji) in order to visualise [35S]methionine-
labelled polypeptides (Fuji FLA-5000 phosphorimager). 
 
2.9.2 Antibodies. 
Antibodies were used for immunoprecipitations and immunostaining (see above), 
immunoblotting, immunofluorescence, and ELISAs. Primary antibodies. All anti-V5 
antibodies (as well as the anti-p85α and anti-p85β antibodies) were purchased from 
Serotec, U.K. The β-actin and GFP antibodies were from Sigma-Aldrich Ltd., U.K. 
Antibodies specific for Akt, phospho-Akt (Ser473), phospho-Akt (Thr308), and 
phospho-eIF2α (Ser51) were from Cell Signaling Technology, U.S.A. The HA-tag 
mAb was from BAbCo, U.S.A. PKR, STAT1, myc-tag, and phospho-tyrosine 
antibodies were purchased from Santa-Cruz Biotechnology, U.S.A. The polyclonal 
rabbit anti-PR8/NS1 antibody was kindly provided by Dr. Paul Digard (University of 
Cambridge, U.K.), and Dr. Alan Douglas (NIMR, U.K.) provided rabbit antisera to 
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the influenza A virus strains X31 (H3N2) and PR8 (H1N1). Secondary antibodies. 
Anti-mouse IgG Texas Red and FITC conjugated antibodies were from Oxford 
Biotechnology Ltd., U.K. Anti-mouse IgG and anti-rabbit IgG HRP conjugated 
antibodies were from Amersham Bioscience, U.K. Goat anti-rabbit IgG AP (alkaline 
phosphatase)-conjugated antibody was from Santa Cruz Biotechnology, U.S.A. 
 
2.9.3 Immunoblotting. 
Polypeptides were separated by SDS-PAGE as described in 2.9.1, and transferred to 
polyvinylidene difluoride (PVDF) membrane using the XCell II Blot Module 
according to the manufacturer’s instructions (Invitrogen, U.K.). Following transfer, 
membranes were blocked for 30 mins in 5% (w/v) skimmed milk powder, 0.1% (v/v) 
Tween 20 in PBS (blocking buffer), and incubated for 1h with the appropriate 
primary antibodies diluted (in blocking buffer) as directed by the supplier. After 
extensive washing with 0.1% (v/v) Tween 20 in PBS, the protein:antibody 
interactions were detected by incubation for 1h with horseradish peroxidase (HRP) 
conjugated anti-mouse or anti-rabbit IgG (Amersham Bioscience, U.K.) diluted 
appropriately in blocking buffer. Following final washing in 0.1% (v/v) Tween 20 in 
PBS, specific polypeptide bands were visualised by enhanced chemiluminescence 
(Amersham Biosciences Ltd., U.K.) according to the manufacturer's protocol. 
 
2.9.4 Immunofluorescence. 
For immunofluorescence analysis, cells grown on 10mm coverslips were fixed for 
10mins in 5% formaldehyde, 2% sucrose (in PBS), before permeabilisation with 0.5% 
NP-40, 10% sucrose (in PBS). After repeated washing with 1% FBS (in PBS), 
monolayers were incubated with appropriately diluted primary antibody for 1h. 
Following further washes, cells were incubated for 1h with a cocktail solution 
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containing Texas Red or FITC conjugated secondary antibody (Oxford Biotechnology 
Ltd., U.K.), together with the DNA-binding fluorochrome 4', 6-diamidino-2-
phenylindole (DAPI; 0.5 µg/ml; Sigma-Aldrich Ltd., U.K.). All reactions were 
performed at room temperature in a humidified chamber. Coverslips were washed in 
PBS and mounted on slides using Citifluor AF-1 mounting solution (Citifluor Ltd., 
U.K.). Immunofluorescence was visualised using a Nikon Microphot-FXA 
microscope. 
 
2.9.5 Enzyme-linked immunosorbant assay (ELISA). 
Wells of a flat-bottomed 96-well plate were coated overnight at 4°C with 100µl of the 
target protein solution (10µg/ml in PBS). Wells were subsequently blocked for 1h at 
room temperature with 400µl skimmed milk solution (3% (w/v) skimmed milk 
powder in PBS). Lysates containing the ligand protein were serially diluted in 
skimmed milk solution and added to the protein-coated wells for 1h. Wells were 
washed 3 times with 0.1% (v/v) Tween-20 in PBS, and bound ligand proteins were 
detected with a specific primary antibody and an HRP-conjugated secondary antibody 
as in 2.3.3. All antibodies were diluted in 3% (w/v) skimmed milk powder in PBS. 
HRP activity was detected using 100µl/well of an equal volume mixture of TMB 
peroxidase substrate (0.4g/l 3,3',5,5'-tetramethylbenzidine in an organic base) and 
peroxidase solution B (0.02% (w/v) H2O2 in citric buffer). After sufficient colour had 
developed, the reaction was stopped by adding 100µl/well 1M HCl, and the OD was 
measured at 450nm. 
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3.1 Host-cell proteins that interact with viral IFN-antagonists. 
 
The initial aim of this study was to develop a methodology for identifying host-cell 
proteins that are bound by virus-encoded proteins. As part of a previous study within 
the group concerning viral evasion of host innate immunity (Galiano, Chen and 
Randall, manuscript in preparation), a panel of HEp2 cell-lines had already been 
isolated that constitutively express C-terminal V5-tagged forms of well-characterised 
virus-encoded IFN-antagonists: Sendai virus V protein (strain Fushimi; SeV/V), 
Sendai virus C protein (strain Fushimi; SeV/C), and influenza A virus NS1 protein 
(strain A/PuertoRico/8/34; PR8/NS1) (Andrejeva et al., 2004, Childs et al., 2007, 
Garcia-Sastre, 2001, Garcin et al., 1999, Komatsu et al., 2004, Krug et al., 2003). As 
host-cell binding partners for these viral proteins have already been identified (see 
Introduction, and below), it was speculated that work on such cell-lines might prove 
useful for determining if protein:protein interactions could be resolved by simple anti-
V5 immunoprecipitations. 
 
3.1.1 Characterisation of cells expressing IFN-antagonists. 
Characterisation of the HEp2 cell-lines was first performed in order to confirm some 
of the previously documented IFN-antagonistic activities associated with the stably 
expressed viral proteins. Western blot analysis of total-cell lysates using the anti-V5 
mAb determined the expression and predicted molecular weight of all three viral 
proteins in their respective HEp2 cell-lines (Fig. 3.1A). Indirect immunofluorescence 
also indicated that >95% (estimated) of cells were expressing each protein (Fig. 
3.1B). As expected, expression of these proteins significantly reduced the ability of 
HEp2 cells to produce IFN in response to infection with CPI-, a virus known to 
normally induce high amounts of IFN (Poole et al., 2002) (Fig. 3.2A). Note that the 
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Fig. 3.1. Expression of different viral IFN-antagonists in HEp2 cells. (A) Protein 
lysates were prepared from monolayers of HEp2 cells constitutively expressing V5-
tagged PR8/NS1, SeV/V, or SeV/C. Naive HEp2 cells acted as a negative control. Lysates 
were separated by SDS-PAGE followed by transfer to PVDF membrane. V5-tagged pro-
teins were detected using an anti-V5 mAb. Detection of β-actin acted as a loading con-
trol. Molecular weight markers (kDa) are indicated on the right. (B) Expression of V5-
tagged proteins in HEp2 cells as determined by indirect-immunoﬂuorescence using an 
anti-V5 Texas Red (TxRd)-conjugated mAb. Naive HEp2 cells acted as a negative control. 
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variation of IFN-antagonism demonstrated by these viral proteins may be due to 
differences in relative expression levels (Fig. 3.1). Alternatively, the efficiency of 
antagonism may be affected by the type of “inducer” used, particularly as each viral 
protein limits IFN production by a distinct mechanism: SeV/V binds mda-5 
(Andrejeva et al., 2004, Childs et al., 2007); PR8/NS1 interacts with RIG-I and/or 
dsRNA (Garcia-Sastre, 2001, Guo et al., 2007, Mibayashi et al., 2007, Opitz et al., 
2006, Pichlmair et al., 2006); and SeV/C binds STAT1 (Takeuchi et al., 2001). Thus, 
SeV/V and PR8/NS1 probably have a direct effect on IFN induction, whilst the 
antagonistic role of SeV/C is likely due to limitation of the IFN induced positive-
feedback loop. 
 
Confirmation that SeV/C (but not PR8/NS1) is able to block a specific step in the IFN 
signalling cascade (Garcin et al., 1999) was determined by examining levels of the 
IFN-inducible STAT1 protein after treatment of cells with exogenous IFNα (Fig. 
3.2B). Further characterisation of these HEp2 cell-lines also verified that PR8/NS1 
limits the activity of the dsRNA-activated protein kinase, PKR (Hatada et al., 1999, 
Li et al., 2006a). Thus, expression of PR8/NS1 prevented the Ser51 phosphorylation 
of eIF2α (the antiviral effector of PKR) in response to both virus infection (CPI-) and 
synthetic dsRNA (poly I:C) (Fig. 3.2C). As the binding of NS1 to PKR may be 
responsible for PKR inactivation (Li et al., 2006a), the co-precipitation of PR8/NS1 
with endogenous PKR was also assessed (Fig. 3.2D). PR8/NS1 was clearly 
precipitated with anti-PKR antibody from PR8/NS1-expressing HEp2 cell extracts, 
and the amount precipitated was proportional to the amount of PKR bound by the 
antibody (protein levels of PKR were increased by prior treatment of cells with 
exogenous IFNα, which did not affect the protein level of PR8/NS1) (Fig. 3.2D).  
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Fig. 3.2. Functional characterisation of different viral IFN-antagonists in HEp2 cells. 
(A) IFN production. Monolayers of HEp2 cell-lines were infected with CPI- at an MOI 
of 5 PFU/cell, and culture supernatants were harvested at 48h post-infection. After UV 
inactivation,  IFN concentration was estimated by EMCV-inhibition assay on Vero cells. 
Bars represent relative units of protection, which has previously been shown to correlate 
well with the total amount of IFN in the supernatant (M.C. Galiano, unpublished obser-
vations).  (B) IFN signalling.  Monolayers of HEp2 cell-lines constitutively expressing 
SeV/C or PR8/NS1 were treated for 20h with recombinant human IFNα (or mock treat-
ed). Naive HEp2 cells acted as a positive control. Protein lysates were separated by SDS-
PAGE followed by transfer to PVDF membrane. Total STAT1 and β-actin were detected 
using speciﬁc antibodies. Expression of V5-tagged proteins was conﬁrmed using an anti-
V5 mAb. (C) PKR activation. PKR activation in naive or PR8/NS1-expressing HEp2 cells 
was assessed by the induction of phospho-eIF2α (Ser51) in response to mock-transfection 
(-), transfection of poly I:C (pI:C), or CPI- infection (MOI of 5 PFU/cell). 20h post-treat-
ment monolayers were harvested, and protein lysates separated by SDS-PAGE followed 
by transfer to PVDF membrane. Phospho-eIF2α (Ser51) and β-actin were detected using 
speciﬁc antibodies. NS1 expression was conﬁrmed using an anti-V5 mAb. (D) PKR co-
precipitation. PR8/NS1-expressing HEp2 cells (or naive HEp2 cells) were treated as for 
(B). Soluble antigen extracts were immunoprecipitated with anti-PKR antibody and sepa-
rated by SDS-PAGE followed by transfer to PVDF membrane. PKR and PR8/NS1 were 
detected in the precipitates using a speciﬁc anti-PKR pAb or an anti-V5 mAb, respectively. 
Levels of PKR, β-actin, and PR8/NS1 were also determined in the input soluble antigen. 
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3.1.2 Identification of IFN-antagonist binding partners. 
Immunoprecipitations were carried out on each HEp2 cell-line in order to identify 
host-cell proteins that specifically interact with the viral IFN-antagonists. Antibody to 
the V5-tag was used to immunoprecipitate each recombinant protein from [35S]-
methionine labelled cell lysates (~5x105 cells per experiment), and precipitated 
protein complexes were separated by SDS-PAGE and visualised by phosphorimager 
analysis. Similarly labelled naïve HEp2 cell extract acted as a negative control (Fig. 
3.3A). A number of radiolabelled protein bands specifically co-precipitating with 
each IFN-antagonist were observed. Bands corresponding to V5-tagged viral proteins 
are marked with an arrow.  
 
In order to identify polypeptides by mass spectrometry, immunoprecipitations were 
performed using extracts from a larger number of cells (~5x107), such that protein 
bands would be visible by Coomassie blue staining. In order to reduce the amount of 
immunoglobulin heavy and light chain on the SDS-polyacrylamide gel, anti-V5 mAb 
was chemically cross-linked onto protein-G beads (see Methods and Materials). 
Coomassie blue staining of co-precipitated proteins revealed a similar (but not 
identical) pattern to that observed using [35S]-methionine labelled extracts (Fig. 3.3B). 
Specifically, the high molecular weight protein band (>200 kDa) co-precipitated with 
SeV/V was only observed in the radiolabelled experiment, as was an apparent doublet 
band of ~40 kDa in the PR8/NS1 immunoprecipitation (Fig. 3.3A, both bands marked 
with an asterix). The thick protein bands of ~20 kDa clearly visible by Coomassie 
blue staining (Fig. 3.3B – not present in the radiolabelled experiment), probably 
correspond to modified anti-V5 immunoglobulin light chain that can dissociate from 
the protein-G bead. 
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Fig. 3.3. Identiﬁcation of host-cell proteins that interact with different viral IFN-an-
tagonists in HEp2 cells. (A) [35S]-methionine labelling. Monolayers of HEp2 cell-lines 
constitutively expressing different viral IFN-antagonists (~5x105 cells per experiment) were 
metabolically labelled for 1h with [35S]-methionine. Soluble antigen extracts were immu-
noprecipitated using anti-V5 mAb. Precipitated protein complexes were separated by SDS-
PAGE and visualised by phosphorimager analysis. Bands presumed to correspond to the 
immunoprecipitated V5-tagged viral proteins are marked with arrows. Bands not identiﬁed 
by Coomassie Blue staining (B) are marked with asterices. (B) Coomassie Blue staining 
and protein identiﬁcation. Soluble antigen extracts from ~2x107 cells were immunopre-
cipitated with anti-V5 mAb cross-linked to protein G Sepharose. Precipitated proteins were 
separated by electrophoresis through 4-12% polyacrylamide gradient gels and visualised 
by Coomassie Blue staining. Polypeptide bands denoted by numbers 1-9 were excised 
and identiﬁed by the University of St. Andrews mass spectrometry service (D). Molecu-
lar weight markers (kDa) are indicated on the right. (C) Immunoblot conﬁrmation. Im-
munoprecipitates were prepared as for (B), and separated by electrophoresis followed by 
transfer to PVDF membrane. STAT1 and p85β were detected using speciﬁc antibodies. 
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Mass spectrometry (performed by the University of St. Andrews Mass Spectrometry 
and Proteomics Facility) showed that, as expected, the ~150 kDa protein associated 
with SeV/V is mda-5, and the two ~90 kDa polypeptides associated with SeV/C are 
both STAT1. This is in agreement with previously described interactions for SeV/V 
and SeV/C that have been shown to play a role in their IFN-antagonistic properties 
(Andrejeva et al., 2004, Childs et al., 2007, Takeuchi et al., 2001). The specific 
interaction of STAT1 with SeV/C protein was confirmed by Western blot analysis of 
similar immuno-precipitates (Fig. 3.3C). Additionally, the ~100 kDa polypeptide 
species precipitated with SeV/C (Fig. 3.3B) was identified as AIP1/Alix, a protein 
previously reported to bind SeV/C (Sakaguchi et al., 2005), and which may play a 
role in either virus maturation/budding (Sakaguchi et al., 2005), or in viral escape 
from the host immune/apoptotic response (Gosselin-Grenet et al., 2007).  
 
Analysis of cellular proteins co-precipitated with the PR8/NS1 protein identified only 
a single polypeptide species of ~90 kDa (Fig. 3.3B). This was surprising given the 
number of host-cell proteins that have been reported to bind NS1 (see Introduction). 
The mass spectrometry service identified this ~90 kDa protein as p85β, a regulatory 
subunit of phosphoinositide 3-kinase (PI3K; see Introduction). Interestingly, p85α (a 
related PI3K adapter subunit that is ~55% identical to p85β at the amino-acid level) 
was not identified in the band. Specificity of the PR8/NS1:p85β interaction was 
confirmed by Western blot analysis of similar immunoprecipitates (Fig. 3.3C). 
 
Given that an interaction between the influenza A virus NS1 protein and host-cell 
p85β had not been reported previously, it was decided that this observation should be 
characterised further. Thus, the remainder of this work focuses on determining a role 
for this interaction in the influenza A virus replication cycle. 
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3.2 Influenza A virus NS1 proteins bind p85β , but not p85α . 
 
3.2.1 Co-precipitation of p85β  with various NS1 proteins. 
To determine if the interaction of p85β with PR8/NS1 is a feature common to other 
influenza A virus strains, the co-precipitation of p85β with the NS1 proteins of 
A/WSN/33 (H1N1; WSN), and A/Victoria/3/75 (H3N2; Vic) was examined. A HEp2 
cell-line stably expressing Vic/NS1 could not be isolated, possibly due to toxicity 
caused by this protein inhibiting cellular pre-mRNA processing (Nemeroff et al., 
1998, Qiu & Krug, 1994); a function not shared by PR8/NS1 (Hayman et al., 2006). 
Therefore, human 293T cells were transfected with plasmids expressing either the C-
terminal V5-tagged NS1 protein of each strain, N-terminal V5-tagged PR8/NS1, or 
empty vector (negative control). Analysis of proteins immunoprecipitated with the V5 
antibody showed that endogenous p85β interacted with the NS1 proteins of all three 
influenza A virus strains (Fig. 3.4A). The position of the V5-tag (N-terminal or C-
terminal) had no effect on the interaction. 
 
3.2.2 Direct binding of NS1 proteins to p85β , but not p85α . 
To confirm the specific and direct binding of NS1 to p85β in vitro, a GST-NS1 fusion 
protein pull-down assay was used. Recombinant GST or GST-NS1 (NS1 of PR8, Vic, 
or Ud) was expressed and purified from E. coli and immobilised onto glutathione-
agarose beads. Equal amounts of these beads were then used as bait to affinity isolate 
an excess of baculovirus-expressed p85α or p85β (the expression of these proteins in 
infected Sf9 cells was confirmed prior to the assay by Western blot [Fig. 3.4B]). 
Strikingly, a single protein band of ~90 kDa was specifically isolated from the p85β 
expressing lysate by each GST-NS1 (PR8, Vic and Ud), but not by GST alone (Fig. 
3.4C). The identity of the ~90 kDa polypeptide was confirmed as p85β by mass 
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Fig. 3.4. The NS1 proteins of several inﬂuenza A virus strains bind efﬁciently to p85β, 
but not p85α. (A) 293T cells were transfected for 48h with either empty vector (-), a plas-
mid expressing the N-terminal V5-tagged NS1 protein of PR8 (nP), or plasmids express-
ing the C-terminal V5-tagged NS1 proteins of PR8 (cP), WSN (cW), or Vic (cV). Soluble 
antigen extracts were immunoprecipitated with anti-V5 antibody and precipitates separated 
by SDS-PAGE followed by transfer to PVDF membrane. Endogenous p85β was detected 
using a speciﬁc mAb. Anti-V5 mAb was used to detect V5-tagged NS1 proteins. (B) Sf9 
cells were infected (or mock [-]) with recombinant baculoviruses expressing either p85α 
or p85β. Equal amounts of soluble lysate were separated by electrophoresis, transferred to 
PVDF membrane, and probed for p85α or p85β expression using speciﬁc mAbs. (C) Equal 
amounts of soluble Sf9 cell lysate from (B) were mixed with GST or GST-NS1 (PR8, Ud or 
Vic) immobilized onto glutathione-agarose beads. After washing, protein complexes were 
dissociated from the beads and separated by SDS-PAGE through 4-12% polyacrylamide gra-
dient gels.  Polypeptides were stained with Coomassie Blue, and protein identiﬁcation was 
conﬁrmed by mass spectrometry. Molecular weight markers (kDa) are indicated on the right.
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spectrometry. As GST-NS1 and p85β were the only protein bands visible in this pull-
down experiment, the interaction between NS1 and p85β is likely to be direct.  
Interestingly, no proteins were precipitated by GST-NS1 from the p85α expressing 
lysate (Fig. 3.4C). 
 
3.3 NS1 induces the PI3K-dependent phosphorylation of Akt. 
 
3.3.1 Influenza A virus infection induces phospho-Akt. 
As described in the Introduction, Akt is a serine/threonine protein kinase that serves 
as a key downstream mediator of PI3K signalling [reviewed in (Brazil et al., 2004, 
Cantley, 2002)]. In response to active PI3K, Akt is recruited to membranes and 
phosphorylated at residues Thr308 and Ser473 [by PDK1 and the mTORC2 complex, 
respectively] (Bayascas & Alessi, 2005, Brazil et al., 2004). As NS1 was found to 
bind the p85β regulatory subunit of PI3K (Fig. 3.4), the phosphorylation of Akt 
following influenza A virus infection was investigated as a marker for PI3K activity. 
Serum-starved monolayers of human 1321N1 astrocytoma cells (used widely in PI3K 
activation studies) were infected with influenza A virus (PR8) at a MOI of ~5 
PFU/cell, and the phosphorylation state of Akt (Thr308 and Ser473) was analysed in 
total cell lysates at various times post-infection (p.i.) (Fig. 3.5A). Increasing levels of 
phosphorylated Akt at both sites were evident during the time-course of infection, and 
phospho-Akt levels appeared concomitant with the expression of NS1 protein (an 
increase in phospho-Akt was first detectable ~4-6h p.i., and was maintained up to 24h 
p.i.). Induction of phospho-Akt (Ser473) was dependent on influenza A virus 
replication, as prior UV-inactivation of the virus prevented phosphorylation of Akt 
(Fig. 3.5B). 
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Fig. 3.5. NS1 induces the Ser473 and Thr308 phosphorylations of Akt in a PI3K-de-
pendent manner. (A) Time-course of Akt phosphorylation at Ser-473 and Thr-308 fol-
lowing inﬂuenza A virus (PR8) infection. Conﬂuent serum-starved monolayers of 1321N1 
cells were infected (or mock [-]) with PR8 at an MOI of 5 PFU/cell, and total cell lysates 
were harvested at various times p.i.. Lysates were separated by SDS-PAGE followed by 
transfer to PVDF membrane. Phospho-Akt (Ser473 and Thr308) was detected using spe-
ciﬁc mAbs. Total Akt was detected using a pAb and acted as a loading control. NS1 ex-
pression was detected using a speciﬁc pAb. (B) UV-inactivated inﬂuenza A virus (PR8) 
does not induce Akt phosphorylation. Serum-starved 1321N1 monolayers were infected 
(or mock [-]) as for (A), with either untreated (WT) or UV-inactivated (UV) virus. Lysates 
were prepared 20h p.i. and analysed as for (A). (C) Serum-starved naive or PR8/NS1-
expressing 1321N1 monolayers were treated (or mock) with 5% FBS for 1h. In a dupli-
cate experiment, cells were also treated with 25µM LY294002 (a speciﬁc PI3K inhibitor; 
LY). Cell lysates were analysed as for (A). PR8/NS1 was detected using an anti-V5 mAb.
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3.3.2 NS1 induces PI3K-dependent phospho-Akt. 
To determine if NS1 is responsible for influenza A virus-mediated activation of PI3K, 
a 1321N1 cell-line was isolated that constitutively expressed V5-tagged PR8/NS1, 
and the phosphorylation state of Akt within these cells was investigated. In naïve 
1321N1 cells, Akt phosphorylation (Ser473) decreased rapidly in response to serum-
withdrawal (Fig. 3.5C, lanes 1-2). In contrast, there was no apparent reduction in 
phospho-Akt when NS1-expressing cells were similarly serum-starved (Fig. 3.5C, 
lanes 3-4). This indicates that NS1 expression alone can induce the phosphorylation 
of Akt without the absolute requirement for additional virus-derived factors. 
Furthermore, it was found that the phosphorylation of Akt induced by NS1 is 
dependent on PI3K activation, as treatment of cells with a well-characterised inhibitor 
of PI3K, LY294002 (Vlahos et al., 1994), was able to negate the effect of NS1 
expression (Fig. 3.5C, lanes 5-8). 
 
3.3.3 Kinetics of Akt phosphorylation during infection. 
The observation that influenza A virus infection causes a sustained increase in the 
level of Akt phosphorylation has recently been challenged by a report noting only 
transient Akt phosphorylation at ~6-8 h p.i., which was not evident at later timepoints 
(Zhirnov & Klenk, 2007). The apparent discrepancy between these two results may be 
explained by the cell-type used, as the experiments presented here were done only in 
1321N1 cells, whilst those of Zhirnov and Klenk were performed in MDCK, CV-1, 
and Vero cells (Zhirnov & Klenk, 2007). Indeed, a comparative study of phospho-Akt 
induction in response to influenza A virus (PR8) infection did reveal kinetic 
differences between 1321N1 cells and MDCK cells  (Fig. 3.6). As previously noted, 
in 1321N1 cells, Ser473 phosphorylation of Akt is first detectable ~4h p.i., and is 
maintained throughout infection (Fig. 3.6A). By contrast, in MDCK cells, Akt 
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phosphorylation peaks at ~8h p.i. before falling significantly – at 24h p.i. phospho-
Akt (Ser473) is not even detectable (Fig. 3.6B). 
 
Interestingly, 1321N1 cells (unlike MDCK cells), appear to lack PTEN (Lackey et al., 
2007, Orchiston et al., 2004), the lipid phosphatase that negatively regulates PI3K 
signalling by dephosphorylating the 3'-OH position of PtdIns(3,4,5)P3 to produce 
PtdIns(4,5)P2 (see Introduction). MDCK cells with a stable shRNA-mediated knock-
down of PTEN have recently been generated by others (Lackey et al., 2007). Thus, 
the kinetics of Akt phosphorylation (Ser473) in response to influenza A virus 
infection were investigated in these MDCKΔPTEN cells, and the results compared 
with the kinetics observed for naïve MDCK cells. As shown in Fig. 3.6C, during the 
course of infection no differences in the phosphorylation state of Akt (Ser473) were 
observed between the two cell-lines. Interestingly, MDCKΔPTEN cells appear to 
undergo less cell death during virus infection than naïve cells (Fig. 3.6D), however it 
is clear from Fig. 3.6C that this is not due to sustained (and potentially anti-apoptotic) 
phosphorylation of Akt. As the expression of some shRNA vectors has been 
implicated in the overproduction of dsRNA, and thus the overstimulation of an IFN 
response (Bridge et al., 2003), this survival effect may be due solely to an enhanced 
anti-viral state within the cells. Although not observed in previous experiments, it is 
also worth noting a band possibly corresponding to cleaved Akt [a known 
consequence of apoptosis induction (Bachelder et al., 2001, Rokudai et al., 2000)], is 
readily detectable in virus-infected MDCK cells at 24h p.i. (Fig. 3.6C). 
 
Overall, the data suggest that PTEN activity does not play a critical role in the 
kinetics of Akt phosphorylation during influenza A virus infection. Clearly some 
other host-cell factor must act directly or indirectly to determine these kinetics. 
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Fig. 3.6. Kinetics of Akt phosphorylation during inﬂuenza A virus infections is cell-type 
speciﬁc. (A & B) Time-course of Akt phosphorylation at Ser473 following inﬂuenza A 
virus (PR8) infection of 1321N1 or MDCK cells. Conﬂuent serum-starved monolayers 
of 1321N1 or MDCK cells were infected (or mock [-]) with PR8 at an MOI of 5 PFU/cell, 
and total cell lysates were harvested at various times p.i.. Lysates were separated by SDS-
PAGE followed by transfer to PVDF membrane. Phospho-Akt (Ser473) was detected us-
ing a speciﬁc mAb. Total Akt was detected using a pAb and acted as a loading control. 
NS1 expression was detected using a speciﬁc pAb. (C) PTEN expression does not alter 
the kinetics of inﬂuenza A virus induced Akt phosphorylation in MDCK cells. Serum-
starved MDCK or MDCK∆PTEN monolayers were infected (or mock [-]) as for (A), and 
total cell lysates were harvested at various times p.i.. Lysates were also analysed as for (A). 
The band labelled cAkt is presumed to be an apoptosis-induced cleavage product of full-
length Akt. (D) Phase-contrast pictures of PR8-infected monolayers from (C) at 24h p.i.. 
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3.4 Binding of PI3K requires Tyr89 and Met93 of NS1. 
 
3.4.1 Assessment of a potential YXXM-like motif in NS1. 
In order to define the NS1-specific role of PI3K signalling during influenza A virus 
infection, it was of interest to identify single-amino acid substitutions in NS1 that 
prevented its binding and activation of PI3K. Tyrosine-phosphorylated YXXM motifs 
are considered consensus docking sites and activators of the SH2 domains of PI3K 
p85 subunits (Songyang et al., 1993). The amino-acid sequence of PR8/NS1 contains 
a single tyrosine residue (Tyr89), which is four residues upstream of a methionine 
(Met93) (Fig. 3.7A).  Alignment of 1546 NS1 protein sequences available in the 
public domain indicated that Tyr89 is absolutely conserved amongst all influenza A 
virus strains sequenced to date. Given the similarity in sequence between NS1 
residues 89-93 and classical YXXM motifs, the importance of this sequence for 
binding p85β was investigated. As the substitution of aspartic acid for glutamic acid 
at position 92 has been previously identified as a potential pathogenicity factor in 
some H5N1 isolates (Seo et al., 2002), it was also included in a panel of NS1 mutants 
that were assessed for their ability to interact with endogenous p85β. V5-tagged NS1 
constructs were expressed transiently in human 293T cells and immunoprecipitated 
with anti-V5 antibody. Co-precipitating p85β was detected by Western blot analysis. 
As shown in Fig. 3.7B, both wild-type PR8/NS1 and PR8/NS1-D92E precipitated 
p85β efficiently. In contrast, PR8/NS1 constructs containing Y89F or M93A 
substitutions were unable to precipitate p85β. The requirement for Tyr89 in binding 
p85β was further investigated by expressing and purifying a GST-PR8/NS1-Y89F 
fusion protein, and testing its in vitro interaction with baculovirus-expressed p85β. As 
expected, the PR8/NS1-Y89F mutant did not bind to either p85α or p85β (Fig. 3.7C). 
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Fig. 3.7. Binding of p85β requires residues from a YXXM-like motif in NS1. (A) Amino-
acid sequence of PR8/NS1 residues 87-95. The putative YXXM-like motif is shown in bold. 
Tyr-89 (denoted by *) is totally conserved among all inﬂuenza A virus NS1 proteins sequenced 
to date. (B) Binding of NS1 to p85β requires Tyr-89 and Met-93. 293T cells were transfected 
for 48h with either empty vector (-), a plasmid expressing WT V5-tagged PR8/NS1, or plas-
mids expressing V5-tagged PR8/NS1 proteins with single amino-acid substitutions (Y89F, 
D92E or M93A). Soluble antigen extracts were immunoprecipitated with anti-V5 antibody 
and precipitates separated by SDS-PAGE followed by transfer to PVDF membrane. p85β 
was detected using a speciﬁc mAb. Anti-V5 mAb was used to detect the V5-tagged NS1 mu-
tants. (C) WT GST-PR8/NS1 and GST-PR8/NS1 with the Y89F mutation were used as bait to 
precipitate p85α or p85β from baculovirus-infected Sf9 cell lysates. GST acted as a negative 
control. Protein complexes were analysed as for Fig. 3.4C. (D) As for (C), but using WT GST-
Ud/NS1 and GST-Ud/NS1-Y89F. Molecular weight markers (kDa) are indicated on the right. 
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These results were confirmed in the context of E. coli expressed GST-Ud/NS1 and 
GST-Ud/NS1-Y89F (Fig. 3.7D). 
 
3.4.2 Mutation of Tyr89 prevents induction of phospho-Akt.  
To investigate if NS1-Y89F was able to activate PI3K signalling, a 1321N1 cell-line 
that constitutively expresses the PR8/NS1-Y89F mutant protein was isolated. The 
intra-cellular localisation of PR8/NS1-Y89F in these cells was, like that of WT 
PR8/NS1 (Fig. 3.1B), predominantly nuclear (but not nucleolar; Fig. 3.8A). Serum-
starvation of both naïve and NS1-Y89F expressing cells for 1h caused a marked 
reduction in phospho-Akt (Ser473) levels (Fig. 3.8B, lanes 1-2, 5-6).  In contrast, 
there was no apparent reduction in Akt phosphorylation when cells expressing WT 
NS1 were similarly serum-starved (Fig. 3.8B, lanes 3-4). These data indicate that the 
binding of p85β (and activation of PI3K) absolutely requires the highly conserved 
tyrosine residue at position 89 of NS1. 
 
3.5 Effect of NS1-Tyr89 mutation on other interactions. 
 
Amino-acid substitution of Tyr89 for phenylalanine in NS1 could potentially disrupt 
the three-dimensional structure of NS1, or inhibit homodimerisation, thus preventing 
other functions of NS1. Although the cellular localisation of PR8/NS1-Y89F is 
similar to that of WT PR8/NS1 (compare Fig. 3.8A with Fig. 3.1B), it was necessary 
to determine if the Y89F mutation would prevent NS1 from interacting with host-cell 
proteins other than p85β. 
 
3.5.1 Interaction of PR8/NS1 with RIG-I, but not mda-5.  
A recently identified cellular partner for PR8/NS1 is RIG-I, a cytoplasmic RNA 
helicase involved in sensing RNA virus infection and initiating the innate antiviral 
Naive
PR8/NS1
(Y89F)
DAPIanti-V5 FITC
1321N1 cells
A
p-Akt
Akt
NS1
WT Y89FNaive
FBS: + + +- - -B
Fig. 3.8. Effect of Y89F amino-acid substitution on PR8/NS1. (A) Expression of PR8/
NS1 with the single amino-acid substitution Y89F does not affect its subcellular locali-
sation. Localisation of V5-tagged PR8/NS1-Y89F in 1321N1 cells was determined by in-
direct-immunoﬂuorescence using an anti-V5 FITC-conjugated mAb. Naive 1321N1 cells 
acted as a negative control. Cell nuclei were stained with DAPI. (B) Expression of PR8/
NS1 with the single amino-acid substitution Y89F does not induce the phosphorylation 
of Akt at Ser473. Serum-starved naive, PR8/NS1-expressing (WT), or mutant PR8/NS1-
expressing (Y89F) 1321N1 monolayers were treated (or mock) with 5% FBS for 1h. Cell 
lysates were separated by SDS-PAGE followed by transfer to PVDF membrane. Phospho-
Akt (Ser473) was detected using a speciﬁc mAb. Total Akt was detected using a pAb and 
acted as a loading control. PR8/NS1 (WT and Y89F) was detected using an anti-V5 mAb. 
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response (Guo et al., 2007, Mibayashi et al., 2007, Opitz et al., 2006, Pichlmair et al., 
2006) [see Introduction]. Thus, the ability of PR8/NS1-Y89F to interact with RIG-I 
was assessed. Initially, V5-tagged PR8/NS1 constructs (full-length or lacking the 
RNA-binding domain: PR8/NS1Δ73) were transiently co-expressed in 293T cells 
with either the GFP-tagged CARD domain or Helicase domain of RIG-I. 
Interestingly, immunoprecipitations using anti-V5 antibody revealed that both full-
length PR8/NS1 and PR8/NS1Δ73 could precipitate the CARD domain of RIG-I (Fig. 
3.9A). In contrast, only full-length PR8/NS1 (and not PR8/NS1Δ73) could efficiently 
precipitate the Helicase domain (Fig. 3.9A), an observation consistent with data 
indicating that the interaction between PR8/NS1 and RIG-I is enhanced by residues in 
the RNA-binding domain of NS1 (Pichlmair et al., 2006). However, the data 
presented here also indicate that PR8/NS1 may form a complex with the CARD 
domain of RIG-I independently of RNA-binding activity. It should be noted that 
(unlike for paramyxovirus V proteins), PR8/NS1 was not found to interact with mda-
5, a CARD/Helicase domain-containing protein functionally related to RIG-I (Fig. 
3.3B, Fig. 3.9B, (Andrejeva et al., 2004, Childs et al., 2007, Pichlmair et al., 2006)). 
 
3.5.2 Interaction of PR8/NS1-Y89F with RIG-I.  
Human 293T cells were co-transfected with plasmids expressing WT V5-tagged 
PR8/NS1, V5-tagged PR8/NS1-Y89F, or empty vector (negative control), together 
with either GFP-tagged RIG-I CARD or GFP-tagged RIG-I Helicase. Western blot 
analysis of proteins immunoprecipitated with the anti-V5 antibody showed that both 
RIG-I domains were co-precipitated with WT PR8/NS1 and PR8/NS1-Y89F (Fig. 
3.9C). Thus, substitution of Tyr89 for phenylalanine specifically prevents PR8/NS1 
from binding p85β, and probably does not disrupt the overall three-dimensional 
structure of NS1. 
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Fig. 3.9. Effect of Y89F amino-acid substitution on the ability of PR8/NS1 to inter-
act with RIG-I. (A) PR8/NS1 interacts with RIG-I.  293T cells were co-transfected for 
48h with a plasmid expressing the GFP-tagged CARD domain of RIG-I, or the GFP-tagged 
Helicase domain of RIG-I, together with either empty vector (-), a plasmid expressing 
V5-tagged full-length PR8/NS1 (WT), or a plasmid expressing the V5-tagged effector do-
main of PR8/NS1 (∆73). Soluble antigen extracts were immunoprecipitated with anti-V5 
antibody and precipitates separated by SDS-PAGE followed by transfer to PVDF mem-
brane. Co-precipitated GFP-tagged proteins were detected using a speciﬁc mAb. Anti-V5 
mAb was used to detect V5-tagged NS1 proteins. (B) PR8/NS1 does not interact with 
mda-5.  293T cells were co-transfected for 48h with a plasmid expressing myc-tagged 
mda-5, together with either empty vector (-), a plasmid expressing V5-tagged SeV/V, or 
a plasmid expressing V5-tagged PR8/NS1. Soluble antigen extracts were immunoprecipi-
tated with anti-V5 antibody and precipitates separated by SDS-PAGE followed by trans-
fer to PVDF membrane. Co-precipitated myc-mda-5 was detected using an anti-myc 
mAb. Anti-V5 mAb was used to detect V5-tagged proteins. (C) Y89F amino-acid sub-
stitution does not affect the interaction of PR8/NS1 with RIG-I.  293T cells were co-
transfected for 48h with a plasmid expressing the GFP-tagged CARD domain of RIG-I, or 
the GFP-tagged Helicase domain of RIG-I, together with either empty vector (-), a plas-
mid expressing V5-tagged PR8/NS1 (WT), or a plasmid expressing V5-tagged PR8/NS1-
Y89F (Y89F). Soluble antigen extracts were immunoprecipitated and analysed as for (A). 
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3.6 Requirement for PI3K during influenza A virus replication. 
 
3.6.1 PI3K inhibitors specifically reduce influenza A virus replication. 
Given that NS1 was found to bind and activate PI3K, the requirement of PI3K 
activation for efficient influenza A virus replication was determined. Initially, low 
multiplicity multi-step growth analyses were performed using commercially available 
PI3K inhibitors (such as the well-characterised LY294002 and wortmannin (Powis et 
al., 1994)). In MDCK cells, neither compound had a detrimental effect on the 
paramyxovirus, PIV5 (Fig. 3.10A), whilst a significant decrease in the yield of PR8 
was noted (Fig. 3.10B). The observed “recovery” of PR8 virus titres 72h and 96h p.i. 
may be due to degradation of the compounds, as only a fixed concentration was added 
to the cells at the time of inoculation. LY294002 and wortmannin are known to 
bind/inhibit a multitude of non-PI3K lipid and protein kinases (and thus may affect 
unrelated signalling pathways (Gharbi et al., 2007)), therefore LY303511 – a 
compound structurally related to LY294002 but which does not inhibit PI3K (Ding et 
al., 1995) – acted as a specific negative control. The results presented here are in 
agreement with those recently published by several other groups (Ehrhardt et al., 
2006, Shin et al., 2007b). However, studies have also shown that inhibitors of PI3K 
may actually block influenza A virus entry into cells (Ehrhardt et al., 2006), and 
LY294002 appears to prevent the production of IFN in HEp2 cells challenged by CPI- 
(data not shown; LY294002 also inhibits dsRNA:TLR3-mediated IRF-3 
phosphorylation/activation (Sarkar et al., 2004)). Thus, interpretation of studies using 
these compounds (particularly with specific regards to NS1-mediated PI3K 
activation) is likely to be confused by off-target effects, or by the inhibition of 
unrelated PI3K pathways. 
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Fig. 3.10. Speciﬁc inhibition of inﬂuenza A virus replication by the PI3K inhibi-
tors, LY294002 and wortmannin. Conﬂuent MDCK monolayers were infected for 1h 
with parainﬂuenza virus-5 (PIV-5; A) or inﬂuenza A virus (PR8; B) at an MOI of 0.001 
PFU/cell. Following virus adsorption, monolayers were treated with DMSO (open cir-
cles) [solvent control], 25µM LY303511 (closed circles) [LY294002 negative control], 
25µM LY294002 (open squares) [PI3K inhibitor], or 1µM wortmannin (closed squares) 
[potent PI3K inhibitor]. Virus containing supernatants were harvested at regular times 
p.i. and titres determined by plaque assay on Vero cells (PIV-5), or MDCK cells (PR8).
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3.6.2 Tissue culture replication of NS1-Y89F viruses.  
Given the potential difficulties in interpreting results from studies using LY294002 
and wortmannin, together with the identification of NS1-Y89F as a construct 
specifically unable to bind or activate PI3K, the particular importance of NS1-
mediated PI3K activation during influenza A virus replication was studied using 
recombinant mutant viruses. Nucleotides encoding the Y89F amino-acid substitution 
in NS1 were engineered into pHH21 vectors containing the Ud or WSN NS segments 
(such a mutation does not affect the amino-acid sequence of NEP). These plasmids 
were then used in the laboratory of Prof. Robert Lamb (Northwestern University, 
U.S.A.) to rescue recombinant rWSN and rUd viruses that expressed their strain-
specific NS1 proteins with Y89F amino-acid substitutions. Subsequent 
characterisation of the viruses by Dr. David Jackson (Northwestern University, 
U.S.A.) showed that the rUd NS1-Y89F mutant virus was clearly attenuated: it 
formed small plaques in MDCK cells (Fig. 3.11A), and grew to infectious titres ~10-
fold lower than WT rUd virus during single-step growth analysis (Fig. 3.11B). 
Haemagglutination assays showed a similar reduction in rUd NS1-Y89F titres, 
indicating that the attenuation was not due to an increase in the number of defective 
virus particles (data not shown). Western blot analysis confirmed that PI3K activation 
(i.e. phosphorylation of Akt at Ser473) did not occur in cells infected with the rUd 
NS1-Y89F virus (Fig. 3.11C). Interestingly, the rWSN mutant virus did not appear to 
exhibit an attenuated phenotype under tissue culture conditions. In MDCK cells, the 
plaque phenotype of rWSN NS1-Y89F was indistinguishable from that of WT rWSN 
NS1-Y89F (Fig. 3.12A), and no replication defects were observed during single-step 
growth analysis (Figs. 3.12B). Despite this, rWSN NS1-Y89F was unable to induce 
the phosphorylation of Akt (Ser473) during infection (Fig. 3.12C). 
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Fig. 3.11. Characterisation of a recombinant Ud virus (rUd) expressing NS1 with the 
Y89F amino-acid substitution. (A) rUd NS1-Y89F forms smaller plaques than WT rUd 
virus. Conﬂuent MDCK monolayers were infected at equal MOI with either WT rUd or rUd 
NS1-Y89F. Plaques were ﬁxed 4 days p.i. and immuno-stained with goat anti-Ud serum. (B) 
Single-step growth analysis of WT rUd (open circles) and rUd NS1-Y89F (closed cir-
cles). Recombinant Ud viruses were used to infect MDCK cell monolayers (in the absence 
of TPCK-trypsin) at an MOI of 3 PFU/cell. Virus-containing supernatants were harvested at 
various times p.i. and titrated by plaque assay. The mean titres from 3 independent experi-
ments are shown - error bars represent standard deviation. (C) Phosphorylation of Akt in 
response to either WT rUd or rUd NS1-Y89F viruses. Conﬂuent serum-starved monol-
ayers of 1321N1 cells were infected at an MOI of 5 PFU/cell, and total cell lysates were 
harvested at various times p.i.. Lysates were separated by SDS-PAGE followed by transfer to 
PVDF membrane. Phospho-Akt (Ser473) was detected using a speciﬁc mAb. Total Akt was 
detected using a pAb, and β-actin acted as a loading control. Ud HA and NP were detected us-
ing goat anti-Ud serum. Data courtesy of Dr. Dave Jackson, Northwestern University, U.S.A. 
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Fig. 3.12. Characterisation of a recombinant WSN virus (rWSN) expressing NS1 with 
the Y89F amino-acid substitution. (A) rWSN NS1-Y89F has a plaque phenotype in-
distingushable from WT rWSN. Conﬂuent MDCK monolayers were infected at equal 
MOI with either WT rWSN or rWSN NS1-Y89F. Plaques were ﬁxed 4 days p.i. and im-
muno-stained with rabbit anti-PR8 serum. (B) Single-step growth analysis of WT rWSN 
(open circles) and rWSN NS1-Y89F (closed circles). Recombinant WSN viruses were 
used to infect MDCK cell monolayers (in the absence of TPCK-trypsin) at an MOI of 3 
PFU/cell. Virus-containing supernatants were harvested at various times p.i. and titrated 
by plaque assay. Mean titres from 3 independent experiments are shown. (D) Phosphor-
ylation of Akt in response to either WT rWSN or rWSN NS1-Y89F viruses. Conﬂu-
ent serum-starved monolayers of 1321N1 cells were infected at an MOI of 5 PFU/cell, 
and total cell lysates were harvested at various times p.i.. Lysates were separated by SDS-
PAGE followed by transfer to PVDF membrane. Phospho-Akt (Ser473) was detected us-
ing a speciﬁc mAb. Total Akt was detected using a pAb, and acted as a loading control. 
Data for ﬁgs. B & C courtesy of Dr. Dave Jackson, Northwestern University, U.S.A. 
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3.6.3 In vivo replication of NS1-Y89F viruses. 
It is not clear why the Y89F mutation in Ud/NS1 should attenuate this virus strain, but 
appears to have no effect on the WSN strain. Ud virus is considered to be more 
closely related to human influenza A viruses than WSN, which is a highly 
neurovirulent and mouse-adapted strain of the virus (Castrucci & Kawaoka, 1993). 
Thus, it is possible that the indistinguishable phenotype between WT rWSN and 
rWSN NS1-Y89F observed in MDCK cells is due to host species differences. 
Therefore, it was determined if these recombinant WSN viruses differed in their 
pathogenicity and/or replication abilities in an in vivo mouse model (collaboration 
with Dr. Daniel Perez, University of Maryland, U.S.A.). 
 
Results indicated that approximately 10-fold less rWSN NS1-Y89F infectious virus 
(compared with WT rWSN) could be detected in the lungs of infected mice 2 days 
post-inoculation (Fig. 3.13A). However, at 4 and 6 days post-inoculation the amount 
of recovered rWSN WT and rWSN NS1-Y89F virus was the same (Fig. 3.13A). The 
body weight of infected mice over the timecourse of infection was also monitored. 
With an input inoculum of 105 PFU/mouse, WT rWSN induced a faster loss of body 
weight than rWSN NS1-Y89F, and the mice died (or had to be sacrificed) 
approximately 1 day earlier (Fig. 3.13B). With a lower infectious dose (104 
PFU/mouse), the differences were even more striking: WT rWSN caused a relatively 
rapid loss of body weight (~30% over 6-10 days) and mice died (or had to be 
sacrificed) at 7, 9 and 11 days (Fig. 3.13C). In contrast, the average body weight loss 
induced by infection with rWSN NS1-Y89F was only ~10%, and all the mice 
appeared to recover (Fig 3.13C). One exception was a single mouse infected with 
rWSN NS1-Y89F which lost body weight at a rate comparable to WT rWSN (dotted 
red line, Fig. 3.13C). The possibility that the virus in this host may have reverted 
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Fig. 3.13. Effect of Y89F amino-acid substitution on the pathogenicity of WSN in mice. 
(A) Mice were inoculated intra-nasally with either rWSN WT or rWSN NS1-Y89F. At 2, 
4, or 6 days post-inoculation mice were sacriﬁced, and virus titres within lung homoge-
nates were determined by plaque assay. Data show mean titres (PFU/g) from 3 mice at 
each time-point. Error bars represent standard deviation. (B & C) Mice were inoculated 
intra-nasally with either rWSN WT or rWSN NS1-Y89F (105 PFU, B; 106 PFU, C). Body 
weight for each mouse was determined daily. Data show mean body weight (%) for  4 mice 
per virus. Error bars represent standard deviation. Asterisks indicate sacriﬁce/death of a 
mouse. For (C), 1 mouse infected with rWSN NS1-Y89F lost body weight with kinetics 
similar to mice infected with WT rWSN (dotted red line), and was therefore excluded from 
analysis (see text). Raw data courtesy of Dr. Daniel Perez, University of Maryland, U.S.A. 
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back to wild-type is currently under investigation. In summary, these in vivo data 
indicate that Tyr89 in NS1 (and thus inferred PI3K activation) may play an important 
role in the pathogenicity and replication of WSN in mice.  
 
3.7 Studies on the biological role of PI3K activation by NS1. 
 
The results presented above demonstrate that NS1-mediated PI3K activation is 
important for the efficient replication of influenza A viruses, both in MDCK cells (for 
Ud) and in an in vivo mouse model (for WSN). In an attempt to define the biological 
reasons for PI3K stimulation during infection, WT rUd and rUd NS1-Y89F viruses 
were used as a comparative model system to investigate the biological role of NS1-
activated PI3K in tissue-culture cells. 
 
3.7.1 Phenotype of rUd NS1-Y89F is not IFN-dependent.  
Given that NS1 is a well-documented IFN-antagonist (Garcia-Sastre, 2005, Garcia-
Sastre et al., 1998, Krug et al., 2003), and that PI3K has been linked to the ability of 
cells to both produce and respond to IFNs (see Introduction), it was of interest to 
determine if the attenuation of rUd NS1-Y89F in MDCK cells was due to the inability 
of NS1-Y89F to counter the host innate immune response. 
 
MDCK cells constitutively expressing the V protein of PIV5 have previously been 
described (Precious et al., 2005). PIV5/V limits IFNβ production by binding directly 
to mda-5 (Andrejeva et al., 2004, He et al., 2002a, Poole et al., 2002), and completely 
blocks the IFN signalling response by targeting STAT1 for proteasome-mediated 
degradation (Didcock et al., 1999). Thus, cells constitutively expressing PIV5/V can 
support the replication of viruses lacking a fully-functional IFN-antagonist (Young et 
al., 2003). Plaque reduction assays clearly showed that rUd NS1-Y89F has a small 
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plaque phenotype in both naïve MDCK cells and MDCK cells constitutively 
expressing PIV5/V (Fig. 3.14A; the ability of PIV5/V to degrade canine STAT1 in 
MDCK cells is confirmed in Fig. 3.14B). These data indicate that the ability of NS1 
to activate PI3K is unlikely to play a major part in the IFN-antagonistic function of 
NS1, as attenuation of rUd NS1-Y89F appears independent of host IFN-mediated 
innate immune responses. 
 
3.7.2 PI3K does not limit host-cell gene expression. 
A number of influenza A virus NS1 proteins can counter cellular antiviral defences by 
inhibiting the processing and nuclear export of host-cell mRNAs (Nemeroff et al., 
1998, Noah et al., 2003, Satterly et al., 2007) [see also Introduction]. To assess if the 
Y89F mutation of NS1 in rUd NS1-Y89F and rWSN NS1-Y89F lead to their inability 
to block pre-mRNA processing, a TNFα-responsive luciferase reporter assay was 
used. A549 cells stably expressing the Firefly luciferase gene under the control of an 
NFκB promoter were infected overnight with either WT rUd, rUd NS1-Y89F, WT 
rWSN, or rWSN NS1-Y89F. Infected monolayers were treated (or not) with 
recombinant human TNFα for 6h in order to stimulate NFκB activity, and lysates 
were subsequently assayed for luciferase activity. As shown in Fig. 3.15, TNFα 
treatment of uninfected cells caused an approximate 8-fold increase in luciferase gene 
expression. In contrast, TNFα treatment of cells pre-infected with either WT rUd or 
rUd NS1-Y89F did not lead to a significant increase in luciferase gene expression 
(Fig. 3.15). Identical results were obtained for WT rWSN and rWSN NS1-Y89F (Fig. 
3.15). Thus, the Y89F mutation in NS1 does not prevent either Ud or WSN viruses 
from inhibiting the expression of host-cell genes, suggesting (as might be expected) 
that this function of NS1 is wholly independent of PI3K activity.  
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Fig. 3.14. Plaque phenotype of rUd NS1-Y89F is not rescued in cells deﬁcient in 
IFN-signalling. (A) Conﬂuent MDCK or MDCK/V monolayers were infected at equal 
MOI with either WT rUd or rUd NS1-Y89F. Plaques were ﬁxed 4 days p.i. and im-
muno-stained with rabbit anti-X31 serum. (B) Protein lysates from conﬂuent uninfect-
ed MDCK or MDCK/V monolayers were separated by SDS-PAGE followed by trans-
fer to PVDF membrane. STAT1 and β-actin were detected using speciﬁc antibodies. 
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Fig. 3.15. Inhibition of host-cell gene expression is not affected by the Y89F amino-acid 
substitution in NS1. A549 cells constitutively expressing the luciferase gene under the con-
trol of an NFkB-dependent promoter were infected (or mock) for 16h with rUd WT, rUd NS1-
Y89F, rWSN WT, or rWSN NS1-Y89F (MOI 5 PFU/cell). Monolayers were then treated (or 
not) with recombinant human TNFα for 6h (in order to stimulate NFkB), and lysates were sub-
sequently assayed for luciferase activity. Data show mean values from triplicate assays (RLU; 
relative light units), and are representative of two independent experiments. Error bars indicate 
standard deviation. Samples were also immunoblotted for β-actin (representative blot shown). 
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3.7.3 PI3K delays virus-induced PARP cleavage. 
Influenza A virus-infected cells often show significant signs of apoptosis (Fesq et al., 
1994, Hinshaw et al., 1994, Lowy, 2003, Takizawa et al., 1993), a defined form of 
cell death that is widely regarded as contributing to host antiviral defence. However, 
NS1 is reported to play a role in limiting the induction of apoptosis during infection 
(Li et al., 2006a, Stasakova et al., 2005, Zhirnov et al., 2002a) [see also 
Introduction]. Given that the PI3K/Akt signalling pathway is often exploited by 
viruses in order to prevent early cell death [see Introduction], a possible function of 
NS1-activated PI3K in delaying influenza A virus-induced apoptosis was 
investigated. A concurrent project within the group (carried out by Ms. Marian Killip) 
was focused on determining viral anti-apoptotic mechanisms, and the data shown 
below were generated as part of that study. 
 
PARP (poly-(ADP-ribose) polymerase) is a nuclear enzyme involved in DNA repair, 
and its direct cleavage by caspase-3 is commonly used as a marker for (influenza A) 
virus-induced apoptosis (Lin et al., 2002, Wurzer et al., 2003). Thus, HEp2 cells were 
infected (or mock) with either WT rUd or rUd NS1-Y89F (~50 PFU/cell), and cell 
lysates were immunoblotted for PARP cleavage at various times post-infection. As 
shown in Fig. 3.16, only the uncleaved (full-length) 116 kDa form of PARP can be 
detected in uninfected cells. In contrast, the 85 kDa proteolytic fragment indicative of 
apoptosis is readily visible in lysates from both WT rUd and rUd NS1-Y89F infected 
cells (Fig. 3.16). For WT rUd, the 85 kDa fragment is first observed at ~20h p.i., 
whilst for rUd NS1-Y89F this fragment is detectable at ~16h p.i. (Fig. 3.16). As rUd 
NS1-Y89F is unable to stimulate PI3K signalling (Fig. 3.11D), yet has no apparent 
defect in countering the innate immune response (Figs. 3.9C, 3.14A and 3.15), it is 
likely that NS1-mediated PI3K activation may delay virus-induced cell death. This 
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Fig. 3.16. rUd NS1-Y89F induces PARP cleavage faster than rUd WT in HEp2 
cells. HEp2 cells were infected (or mock, [-]) with rUd WT or rUd NS1-Y89F (MOI 50 
PFU/cell), and monolayers were harvested at 16h, 20h, and 24h p.i.. Lysates were sepa-
rated by SDS-PAGE followed by transfer to PVDF membrane. Full-length (PARP) 
and cleaved PARP (cPARP) were detected using a speciﬁc pAb. NS1 was detected us-
ing a rabbit pAb. Data courtesy of Ms. Marian Killip, University of St. Andrews. 
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hypothesis has recently been supported by indirect evidence from a number of groups 
(Ehrhardt et al., 2007a, Zhirnov & Klenk, 2007), and is currently being investigated 
further by another member of the laboratory (Ms. Marian Killip). Preliminary data 
also suggest that (in HEp2 cells), there is little difference in PARP cleavage 
(apoptosis induction) between the WT rWSN virus and the rWSN NS1-Y89F mutant 
(data not shown), which may explain why NS1-mediated PI3K activation appears to 
play no role in the replication cycle of WSN in MDCK cells (Fig. 3.12). Potential 
differences between Ud and WSN with regards apoptosis induction are also currently 
under investigation. 
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3.8 Investigating the mechanism of PI3K activation by NS1. 
 
3.8.1 NS1 RNA binding is not essential for p85β  binding. 
The ability of influenza A virus NS1 to bind RNA has been mapped to a number of 
basic residues in the first 73 amino-acids of the protein (Qian et al., 1995, Wang et 
al., 1999). In particular, arginine-38 probably interacts directly with the RNA target, 
whilst lysine-41 contributes significantly towards binding affinity (Wang et al., 
1999). As these residues have been implicated in the NS1-mediated regulation of 
numerous host-cell processes (Donelan et al., 2003, Min & Krug, 2006, Pichlmair et 
al., 2006, Talon et al., 2000a, Wang et al., 2000), their importance for the interaction 
of NS1 with p85β was investigated. 293T cells were transfected with plasmids 
expressing either WT V5-tagged PR8/NS1, or a V5-tagged PR8/NS1 construct that 
lacks RNA-binding activity (R38A and K41A amino-acid substitutions). Immunoblot 
analysis of proteins co-precipitated with the anti-V5 antibody revealed that both WT 
PR8/NS1 and PR8/NS1-R38AK41A efficiently precipitated endogenous p85β (Fig. 
3.17A). As described previously (section 3.5.1), a PR8/NS1 construct containing the 
single Y89F substitution is unable to precipitate p85β (Fig. 3.17A). 
 
To confirm that the entire RNA-binding domain of NS1 is not essential for binding 
p85β, the in vitro interaction of p85β with a recombinant E. coli expressed GST-
PR8/NS1 protein lacking the first 72 amino-acids of NS1 (termed GST-PR8/NS1Δ72) 
was tested. GST-PR8/NS1 fusion proteins (WT, Y89F, or Δ72) were immobilised 
onto glutathione-agarose beads and used to affinity isolate an excess of baculovirus-
expressed p85β. SDS-PAGE and Coomassie blue staining revealed that a single 90 
kDa protein (p85β) could be specifically isolated by both WT GST-PR8/NS1 and 
GST-PR8/NS1Δ72, but not by the GST-PR8/NS1-Y89F mutant (Fig. 3.17B). These 
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Fig. 3.17. The RNA-binding domain of PR8/NS1 is not required for the interaction with 
p85β. (A) 293T cells were transfected for 48h with empty vector (-), a plasmid express-
ing WT V5-tagged PR8/NS1, or plasmids expressing V5-tagged PR8/NS1 proteins with 
the amino-acid substitutions Y89F or R38AK41A. Soluble antigen extracts were immuno-
precipitated with anti-V5 antibody and precipitates separated by SDS-PAGE followed by 
transfer to PVDF membrane. Endogenous p85β and V5-tagged NS1 proteins were detected 
using speciﬁc mAbs. (B) Equal amounts of soluble Sf9 cell lysate (expressing p85β) were 
mixed with recombinant GST-NS1/Y89F, GST-NS1/WT, or GST-NS1∆72 protein immo-
bilized onto glutathione-agarose beads. After washing, protein complexes were dissociat-
ed from the beads and separated by SDS-PAGE through 4-12% polyacrylamide gradient 
gels.  Polypeptides were stained with Coomassie Blue, and protein identiﬁcation was con-
ﬁrmed by mass spectrometry. Molecular weight markers (kDa) are indicated to the right.
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data indicate that the C-terminal effector domain of NS1 alone is sufficient to form a 
stable complex with p85β. 
 
3.8.2 NS1 binds the inter-SH2 domain of p85β . 
In order to determine the domain of p85β that NS1 targets, N-terminal myc-tagged 
constructs corresponding to four domains of p85β were generated: SH3 (aa 1-100), 
nSH2 (aa 313-433), iSH2 (aa 433-610), and cSH2 (aa 611-724) (Fig. 1.14B). 
Transient expression of these constructs in 293T cells was followed by affinity 
isolation using E. coli expressed WT GST-PR8/NS1. Immunoblot analysis using an 
anti-myc antibody revealed that only the inter-SH2 domain of p85β (herein referred to 
as β-iSH2) co-precipitated with GST-PR8/NS1 (Fig. 3.18A). 
 
To verify the specific interaction between PR8/NS1 and β-iSH2 in a wholly 
mammalian expression system, [35S]methionine-labelled 6His-tagged β-iSH2 and 
unlabelled 6His-tagged PR8/NS1 were synthesised in reticulocyte lysates, mixed, and 
then immunoprecipitated with anti-NS1 antibody [unlabelled PR8/NS1 was used as it 
has a molecular weight similar to that of β-iSH2]. SDS-PAGE followed by 
phosphorimager analysis showed that β-iSH2 was efficiently precipitated from lysate 
mixtures containing both β-iSH2 and NS1, but not from lysates containing β-iSH2 
only (Fig. 3.18B). Similar experiments using an unrelated “prey” protein revealed that 
the observed interaction was not due to both β-iSH2 and PR8/NS1 constructs 
encoding 6His tags (data not shown, see also Fig. 3.21A). In addition, a recombinant 
6His-tagged form of β-iSH2 was expressed and purified from E. coli (see construct in 
Fig. 3.19A), and was assessed for its ability to compete with full-length p85β in the 
binding of WT GST-PR8/NS1. As shown in Fig. 3.18C, the binding of increasing 
amounts of β-iSH2 to E. coli expressed GST-PR8/NS1 prevented the subsequent 
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Fig. 3.18. PR8/NS1 binds the inter-SH2 domain of p85β. (A) 293T cells were transfected 
for 48h with plasmids expressing myc-tagged domain constructs of p85β: SH3, nSH2, iSH2 
or cSH2. Soluble antigen extracts were mixed with GST-NS1 glutathione-agarose beads and 
precipitates were analysed by SDS-PAGE followed by immunoblotting using an anti-myc 
mAb. Input GST-NS1 amount was conﬁrmed by detecting NS1 with a speciﬁc pAb. The 
original soluble antigen extracts were also probed with an anti-myc mAb in order to as-
sess relative expression of the myc-tagged constructs. (B) In vitro synthesised [35S]-methio-
nine-labelled β-iSH2 was mixed with unlabelled PR8/NS1 and immunoprecipitated using 
anti-NS1 pAb. Immunoprecipitation of β-iSH2 alone acted as a negative control. Protein 
complexes were separated by SDS-PAGE through 4-12% polyacrylamide gradient gels and 
subjected to phosphorimager analysis. (C) The inter-SH2 domain of p85β is the primary 
site of interaction for NS1. GST-NS1 immobilized onto glutathione-agarose beads was 
mixed with 2-fold increasing amounts of puriﬁed 6His-tagged β-iSH2 (E. coli expressed). 
After washing, a ﬁxed amount of soluble p85β-expressing Sf9 cell lysate was added. Sub-
sequent protein complexes were separated by SDS-PAGE, and GST-NS1 and β-iSH2 were 
visualised by Coomassie Blue staining. Levels of precipitated full-length p85β were deter-
mined by immunoblot analysis. Molecular weight markers (kDa) are indicated to the right.
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interaction of GST-PR8/NS1 with baculovirus-expressed p85β. Overall, these data 
reveal that β-iSH2 is the primary site of interaction between NS1 and p85β. 
 
3.8.3 Purification of NS1 in complex with β-iSH2. 
To further confirm direct binding between the C-terminal effector domain of NS1 and 
β-iSH2, an un-tagged complex of these proteins was purified. Constructs encoding 
GST-PR8/NS1Δ72 and 6His-tagged β-iSH2 (Fig. 3.19A) were co-expressed in E. 
coli, and glutathione-agarose beads were used to affinity isolate GST-PR8/NS1Δ72 
together with any associated proteins. It should be noted that both constructs have a 
cleavage sequence for the Tobacco Etch virus (TEV) protease between the protein of 
interest and the affinity tag. Glutathione eluted the bound proteins (Fig. 3.19B lane 
(i)), and this eluate was further purified on Ni-NTA resin. After imidazole elution 
(Fig. 3.19B, lane (ii)), the GST and 6His tags were cleaved from the recombinant 
proteins by TEV protease (Fig. 3.19B, lane (iii)). A second glutathione-agarose 
column removed free GST and uncleaved GST-PR8/NS1Δ72 (Fig. 3.19B, lane (iv)), 
whilst a second Ni-NTA column removed TEV (also 6His-tagged), uncleaved 6His-β-
iSH2, and the small ~2kDa cleavage product from 6His-β-iSH2. The flow-through 
from this column contained only two polypeptide species [as revealed by SDS-PAGE 
and Coomassie blue staining – Fig. 3.19B, lane (v)], which were confirmed as 
untagged PR8/NS1Δ72 and untagged β-iSH2 by mass spectrometry. In collaboration 
with Dr. Rupert Russell (University of St. Andrews, U.K.), protein complexes from 
similar purifications are currently in crystallisation trials. 
 
3.8.4 Does NS1:p85β  interaction require phospho-Tyr89? 
The observation that an NS1:β-iSH2 complex can be formed in vitro from E. coli 
expressed recombinant proteins argues against a phosphorylation-dependent 
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Fig. 3.19. Puriﬁcation of an untagged NS1∆72:β-iSH2 complex. (A) Schematic repre-
sentation of the GST-NS1∆72 and 6His-tagged β-iSH2 constructs. Numbers refer to resi-
dues from full-length PR8/NS1 and p85β. Sites of TEV protease cleavage are indicated. (B) 
SDS-PAGE analysis of the puriﬁcation process. Co-expressed GST-NS1∆72 and 6His-
β-iSH2 from E. coli were puriﬁed on glutathione-agarose beads and eluted using 10mM 
glutathione (i). The eluate was further puriﬁed on Ni-NTA resin and eluted in 100mM im-
idazole (ii). After TEV protease cleavage (iii), a second glutathione-agarose column was 
used to remove free GST (~25 kDa) and uncleaved GST-NS1∆72 (iv). A second Ni-NTA 
column was used to remove 6His-TEV (~25 kDa), uncleaved 6His-β-iSH2 (~25 kDa), and 
the small ~2 kDa cleavage product from 6His-β-iSH2 (band z). The ﬂow-through (v) con-
tained only two polypeptide species as determined by Coomassie Blue staining – untagged 
NS1∆72 (band y) and untagged β-iSH2 (band x). Molecular weight markers (kDa) are in-
dicated to the right. (C) The interaction is independent of NS1 Tyr-89 phosphorylation. 
293T cells were transfected for 48h with empty vector (-), a plasmid expressing WT V5-
tagged PR8/NS1, or plasmids expressing V5-tagged PR8/NS1 proteins with the amino-acid 
substitutions Y89F or Y89E. Soluble antigen extracts were immunoprecipitated with anti-
V5 antibody and precipitates separated by SDS-PAGE followed by transfer to PVDF mem-
brane. Endogenous p85β and V5-tagged NS1 proteins were detected using speciﬁc mAbs.
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interaction. However, abrogation of NS1 binding to p85β by a single Y89F mutation 
in NS1 (Fig. 3.7) is highly suggestive of a role for tyrosine-89 phosphorylation. In 
order to investigate the possibility that tyrosine-89 must first be phosphorylated in 
order to allow NS1 to bind p85β, a construct encoding V5-tagged PR8/NS1 with a 
Y89E amino-acid substitution (a mimic for the negative charge of phospho-tyrosine) 
was generated. Thus, plasmids encoding V5-tagged PR8/NS1-Y89E, V5-tagged 
PR8/NS1-Y89F, or V5-tagged WT PR8/NS1 were transiently expressed in human 
293T cells and subsequently immunoprecipitated with anti-V5 antibody. Western blot 
analysis of the immunoprecipitates revealed that only WT PR8/NS1 (and not the 
Y89F or Y89E mutants) was able to precipitate endogenous p85β (Fig. 3.19C). 
Together with the direct in vitro binding results from Fig. 3.19B, the data imply that 
phosphorylation of tyrosine-89 is not a determinant of the NS1:p85β interaction. 
 
3.8.5 Binding of NS1 to β-iSH2 does not displace p110. 
In the original identification of p85β as a direct binding partner for NS1, no other 
polypeptide band corresponding to any p110 isoform could be detected in NS1 
immunoprecipitates from HEp2 cells (Fig. 3.3B). This was surprising given that class 
IA PI3Ks are reported to be obligate p85:p110 heterodimers (Geering et al., 2007, Yu 
et al., 1998). Thus, an equimolar amount of p110 and p85β might have been expected 
to be co-precipitated with NS1. One explanation for this discrepancy might come 
from the observation that HEp2 cells express relatively low levels of p110α protein as 
compared with other commonly used laboratory cell-lines (Vanhaesebroeck et al., 
1997b). However, given that both p85 and p110 are unstable in the absence of their 
corresponding PI3K binding partner (Brachmann et al., 2005, Yu et al., 1998, Zhao et 
al, 2006), it is supposed that the level of p85β in HEp2 cells would mirror the reduced 
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level of p110α. An alternative explanation might therefore be that the 
immunoprecipitation conditions used in the initial study caused disruption of 
p85:p110, or that the C-terminal V5-tag of NS1 in complex with antibody caused the 
dissociation of p85 from p110. A combination of these factors may be possible, as 
analysis of NS1 immunoprecipitates from HEp2 cell extracts at low NaCl 
concentrations (150mM) did reveal a protein that was later identified as p110α by 
mass spectrometry (data not shown). 
 
Despite this, given that NS1 interacts directly with the p110-binding domain of p85β 
(section 3.8.2), it was necessary to investigate the possibility that NS1 might displace 
p110 subunits from p85β. Thus, in collaboration with Prof. Peter Downes and Dr. Ian 
Batty (University of Dundee, U.K.), a kinase activity assay was used to determine if 
NS1 could associate with a p110-containing complex. V5-tagged WT PR8/NS1 or 
V5-tagged PR8/NS1-Y89F were immunoprecipitated from human 1321N1 cells 
stably expressing the appropriate construct, and these immunoprecipitates were 
subjected to in vitro PI3K activity assays (immunoprecipitates from naïve 1321N1 
cells acted as a negative control). It should be noted that these immunoprecipitations 
were performed using NaCl concentrations of ~150mM. As shown in Fig. 3.20A, 
significant PI3K activity was readily detectable in V5 immunoprecipitates from 
lysates expressing WT PR8/NS1, but not from naïve lysates, or from lysates 
expressing PR8/NS1-Y89F (which is unable to bind p85β). 
 
The ability of WT PR8/NS1 (but not PR8/NS1-Y89F) to precipitate PI3K activity is 
most likely due to the indirect co-precipitation of a p110 catalytic subunit via p85β, 
although attempts to physically detect co-precipitating p110α by immunoblot failed. 
Therefore, to truly establish if the interaction was possible, the formation of a 
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heterotrimeric complex comprising NS1, β-iSH2, and the p85-binding domain of 
p110α (also known as the p110α adaptor binding domain; p110α-ABD) was 
investigated. Initially, [35S]methionine-labelled β-iSH2 and HA-tagged p110α-ABD 
were individually or co-synthesised in reticulocyte lysates and immunoprecipitated 
using anti-HA antibody. SDS-PAGE and phosphorimager analysis showed that β-
iSH2 could be specifically co-precipitated together with p110α-ABD (Fig. 3.20B), 
indicating that the β-iSH2 construct was able to interact with p110α-ABD. 
Individually synthesised [35S]methionine-labelled β-iSH2 or p110α-ABD, as well as 
unlabelled PR8/NS1, were mixed in various combinations and immunoprecipitated 
with anti-NS1 antibody. As expected, only β-iSH2 (and not p110α-ABD) could be 
co-precipitated directly with PR8/NS1 (Fig. 3.20C, lanes 4-7). However, p110α-ABD 
was clearly evident in immunoprecipitates of PR8/NS1 that contained β-iSH2 (Fig. 
3.20C, lane 8). This confirms that the binding of NS1 to β-iSH2 does not prevent 
interactions between β-iSH2 and p110α-ABD, and suggests that a heterotrimeric 
complex consisting of NS1, p85β, and p110α could potentially form. 
 
3.8.6 Binding of NS1 requires the C-terminus of β-iSH2. 
As the interaction between NS1 and β-iSH2 is independent of the p110-binding site 
(Fig. 3.20C), it is likely that NS1 must bind elsewhere on the molecule. Previously, it 
has been shown that truncation of p85α at residue 571 causes constitutive p110 
catalytic activity (Jimenez et al., 1998). Thus, given that residues downstream of 571 
in p85α must therefore play an inhibitory role with regards to PI3K activation, it was 
investigated whether this same regulatory region in p85β was targeted (and thus 
potentially masked) by NS1. In vitro synthesised [35S]methionine-labelled β-iSH2, or 
a β-iSH2 construct lacking residues downstream of amino-acid 564 (equivalent to 
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Fig. 3.20. NS1 can form a heterotrimeric complex containing β-iSH2 and p110. (A) V5-
tagged WT PR8/NS1 or V5-tagged PR8/NS1-Y89F were immunoprecipitated from equal 
amounts of stably expressing 1321N1 cell lysates and assayed for associated PI3K activity. 
Naïve 1321N1 cell lysate acted as a negative control. Results show the mean and stand-
ard deviation of triplicate values obtained in a single experiment, and are representative of 
two similar experiments. (B) Individually synthesised [35S]-methionine-labelled β-iSH2 and 
HA-tagged p110α-ABD (or co-synthesised β-iSH2 and HA-p110α-ABD) were immunopre-
cipitated using anti-HA mAb. Labelled complexes were separated by SDS-PAGE through 
4-12% polyacrylamide gradient gels and subjected to phosphorimager analysis. (C) [35S]-
methionine-labelled β-iSH2 and HA-p110α-ABD were mixed individually (or together) 
with unlabelled PR8/NS1, and immunoprecipitated using anti-NS1 pAb. Labelled proteins 
co-precipitating with PR8/NS1 were visualised as for (B). The immunoprecipitations and in 
vitro PI3K activity assays for (A) were performed by Dr. Ian Batty, University of Dundee.
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truncation at residue 571 in p85α; termed β-iSH2’565), were mixed with unlabelled 
PR8/NS1 and then immunoprecipitated with anti-NS1 antibody. SDS-PAGE and 
phosphorimager analysis clearly showed that β-iSH2’565, unlike β-iSH2, was not 
precipitated by PR8/NS1 (Fig. 3.21A, lanes 1-6). These data were replicated using 
longer β-iSH2 constructs that also contained the adjacent nSH2 domain of p85β (Fig. 
3.21A, lanes 7-12). The inability of PR8/NS1 to bind β-iSH2’565 is unlikely to be 
caused by gross non-specific disruption of the coiled-coil structure, as the nSH2-
iSH2’565 construct could still interact with p110α-ABD (Fig. 3.21B). These data 
indicate that residues at the C-terminal end of β-iSH2 are required for NS1 binding. 
To confirm this, the C-terminal 45 residues of β-iSH2 (i.e. amino acids 565-610 of 
full-length p85β) were expressed and purified as a GST fusion protein, and 
subsequently used to affinity isolate in vitro synthesised [35S]methionine-labelled 
PR8/NS1. As shown in Fig. 3.21C, the GST-tagged form of β-iSH2 (565-610) was 
able to precipitate more PR8/NS1 than the GST control alone. 
 
3.8.7 Other proteins and NS1-mediated PI3K activation? 
As NS1 expression alone causes the constitutive Ser473 phosphorylation of Akt (Fig. 
3.5), it is apparent that no other influenza A virus-derived factors are required to 
activate PI3K signalling. However, it is unclear exactly how NS1 can increase p110 
catalytic activity simply by binding to a C-terminal site of β-iSH2 (the means by 
which this region normally negatively regulates p110 function is currently unknown). 
Thus, it may be that NS1 recruits a host-cell “activating” factor to the p85β:p110 
complex rather than masking an inhibitory domain. In this regard, it is of interest to 
note that the NS1:p85β complex can precipitate a host-cell protein of ~180 kDa (Fig. 
3.22A). This interaction was identified as part of the initial effort to determine if NS1 
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Fig. 3.21. Interaction between NS1 and β-iSH2 requires residues at the C-terminus of 
β-iSH2. (A) [35S]-methionine-labelled β-iSH2 and nSH2-iSH2 (or similar constructs con-
taining a stop codon at residue 565: β-iSH2ʼ565 and nSH2-iSH2ʼ565) were mixed individu-
ally with unlabelled PR8/NS1, and immunoprecipitated using anti-NS1 pAb. An identical 
procedure in the absence of PR8/NS1 (-) acted as a negative control.  Precipitated labelled 
proteins were visualised as for Fig. 3.19B. (B) Truncation at residue 565 of the nSH2-iSH2 
construct does not affect the p110-binding site. [35S]-methionine-labelled nSH2-iSH2ʼ565 
and HA-tagged p110α-ABD were individually synthesised, mixed, and immunoprecipitat-
ed with anti-HA mAb. Immunoprecipitation of nSH2-iSH2ʼ565 alone acted as a negative 
control. Detection of labelled proteins was as for (A). (C) Equal amounts of [35S]-methio-
nine-labelled PR8/NS1 were mixed with recombinant GST or GST-iSH2(565-610) immo-
bilized onto glutathione-agarose beads. After washing, protein complexes were dissociated 
from the beads and separated by SDS-PAGE through 4-12% polyacrylamide gradient gels. 
Polypeptides were visualised by either phosphormager analysis or Coomassie Blue staining. 
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was tyrosine phosphorylated. V5-tagged PR8/NS1 immunoprecipitates from 
transiently transfected 293T cells were immunoblotted using an anti-phosphotyrosine 
antibody. Although, a phospho-tyrosine band corresponding to NS1 could not be 
detected due to the experimental procedure used (it was obscured by immunoglobulin 
light chain), a single tyrosine-phosphorylated host-cell polypeptide of ~180 kDa was 
observed specifically co-precipitating with WT PR8/NS1, but not with PR8/NS1-
Y89F (Fig. 3.22A). As PR8/NS1-Y89F cannot bind p85β, this indicated that the 
tyrosine-phosphorylated protein was either competing with p85β for the same site on 
NS1, or was co-precipitated indirectly via p85β. To address this (and to identify the 
protein), GST-PR8/NS1 alone, or GST-PR8/NS1 complexed with baculovirus-
expressed p85β, was used to affinity isolate proteins from a 293T cell extract (~1x107 
cells). SDS-PAGE and Coomassie Blue staining revealed a single protein (~180 kDa) 
that specifically precipitated with the GST-PR8/NS1:p85β complex, but not with 
GST-PR8/NS1 alone (Fig. 3.22B), indicating that p85β probably acted as a bridge 
between NS1 and the host-cell protein. Mass spectrometry identified the ~180 kDa 
protein as insulin receptor substrate 4 (IRS-4), a highly tyrosine-phosphorylated 
protein abundantly expressed in 293 cells (Fantin et al., 1998, Kuhne et al., 1995, 
Lavan et al., 1997). IRS-4 normally binds to the SH2 domains of p85 molecules, and 
thus acts as an activating adapter between insulin/growth factor receptors and the 
PI3K heterodimer (Fantin et al., 1998). As IRS-4 is estimated to be the major IRS in 
293 cells (Fantin et al., 1998), it is possible that the observed co-precipitation of IRS-
4 with GST-PR8/NS1:p85β is an artifact of excess soluble IRS-4 being "mopped-up" 
by the free SH2 domains of p85β. Thus, work in other cell-lines is currently 
underway to determine if IRS-4 (or any other IRS) actually plays a specific role in 
NS1-mediated PI3K activation.  
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Fig. 3.22. Identiﬁcation of IRS-4 as a host-cell protein that co-precipitates with the PR8/
NS1:p85β complex in 293T cells. (A) 293T cells were transfected for 48h with either a plas-
mid expressing the WT V5-tagged PR8/NS1 protein, or the V5-tagged PR8/NS1-Y89F mutant. 
Soluble antigen extracts were immunoprecipitated with anti-V5 antibody (rabbit) and precip-
itates separated by SDS-PAGE followed by transfer to PVDF membrane. Tyrosine phosphor-
ylated (pY) proteins were detected using a speciﬁc mouse mAb.  Endogenous co-precipitating 
p85β was detected using a speciﬁc mAb. Anti-V5 mAb was used to detect V5-tagged NS1 pro-
teins. Molecular weight markers (kDa) are indicated to the right. (B) Equal amounts of soluble 
Sf9 cell lysate (expressing p85β, or mock [-]) were mixed with E. coli expressed recombinant 
GST-PR8/NS1 (WT) immobilized onto glutathione-agarose beads and subsequently mixed 
with 293T cell extract equivalent to ~5x106 cells. After washing, protein complexes were dis-
sociated from the beads and separated by SDS-PAGE through 4-12% polyacrylamide gradi-
ent gels.  Polypeptides were stained with Coomassie Blue, and protein identiﬁcation was per-
formed by the University of St. Andrews mass spectrometry facility. Breakdown products of 
GST-NS1 are indicated by asterisks. Molecular weight markers (kDa) are indicated to the right.
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3.9 PI3K signalling as a potential anti-influenza drug target. 
 
3.9.1 Engineering of cell-lines that limit virus replication. 
Blocking the ability of NS1 protein to bind one of its cellular targets has recently been 
described as a “proof-of-principle” approach to limit influenza A virus replication 
(Twu et al., 2006). Twu et al. generated an MDCK cell-line stably expressing a ~60 
amino acid fragment of CPSF30 that interacts with NS1, and demonstrated that 
expression of this fragment could prevent Ud virus from inhibiting the post-
transcriptional processing of cellular pre-mRNAs (Twu et al., 2006). This lead to 
attenuation of Ud virus replication, presumably via a mechanism involving an 
increased innate immune response (Twu et al., 2006). 
 
In this study, a similar approach was undertaken to determine if blocking the 
NS1:p85β interaction could attenuate influenza A virus replication. Lentivirus 
technology was used to generate MDCK cell-lines that stably express either C-
terminal V5-tagged β-iSH2, or identically tagged β-iSH2 with an N-terminal nuclear 
localisation sequence (NLS; MPKKKRKV, derived from the SV40 T antigen). β-
iSH2 is able to compete with full-length p85β for binding to NS1 (Fig. 3.18C), 
therefore the rationale was to express a polypeptide that would prevent NS1 from 
forming a complex with, and activating, PI3K. The V5-tag facilitated detection of the 
recombinant proteins, whilst the NLS was added in order to redirect the protein to the 
nucleus (where NS1 is usually predominantly localised in virus-infected cells). 
Immunoblot analysis of the cell lysates using anti-V5 antibody verified the stable 
expression of each construct (Fig. 3.23A). As expected, treatment of starved, naïve 
MDCK cells with either 10% FBS or PR8 infection (MOI ~5 PFU/cell) resulted in the 
phosphorylation of Akt at Ser473 (Fig. 3.23A). Similar treatment of β-iSH2 
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expressing MDCK cells yielded identical results, indicating that this construct had no 
effect on the ability of either FBS or influenza A virus to activate PI3K (Fig. 3.23A). 
Surprisingly, no Ser473 phosphorylation of Akt could be detected in cells expressing 
the N-terminally NLS-tagged β-iSH2 construct (Fig. 3.23A). Basal levels of phospho-
Akt were also undetectable in these cells (Fig. 3.23A), suggesting that this construct 
inhibited general PI3K activity independently of the stimulus (i.e. FBS or influenza A 
virus infection). The reasons why such a nuclear localised construct might block PI3K 
are unknown, but one possibility may be that NLS-β-iSH2 sequesters p110 into the 
nucleus away from its plasma membrane substrates, or that the NLS from SV40 T 
antigen has some effect. Nevertheless, plaque reduction assays revealed that WT Ud 
virus was attenuated in the MDCK cell-line expressing NLS-β-iSH2, as compared 
with the naïve cell-line and the cell-line expressing β-iSH2 only (Fig. 3.23B). 
 
Given the previous observation that rWSN NS1-Y89F showed no attenuation in naïve 
MDCK cells despite its inability to activate PI3K (Fig. 3.12), it was perhaps not 
surprising that WT WSN did not display any attenuation (as determined by plaque 
reduction assays) in the cells expressing NLS-β-iSH2 (Fig. 3.23B). Together, these 
data confirm previous results which indicate that PI3K activation is important for the 
tissue-culture replication of Ud (but not WSN) influenza A viruses. However, it 
should be noted that the ability to activate PI3K still appears to be important for the 
pathogenicity of WSN in vivo (Fig. 3.13). 
 
3.9.2 Assay development to screen for NS1:p85β  interaction inhibitors. 
Small molecules are not generally considered suitable for disrupting the large and 
hydrophobic interfaces that often mediate protein:protein interactions (Cochran, 2000, 
Cochran, 2001, Toogood, 2002). Nevertheless, several studies have shown that 
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Fig. 3.23. Characterisation of MDCK cell-lines constitutively expressing β-iSH2 con-
structs. (A) Phosphorylation of Akt in response to either serum or PR8. Conﬂuent 
serum-starved monolayers of naive MDCK cells, or MDCK cells constitutively express-
ing either V5-tagged β-iSH2 (iSH2-V5) or V5-tagged β-iSH2 with an N-terminal NLS 
(NLS-iSH2-V5)  were left untreated, treated with 10% FBS, or infected with PR8 at an 
MOI of 5 PFU/cell, and total cell lysates were harvested ~8h p.i.. Lysates were separat-
ed by SDS-PAGE followed by transfer to PVDF membrane. Phospho-Akt (Ser473) was 
detected using a speciﬁc mAb. Detection of β-actin acted as a loading control. Anti-V5 
mAb was used to detect V5-tagged β-iSH2 constructs, and a speciﬁc pAb was used to de-
tect NS1. (B) Ud virus (but not WSN virus) forms smaller plaques in MDCK cells ex-
pressing NLS-iSH2-V5 than in naive MDCK cells. Conﬂuent MDCK cell-line monol-
ayers were infected at equal MOI with either WT rUd or WT rWSN. Plaques were ﬁxed 
4 days p.i. and immuno-stained with either rabbit anti-X31 or rabbit anti-PR8 serum. 
3. Results 
(v) PI3K as an antiviral target 
 - 118 - 
protein associations can be inhibited by small molecules (Berg et al., 2002, Degterev 
et al., 2001, Duncan et al., 2001, Lepourcelet et al., 2004, Stoll et al., 2001), leading 
to the possibility that aberrant protein:protein interactions (including virus:host 
interactions) could be novel sites for drug intervention. Protein binding events 
commonly rely on a few important amino-acid contacts that would be ideal targets. 
Although the x-ray crystal structure of the NS1:p85β complex interface would 
provide detailed information on these essential residues, single point mutation 
analysis has already shown that Tyr89 of NS1 is a critical determinant (Fig. 3.7). 
 
In an identical strategy to the successful ELISA-based screening technique utilised by 
others (Lepourcelet et al., 2004), an assay was developed that might be used to 
identify small molecular weight compounds that specifically inhibit the interaction 
between NS1 and p85β. Purified GST-NS1 was coated onto microtitre plates and 
incubated with Sf9 cell lysate expressing p85β. GST alone, or naive Sf9 cell lysate 
acted as the relevant negative control. Anti-p85β antibody was used to detect bound 
p85β, which was visualised using an alkaline phosphatase conjugated secondary 
antibody, together with the appropriate substrate. As shown in Fig. 3.24A, a positive 
result (binding) was clearly obtained when p85β-expressing lysate was incubated with 
GST-NS1. No alkaline phosphatase activity was detectable when using GST alone as 
“bait”, or when using naïve Sf9 cell lysate as “prey”, indicating the specificity of the 
ELISA. The results are quantified and plotted in Fig. 3.24B. This strategy has been 
used in preliminary assays to screen ~200 compounds for potential inhibitory effects 
on the NS1:p85β interaction (collaboration with Dr. Nick Westwood, University of 
St. Andrews, U.K.). As might be expected from such a small-scale screen, no 
potential "hits" were identified. The methodology is currently under refinement in 
order to make it more amenable to high-throughput screening. 
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Fig. 3.24. Development of an ELISA-based assay to screen for inhibitors of the NS1:
p85β interaction. (A) 1µg of recombinant, puriﬁed, E. coli expressed GST or GST-NS1 
was adsorbed to wells of a ﬂat-bottomed 96-well ELISA plate, and doubling dilutions of 
Sf9 cell lysate expressing (or not) p85β were applied in duplicate. After washing, bound 
p85β was detected using a speciﬁc mAb in combination with an HRP-conjugated sec-
ondary antibody. TMB peroxidase substrate was used to visualise wells containing p85β 
(yellow). (B) Plot of the relative absorbance units (450nm) per well determined for the 
plate shown in (A). Data represent the mean values for each duplicate. Legend: blue, 
GST + mock; red, GST + p85β; yellow, GST-NS1 + mock; green, GST-NS1 + p85β.
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4.1 Influenza A virus NS1 protein binds and activates PI3K. 
In this thesis, the interaction of several influenza A virus NS1 proteins with the p85β 
regulatory subunit of PI3K is reported. PI3K activity could be co-precipitated with 
NS1 from cell-lysates, and expression of NS1 alone in cells was sufficient to cause 
the PI3K-dependent phosphorylation of Akt, a major downstream effector of PI3K. 
During the course of this study, these results were confirmed and published by several 
other groups (Ehrhardt et al., 2007a, Shin et al., 2007a, Shin et al., 2007b, Shin et al., 
in press, Zhirnov & Klenk, 2007). 
 
4.1.1 NS1 proteins bind p85β , but not p85α . 
The two PI3K p85 isoforms (p85α and p85β) are encoded by separate genes, yet 
exhibit ~55% protein sequence identity and high structural homology. Both are 
expressed in a wide range of tissues, but p85α is generally thought to be involved in 
the major response pathway for most PI3K-mediated stimuli. The physiological role 
of p85β in vivo is largely unknown. Given that p85β expression is reported to be 
~40% that of p85α (Ueki et al., 2003), it was remarkable to find that influenza A 
virus NS1 proteins directly bind to p85β (and activate PI3K), whilst no evidence for 
NS1 binding p85α could be established. This intriguing observation has recently been 
confirmed by Shin and colleagues, who used different experimental conditions to 
those described here (Shin et al., in press).  
 
Subsequent to this study, Ehrhardt and colleagues reported the co-precipitation of 
NS1 with both p85α and p85β from influenza A virus-infected human cells (Ehrhardt 
et al., 2007a). However, the co-precipitation of NS1 with p85α was weak, and could 
not be detected when both NS1 and p85α were transiently expressed from plasmids 
(Ehrhardt et al., 2007a). Additionally, no significant interaction between NS1 and 
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p85α was observed in yeast two-hybrid assays (Ehrhardt et al., 2007a). Together, 
these data suggest that the observed NS1:p85α interaction is indirect, and may require 
an important (and possibly virus-encoded) co-factor. Alternatively, NS1 may have a 
significantly higher binding affinity for p85β than for p85α. 
 
A number of studies have attempted to establish distinct roles for p85α and p85β in 
the regulation of different PI3K-dependent or -independent pathways (Deane et al., 
2004, Hartley et al., 1995, Ueki et al., 2003, Ueki et al., 2002, Vanhaesebroeck et al., 
2005), but other than a possible function in limiting T-cell expansion (Deane et al., 
2004), p85β has yet to be specifically associated with a role directly relevant to virus 
infection. As detailed below, further work is clearly required to determine the (as yet 
unknown) consequences of NS1 primarily targeting p85β, both for the virus and for 
the host. Excitingly, such studies may yield valuable information regarding the 
normal cellular function of p85β in specific PI3K signalling pathways. Additionally, 
there is the possibility that NS1 also discriminates between the various differentially 
expressed p110 isoforms, which may contribute to cell-type dependent NS1-mediated 
PI3K responses. 
 
4.1.2 Mechanism of PI3K activation by NS1. 
A major part of this study was to map the interaction between NS1 and p85β in an 
attempt to determine the mechanism of NS1-mediated PI3K activation. Although it is 
clear that NS1 proteins from different strain origins may possess distinct biological 
properties (as determined by their ability to differentially interact with some host-cell 
proteins [Kochs et al. 2007a]), there is no reason at present to believe that NS1 
proteins bind and activate PI3K by separate means. Thus, PR8/NS1 was used as the 
sole model to investigate NS1-mediated binding to p85β. 
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4.1.2.1 The binding site on NS1. 
Here it is demonstrated that the direct binding of NS1 to p85β is independent of NS1 
RNA-binding activity, and is primarily mediated via the C-terminal effector domain 
of NS1. Additionally, tyrosine-89 and methionine-93 (both in the C-terminal effector 
domain of NS1) were identified as essential residues for binding p85β. These two 
residues were initially of interest as they formed part of a putative motif with 
similarity to the well-documented PI3K SH2-binding motif, phospho-YXXM 
(Songyang et al., 1993). 
 
Results from this and other studies indicate that the activation of PI3K by NS1 
probably does not involve tyrosine-phosphorylated NS1 occupying a p85β SH2 
domain. Firstly, an interaction could not be detected between NS1 and either of the 
two p85β SH2 domains. Secondly, NS1 with glutamic acid substituted as a mimic of 
phospho-tyrosine at residue 89 was unable to bind full-length p85β, and the 
interaction domains of NS1 and p85β could be expressed and purified as a protein 
complex entirely from E. coli. Thirdly, previous YXXM phosphopeptide binding 
studies have shown relatively conserved pockets in both p85 SH2 domains, which are 
strongly selective for methionine only at the Tyr+3 position (Songyang et al., 1993). 
In NS1, the relevant methionine is at the Tyr+4 position and is thereby unlikely to be 
presented in the appropriate orientation. Finally, recent structural analysis of the 
PR8/NS1 effector domain indicates that whilst tyrosine-89 appears exposed within a 
cleft formed at the interface between the two PR8/NS1 monomers, methionine-93 is 
mostly buried within the PR8/NS1 homodimer (Bornholdt & Prasad, 2006) (Fig. 4.1). 
Thus, whilst the location of tyrosine-89 on the border of an extended chain 
region/helix means it is well positioned for a role in binding p85β, it is not possible 
for methionine-93 to be directly involved in the interaction with p85β without a major 
AFig. 4.1. Position of tyrosine-89 and methionine-93 in the C-terminal effector domain of 
NS1. (A) Front-surface and front-cartoon representations of the C-terminal effector domain 
homodimer with tyrosine-89 highlighted in red. The two monomers are coloured green and 
blue. (B) Front-cartoon representation of the C-terminal effector domain with methionine-
93 highlighted in red. A surface representation cannot be shown as methionine-93 is buried 
within the homodimer. Images were prepared using MacPyMol (Protein Data Bank ﬁle: 
2GX9). 
B
D
A Surface - Front
Cartoon - Front (Y89)
Cartoon - Front (M93)
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conformational change in NS1. The observation that mutation of methionine-93 
abrogates p85β binding may therefore be due to destabilisation of the NS1 
homodimer, as this residue could be important for maintaining the functional integrity 
of the NS1 structure. 
 
Of course, it is entirely possible that substitution of phenylalanine for tyrosine-89 also 
destabilises NS1. However, the observation that this mutant (PR8) protein, like WT, 
predominantly localises to the nucleus of cells (and can co-precipitate RIG-I), 
strongly argues against structural disruption of the protein. Moreover, the rUd NS1-
Y89F virus was only attenuated ~10-fold in MDCK cells compared to WT rUd, 
whilst influenza A viruses completely unable to express NS1 are reported to be 
attenuated ~1000-fold in MDCK cells (Garcia-Sastre et al., 1998). Indeed, a 
substitution of phenylalanine for tyrosine is relatively conservative (as compared with 
alanine for methionine), and it is difficult to envisage how this change could seriously 
affect protein structure (Fig. 4.2). 
 
4.1.2.2 The binding site on p85β . 
Competition assays from this work clearly establish that the primary direct binding 
site for NS1 in p85β is the iSH2 domain. Structurally, iSH2 is predicted to be a rigid 
100-110Å coiled-coil of two anti-parallel α-helices (Dhand et al., 1994, Fu et al., 
2003). The helices are ~70 amino-acids long (helix-1; residues 434-505, and helix-2; 
residues 511-581), and are connected by a loop of 5 residues (506-510) (Dhand et al., 
1994). At the C-terminal end of helix-2 is a ~30 residue “tail” that links the coiled-
coil to the cSH2 domain. The acidic nature of this stretch of amino-acids suggests that 
it could fold back and pack against exposed basic residues at the C-terminus of helix-
2 (Dhand et al., 1994). Biochemical studies to determine the p110-binding site on 
AlanineMethionine
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B
Fig. 4.2. Amino-acid changes made in NS1. (A) Tyrosine to (B) phenylalanine. (C) Me-
thionine to (D) alanine. Amino- and carboxyl- ends of the backbone are shown . The major 
colour of each amino-acid represents carbon. Hydrogen is represented in silver.  Images were 
prepared in MacPyMol using PDB ﬁles  from http://www.chemistry.gsu.edu/glactone.
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p85β have indicated essential residues in helix-1 as 445-485 (and in particular 475-
477) (Dhand et al., 1994, Fu et al., 2004). Important residues for p110-binding in 
helix-2 (adjacent to the binding site on helix-1) are 525-534 (Fu et al., 2004). 
 
Truncation of p85α at residue 571 removes part of helix-2 from the iSH2 domain and 
the whole of cSH2, but leaves the p110-binding site intact. Consequently, this mutant 
leads to constitutive activation of the resulting p85α:p110α heterodimer (Jimenez et 
al., 1998). It is not absolutely clear why this mutant (unlike full-length p85α) is 
unable to repress PI3K function. However, one possibility is that deletion of the auto-
inhibitory phosphorylation site at Ser608 (in the “tail” of iSH2) leads to the de-
regulated phenotype (Carpenter et al., 1993b, Foukas et al., 2004). Alternatively, 
specific inter- or intra- subunit interactions that repress p110 activity might be lost 
(Chan et al., 2002, Shekar et al., 2005). For example, evidence suggests that the nSH2 
domain of p85α is normally in close contact with residues 581-593 of iSH2, a 
conformation which may present nSH2 in such a way as to inhibit p110 activity 
(Shekar et al., 2005). Indeed, whilst this thesis was in preparation, the x-ray 
crystallographic structure of the p85α-iSH2:p110α-ABD complex was solved (Miled 
et al., 2007). The authors of this paper (Miled et al., 2007) were able to propose a 
model whereby kinase activity is negatively regulated by a charge-charge interaction 
between the p85 nSH2 domain and the p110 helical domain, an interaction which 
would be disrupted upon competitive phosphopeptide binding to nSH2, thus leading 
to increased PI3K activity (Miled et al., 2007) (Fig. 4.3A). 
 
4.1.2.3 Possible model for PI3K activation by NS1. 
It is intriguing to find that the binding of influenza A virus NS1 protein to the p85β 
iSH2 domain requires residues equivalent to those lost in the constitutively active 
Fig. 4.3. (A) Model of p110 lipid kinase regulation by p85. p110 binds the inter-SH2 
(coiled-coil) domain of p85. Charge-charge contacts between the p85-nSH2 domain 
and the p110 helical domain maintain p110 in an inactive state. Activation of PI3K re-
sults from a phospho-YXXM motif in an activated receptor out-competing p110 for bind-
ing the p85-nSH2 domain, thus relieving p85-mediated inhibition of p110. (B) Proposed 
model of PI3K activation by NS1. NS1 binds the C-terminal region of the p85β inter-
SH2 domain, but does not displace p110. The binding of NS1 to this region may disrupt 
the regulatory charge-charge contact between p85β−nSH2 and p110, resulting in a re-
ceptor-independent increase in PI3K activity. Images modiﬁed from Miled et al., 2007. 
Original image can be found at the reference given below.
Alternatively, e-mail bgh1@st-andrews.ac.uk for a full copy of this the-
sis, including all ﬁgures.
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p85α mutant (i.e. part of helix-2 and the acidic “tail”) (Fig. 4.4). Thus, these data are 
suggestive of a novel mode-of-action whereby NS1 interacts with and activates 
heterodimeric PI3K by potentially masking the p110-inhibitory function of the p85β 
iSH2 domain. Currently the mechanistic details can only be speculated upon: NS1 
may modify inter- and intra- molecular contacts within the PI3K heterodimer, 
displace an unknown repressive element, or recruit additional cellular co-stimulatory 
factors to the complex (such as IRS-4). 
 
Given the model recently proposed by Miled et al. (Miled et al., 2007), it is tempting 
to think that NS1 simply displaces nSH2 from the p110 helical domain (Fig. 4.3B). 
Such a mode-of-action would directly target mechanical aspects of PI3K regulation, 
and would be an efficient way to activate the kinase, as the multiple inputs that 
normally regulate p85:p110 function would be short-circuited (Carpenter et al., 
1993a, Cuevas et al., 2001, Foukas et al., 2004, Gout et al., 2000, Rordorf-Nikolic et 
al., 1995, Tolias et al., 1995, Zheng et al., 1994). For example, stimulation of PI3K 
by NS1 during virus infection would be independent of phosphopeptide binding, thus 
ensuring that signalling was not linked to host activity and could occur even if the 
infected cells were quiescent (when normal receptor signalling might be low). 
Additionally, NS1 might also mask the inhibitory Ser608 autophosphorylation site, 
and in this way circumvent any automatic negative feedback by p110 (Foukas et al., 
2004). It is noteworthy that analogous host-cell or viral proteins that regulate PI3K 
activity by binding to the iSH2 domain of p85β (or even p85α) have yet to be 
identified. 
 
The in vitro binding studies presented here are unable to account for the possibility 
that other regions of either full-length NS1 or full-length p85β may play some minor 
BA
p85-iSH2
↑
p110-ABD↑
↑
Potential
NS1-binding site
p110-ABD↑
↑
Potential
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p85-iSH2
↑
Fig. 4.4. Structure of the p85-iSH2 domain in complex with the p110-ABD. Cartoon (A), 
and surface (B) representations of the p85-iSH2 domain (coiled-coil; blue) bound to p110-
ABD (green). Full-length p110 is predicted to extend over the whole length of iSH2. Residues 
that are absent in the truncated p85-iSH2 construct are highlighted in red. These make up the 
putative NS1-binding site. It should be noted that both the nSH2 and cSH2 domains are lo-
cated at this end of iSH2, and thus may form secondary contacts with NS1. Charge-charge 
contacts between nSH2 and the p110 helical domain are thought to normally negatively-reg-
ulate PI3K activity. Images were prepared using MacPyMol (Protein Data Bank ﬁle: 2V1Y). 
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role in the functional interaction in vivo. For example, the RNA-binding domain of 
NS1 is not absolutely essential for complex formation, but residues within this 
domain could contribute to NS1:p85β stability and/or the activation of PI3K. Indeed, 
Ehrhardt et al. noted that transient expression of a WSN/NS1 construct containing 
amino-acid substitutions at arginine-38 and lysine-41 (which abrogate the binding of 
NS1 to RNA) induced less Akt phosphorylation than the wild-type construct 
(Ehrhardt et al., 2007a). However, interpretation of such data is complicated by a 
report that mutation of arginine-38 may cause mislocalisation of WSN/NS1 in 
infected cells (Min & Krug, 2006). Additional work is therefore required to 
investigate any potential role for the NS1 RNA-binding domain with respect to PI3K 
stimulation. 
 
The data presented here also appear to contradict a recent publication in which the co-
precipitation of NS1 with the SH3 and cSH2 domains of p85 [isoform not reported]  
is noted (Shin et al., 2007a). Although such interactions were not identified under the 
experimental conditions described here, it is possible that the binding of NS1 to p85β 
is relatively complex, and dynamic interplay between NS1 and multiple domains of 
p85β occurs in vivo. Indeed, the proposed positioning of NS1 with respect to the iSH2 
domain (Figs. 4.3B & 4.4) would potentially bring it into close contact with the SH3 
and cSH2 domains of p85β, which are likely to be distal from the p110-binding site 
on iSH2 (Fig. 4.4). Thus, the observed co-precipitation of NS1 with these two 
domains by Shin et al. (Shin et al., 2007a) may yet be compatible with this model. 
Indeed, it is clear that mutation of a single polyproline motif (residues 164-167 
[PXXP]; putative p85 SH3-binding motif) in NS1 completely abrogates the ability of 
NS1 to interact with p85β and activate PI3K (Shin et al., in press). However, 
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mutation of proline residues can severely disrupt protein structure, and the specificity 
of these amino-acid substitutions for NS1 function has yet to be demonstrated. 
 
The model proposed here also does not yet take into account the recent unpublished 
finding that NS1 proteins of some avian influenza A virus strains display enhanced 
PI3K-activating abilities, which may be due to their direct interaction with the SH3 
domains of cellular Crk/CrkL proteins (Heikkinen et al., 2007). Work to refine this 
model and define the possible role of Crk/CrkL is currently underway. 
 
4.2 Consequences of PI3K activation for virus replication. 
The biological consequences of NS1 binding and activating PI3K were not fully 
tackled as part of this thesis, and still remain to be fully elucidated. However, from 
the preliminary work done it is clear that PI3K activity is important for multiple 
stages of efficient influenza A virus replication. 
 
4.2.1 PI3K and influenza A virus entry into cells. 
Chemical inhibition of PI3K (using wortmannin or LY294002) specifically reduced 
the infectious titres of PR8 in MDCK cells (Fig. 3.10). This is in agreement with a 
previous study performed by Ehrhardt and colleagues, who also observed that 
inhibition of PI3K activity lead to a decrease in the growth of influenza A virus 
(Ehrhardt et al., 2006). Interestingly, a decrease was only noted if PI3K was inhibited 
prior to 4h p.i., after which PI3K inhibition had no effect on virus yield in single-step 
growth analyses (Ehrhardt et al., 2006). As determined by immunofluorescence 
studies, the block on virus replication appears to be at the level of early virus uptake 
into cells (Ehrhardt et al., 2006). Such a role for PI3K is likely to be independent of 
Akt activity, as transient expression of a kinase-dead, dominant-negative form of Akt 
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was unable to suppress the amount of infectious influenza A virus generated 
(Ehrhardt et al., 2006). 
 
It is unlikely that NS1-activated PI3K is responsible for promoting virus uptake, as 
the NS1 protein is non-structural and is thus only produced subsequent to RNP 
delivery into the nucleus. Indeed, Ehrhardt and colleagues noted that PI3K activation 
(as determined by Akt phosphorylation) occurs in a bivalent manner during infection, 
with an initial weak "peak" at 30mins-1h p.i., followed by a much greater and 
sustained "peak" beginning ~4h p.i. (Ehrhardt et al., 2006, Ehrhardt et al., 2007b). 
The early activation of PI3K could be due to virus adsorption, and might be 
responsible for the noted role of PI3K in viral entry processes. 
 
Interestingly, this specific early requirement for PI3K activation may be conserved 
among other members of the Orthomyxoviridae family, as weak transient Akt 
phosphorylation at 30mins-1h p.i. has also been observed during influenza B virus 
infection of tissue-culture cells (Ehrhardt et al., 2007b). In a situation similar to 
influenza A virus, PI3K inhibitors also reduce the infectious titres of influenza B 
virus, but only when treatment is applied up to ~4h p.i. (Ehrhardt et al., 2007b). 
 
4.2.2 PI3K and influenza A virus replication. 
The induction of Akt phosphorylation beginning at ~4h p.i. during influenza A virus 
infections is likely due to activation of PI3K by the NS1 protein. In this study, to 
dissect the direct contribution of NS1-activated PI3K with regards virus replication, 
recombinant influenza A viruses expressing NS1 proteins specifically unable to 
activate PI3K (NS1-Y89F) were generated. These viruses are convenient tools, given 
that they can be used to circumvent the problem of LY294002 and wortmannin 
blocking influenza A virus entry into cells, as well as other "off-target" effects of 
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these compounds. Surprisingly, characterisation of these viruses in MDCK cells 
revealed a strain-specific requirement for NS1-mediated PI3K activation. Whereas 
rUd NS1-Y89F exhibited a small plaque phenotype and grew to titres lower than WT 
rUd virus, rWSN NS1-Y89F did not exhibit an altered phenotype as compared with 
WT rWSN. The reasons for this remain unclear, but given that Tyr89 of NS1 is totally 
conserved (and if its sole function is to promote the interaction of NS1 with p85β), it 
seems probable that the activation of PI3K is necessary for all natural non-laboratory 
adapted strains of influenza A virus. Indeed, the need to activate PI3K may be a 
requirement primarily for efficient virus replication and spread in vivo, as such a 
function appears to enhance the pathogenicity of WSN in mice. 
 
Recent unpublished work by Dr. Dave Jackson (Northwestern University, U.S.A.) 
suggests that NS1-mediated PI3K activation may be required to counter another 
function encoded by the influenza A virus NS segment. Recombinant Ud viruses were 
generated that contained either the WT WSN NS segment, or the WSN NS segment 
that expresses NS1-Y89F. Initial characterisation of these rUd/WSN viruses in 
MDCK cells revealed that both viruses replicate to the same titres in single-cycle and 
multi-cycle growth analyses (Dr. Dave Jackson, unpublished observations). Thus, the 
inability of WSN NS1-Y89F to activate PI3K does not attenuate virus replication in a 
Ud background. This observation may indicate that PI3K activation is required by Ud 
virus in order to counter a putative effect encoded by its virus-specific NS segment. In 
contrast, the ability to carry out such a "putative function" in MDCK cells may have 
been lost by the WSN NS segment, possibly as a result of its adaptation to the mouse 
host. Despite this, it would appear that activation of PI3K by the WSN/NS1 protein 
has been retained, which may still be required for WSN to oppose the "putative 
function" in murine cells, or in vivo. Clearly, further work is required to determine if 
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NS1-mediated PI3K activity counters a host-species and/or strain specific function of 
the NS segment. It is not without precedent for an influenza A virus NS segment 
derived from one host species to encode products that function inefficiently in another 
host (Basler et al. 2001, Treanor et al., 1989). 
 
It is worth noting that there are 6 amino-acid differences (2 conservative) between the 
NEP proteins of Ud and WSN, and 26 amino-acid differences (12 conservative) 
between the NS1 proteins of Ud and WSN. In addition, the NS1 protein of Ud has a 7 
amino-acid extension at its C-terminus. A recently described phenotypic difference 
between the Ud and WSN NS1 proteins has been attributed to some of these 
differences; namely, their nuclear localisation within both infected and transfected 
human tissue-culture cells (Melen et al., 2007). Thus, whilst Ud/NS1 is distributed 
throughout the nucleus, WSN/NS1 appears to be excluded from intra-nuclear regions 
likely to be nucleoli (Melen et al., 2007). Furthermore, given the striking difference 
with regards WSN/NS1 localisation during infection of MDCK cells (nuclear) and 
primary murine epithelial cells (cytoplasmic) [Newby et al., 2007], it is possible that 
this protein displays cell-type and/or species specific functions. These data are not 
incompatible with the notion that WSN/NS1 has lost a function in certain cell-types 
that requires counter-balance by PI3K signalling. It will be intriguing to determine 
whether a specific nucleolar function of Ud/NS1 is countered by NS1-activated PI3K. 
 
4.2.3 PI3K and influenza A virus-induced apoptosis. 
The PI3K/Akt signalling pathway is commonly activated by viruses in order to limit 
apoptosis during infection (see Introduction). Thus, it was not surprising to find that 
the rUd NS1-Y89F virus induced the cleavage of PARP slightly faster than WT rUd 
in HEp2 cells. However, given the diverse array of PI3K-regulated physiological 
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processes [reviewed in (Manning & Cantley, 2007, Vanhaesebroeck et al., 2005)], it 
is possible that other apoptosis-independent, cell-type specific consequences of NS1-
mediated PI3K activation exist. Nevertheless, other groups have confirmed the 
observation made here that markers of apoptosis are more prominent during influenza 
A virus infections when PI3K/Akt signalling is blocked (Ehrhardt et al., 2007a, Shin 
et al., in press, Zhirnov & Klenk, 2007). Thus, a functional model has been proposed 
whereby NS1-activated PI3K causes the phosphorylation and activation of Akt, which 
further leads to the phosphorylation and inactivation of pro-apoptotic GSK-3β, and 
the inhibition of several pro-caspase cleavage events (Ehrhardt et al., 2007a). 
 
Interestingly, given the influenza A virus-induced kinetics of Akt phosphorylation in 
MDCK cells (i.e. increasing to peak at ~8h p.i. before declining; Zhirnov & Klenk, 
2007), it may be that NS1 only activates PI3K in order to limit virus-induced cell-
death at early/mid times post-infection (Zhirnov & Klenk, 2007). Indeed, the apparent 
dephosphorylation of Akt observed after 8h p.i. correlates well with increased 
activation of p53 signalling and the induction of apoptosis (Zhirnov & Klenk, 2007). 
It is not entirely clear what is responsible for causing the dephosphorylation of Akt 
during infection, but data from this work indicate that negative-regulation of PI3K 
signalling by PTEN does not play a major role. Although dephosphorylation of Akt 
was not observed in infected 1321N1 cells, a host-cell factor need not be responsible, 
as it has not yet been determined if influenza A viruses replicate productively in these 
cells. Thus, specific expression of another viral protein later in infection may 
contribute in some way to dephosphorylation of Akt. Alternatively, non-specific 
build-up of all viral proteins at later times post-infection may overwhelm the cell, and 
induce an apoptotic stress response which begins with the cell-mediated "switching-
off" of PI3K/Akt signalling. 
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An intriguing observation is that an engineered influenza A virus unable to express 
NS1 (PR8delNS1) not only fails to induce Akt phosphorylation during infection, but 
also fails to activate p53 signalling (Zhirnov & Klenk, 2007). This is surprising given 
that p53 has been proposed to have roles in influenza A virus-induced IFN responses 
and/or cell-death (Turpin et al., 2005), both processes that are likely to be 
significantly increased upon infection with PR8delNS1 (Egorov et al., 1998, Garcia-
Sastre et al., 1998, Talon et al., 2000a, Wang et al., 2000, Zhirnov et al., 2002a). As 
PI3K/Akt activation efficiently down-regulates p53 activity [reviewed in (Manning & 
Cantley, 2007)], it might have been expected that p53 signalling would be increased 
(and occur earlier) during infection with a virus unable to activate PI3K. However, the 
inability of PR8delNS1 (unlike WT PR8) to stabilise p53 by inducing its Ser15 
phosphorylation (Zhirnov & Klenk, 2007) suggests that NS1 has a direct effect on 
p53 activity. Indeed, previous work has hinted at an interaction between NS1 and p53 
during virus infection (Luke et al., 2005). 
 
One hypothesis to account for these observations is that NS1 may act as a "dynamic 
switch" in cell survival and cell-death signalling. Thus, at early times post-infection 
NS1 binds and activates PI3K, thus limiting virus-induced apoptosis by suppression 
of (among other things) p53 signalling. Later, NS1 may dissociate from PI3K (or this 
complex becomes inactive), and an alternative NS1 population interacts with and 
activates p53, leading to defined cell-death. This could account for the apparently 
conflicting data on the role of NS1 for apoptosis induction (Schultz-Cherry et al., 
2001, Zhirnov et al., 2002a). This hypothesis does not exclude the possibility that p53 
activation subsequent to attenuation of NS1-mediated PI3K signalling occurs 
indirectly via the potentially toxic effects of NS1 limiting host-cell mRNA 
processing. Work is currently underway to determine if NS1 remains complexed with 
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p85β late in infection, and if NS1 thereby constantly activates PI3K. It will also be of 
interest to determine the kinetics of NS1 interacting with and modulating p53 activity. 
 
4.2.4 PI3K and other stages of the virus replication cycle? 
 
4.2.4.1 NS1-activated PI3K and cytokine responses. 
It is of note that NS1 has recently been shown to limit the induction of numerous 
specific transcriptional events associated with the maturation of human dendritic cells 
(DCs) in response to virus infection (Fernandez-Sesma et al., 2006). In particular, 
expression of IL-12 p35 (a subunit of the proinflammatory and immunoregulatory 
cytokine IL-12) was found to be inhibited in DCs infected with recombinant 
heterologous viruses expressing NS1 (Fernandez-Sesma et al., 2006). IL-12 is a key 
regulator of host innate and adaptive immune responses during infection: it enhances 
the cytolytic activity of natural killer cells and CD8+ T-cells, and contributes to the 
optimal production of IFNγ (Trinchieri, 1995). As IL-12 synthesis by DCs has 
previously been shown to be negatively controlled by PI3K signalling (Fukao et al., 
2002), it will be of great interest to determine if NS1-mediated PI3K activation is 
responsible for down-regulating IL-12 production during influenza A virus infection 
of DCs. Likewise, the effect of NS1-activated PI3K for TLR-mediated innate-immune 
responses may be worth investigating. 
 
4.2.4.2 NS1-activated PI3K and mRNA translation. 
For some viruses (particularly HCV), PI3K activation has been linked not only to 
reducing apoptosis, but also to enhancing translation of viral mRNAs by upregulating 
mTORC1 (Mannova & Beretta, 2005). As stated in the Introduction, activation of 
mTORC1 inhibits 4E-BP1 by direct phosphorylation, which subsequently leads to the 
activation of eIF4E, and the promotion of cap-dependent mRNA translation (Mamane 
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et al., 2004). Although NS1 has been shown to play a role in enhancing influenza A 
virus translation, this is likely due to its interactions with the cellular proteins eIF4GI 
and PABI (Aragon et al., 2000, Burgui et al., 2003), rather than the activation of 
PI3K. Indeed, a recent study has shown that influenza A virus mRNA translation is 
largely independent of eIF4E activity, and is functionally substituted by the virus-
encoded polymerase complex (Burgui et al., in press). Viral mRNA translation 
occurred normally in cells treated with the general mTOR inhibitor, rapamycin, and in 
cells expressing eIF4E shRNA (Burgui et al., in press). Additionally, transfection of a 
dominant-negative, non-phosphorylatable mutant of 4E-BP1 had no effect on 
influenza A virus replication (Burgui et al., in press). Thus, if NS1 recruits the 
mTOR/4E-BP1 arm of PI3K signalling during virus infection, it is not likely to be 
essential for efficient mRNA translation, and may have an as yet unidentified 
function.  
 
4.2.4.3 NS1-activated PI3K and ENaC function. 
It should be stressed that PtdIns(3,4,5)P3 generated by class IA PI3K can recruit and 
activate ~20 different PH domain-containing substrates, many of which may be 
activated in a cell-type specific manner (Krugmann et al., 2002). Although Akt is 
very well characterised, activation of PI3K by NS1 may result in downstream 
signalling to a number of other Akt-independent effectors. As an example, 
preliminary unpublished work done in collaboration with Michael Gallacher and Dr. 
Stuart Wilson (University of Dundee, U.K.) has shown that NS1-mediated PI3K may 
also induce the activation of SGK1, a serum- and glucocorticoid- induced kinase that 
is directly activated downstream of PI3K-PDK1. Furthermore, in polarised H441 
human epithelial airway cells, transient expression of wild-type PR8/NS1, but not 
PR8/NS1-Y89F, caused the activation of epithelial sodium channels (ENaCs), a 
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process which (in vivo) would result in the diffusion of water from the apical (air) 
surface of the lung into the bloodstream (Michael Gallacher, personal 
communication). SGK1 activity is known to increase ENaC function in at least two 
ways: overall stimulation of ENaC mRNA transcription; and phosphorylation and 
inhibition of Nedd4-2, an E3-ligase that would otherwise cause the ubiquitination and 
proteasome-mediated degradation of ENaC [reviewed in (Lang et al., 2006)]. Further 
work to characterise a role for NS1-activated ENaC in influenza A virus infections is 
currently under way. 
 
4.3 Outlook. 
 
4.3.1 PI3K as a novel anti-influenza drug target. 
Antivirals may provide an important initial defence against rapidly emerging and 
antigenically novel strains of influenza A virus (De Clercq, 2006). Targeting virus-
activated signalling cascades (such as PI3K) could be an attractive strategy for anti-
influenza drugs (De Clercq, 2006). As shown here, PI3K inhibition (using LY294002 
or wortmannin) greatly reduces the yield of influenza A virus under tissue-culture 
conditions (Fig. 3.10B). Various PI3K inhibitors are already under investigation as 
potential long-term therapies for cancer and chronic inflammatory disorders, thus it 
may be possible to develop similar compounds for use as short-term antivirals. 
 
The advantage of targeting a host-cell pathway is that treatments may be less 
susceptible to virus mutation and drug resistance. However, unknown toxic side-
effects on uninfected tissues could be cause for concern, and inhibitors such as 
wortmannin and LY294002 clearly affect multiple essential cellular events [see 
Introduction; (Gharbi et al., 2007, Sarkar et al., 2004)]. An alternative strategy 
would be to specifically inhibit the activation of PI3K by NS1. However, as this is a 
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virus-specific target there is potential for the development of drug resistance. 
Nevertheless, this approach is very attractive as Tyr89 of NS1 appears wholly 
conserved among human and avian influenza A viruses, thus compounds targeting 
this virus-host interaction may be effective against many influenza A virus strains. 
 
4.3.2 PI3K and live-attenuated influenza vaccines. 
The potential use of recombinant influenza A viruses with truncated/mutated NS1 
proteins as live-attenuated vaccines has been demonstrated (Ferko et al., 2004, Richt 
et al., 2006, Talon et al., 2000b). Such viruses are partially debilitated in their ability 
to counteract the host IFN-response, yet can grow efficiently to high titres in suitable 
IFN-deficient systems, such as Vero cells or embryonated chicken eggs (<6 days old) 
(Talon et al., 2000b). However, as the viruses are replication competent in the host 
(unlike delNS1 viruses, which are overwhelmed by innate immunity), they can be 
administered intranasally. Together, these properties mean NS1-truncated viruses 
elicit antibody, cell-mediated, and mucosal protective immune-responses (Ferko et 
al., 2004, Talon et al., 2000b). 
 
4.3.2.1 Virus design. 
As another strategy to generate live-attenuated influenza vaccines, residues of NS1 
involved in PI3K activation could be targeted (together with residues involved in 
IFN-antagonism or other functions) to generate mutant viruses expressing full-length 
"designer" NS1 molecules. Viruses could thus be specifically constructed in such a 
way as to possess the optimal balance of replication ability vs. in vivo 
attenuation/immunogenicity. Although, influenza A viruses with specific point 
mutations are likely to be unstable and prone to genotypic/phenotypic reversion 
(Falcon et al., 2005, Schickli et al., 2001), it may be advantageous to have a vaccine 
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virus possessing a full-length NS segment in which NS1 function is finely "tuned". 
Despite this, the use of NS1-truncated viruses as potential vaccines has most 
commonly been evaluated, and no comparison between NS1-truncated and NS1-
designer viruses has yet been done. The obvious benefit of NS1-truncated viruses is 
that they are likely to display increased genetic stability, a property ascribed to the 
multiple stop codons and/or large nucleotide deletions/insertions they contain (Ferko 
et al., 2004, Quinlivan et al., 2005, Richt et al., 2006, Schickli et al., 2001, Talon et 
al., 2000b). 
 
4.3.2.2 Cell-line design. 
Propagation of live-attenuated influenza A viruses in 6-day old embryonated chicken 
eggs for 2 days may not yield industrial quantities of vaccine. Thus, cell-based 
production of NS1-truncated mutants in cell-lines with phenotypes similar to Vero 
cells (i.e. lacking IFNα/β genes) may be more commercially viable. With this in 
mind, it is interesting to note that influenza A viruses lacking NS1 expression are 
attenuated ~10-100-fold in Vero cells as compared with wild-type viruses (Garcia-
Sastre et al., 1998, Kochs et al., 2007b), demonstrating that NS1 has functions 
independent of classical IFN-antagonism. As shown in this thesis, one such additional 
function of NS1 is PI3K activation. Indeed, most NS1-truncated viruses used to date 
have large deletions in the C-terminal effector domain of NS1, which is essential for 
binding p85β. Additionally, such viruses have been shown to be poor inducers of Akt 
phosphorylation (Ehrhardt et al., 2007a). Thus, if Vero cells could be engineered to 
have constitutively active PI3K signalling, it may be that this cell-line would augment 
the growth characteristics of NS1-truncated influenza A viruses. This approach could 
of course be extended to any cell-line (or identified function of NS1) with the aim of 
increasing live-attenuated influenza A virus vaccine yields. 
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4.3.3 PI3K and influenza A virus as an oncolytic therapy. 
Previously, PR8delNS1 has been shown to replicate efficiently and cause cell-death in 
cells expressing high levels of oncogenic Ras, a known enhancer of PI3K function 
(Bergmann et al., 2001). Conversely, growth of PR8delNS1 is restricted in non-
malignant cells. This suggested that PR8delNS1 can act as a conditionally replicating 
oncolytic virus in cell-lines with active Ras (Bergmann et al., 2001). The reason for 
this was originally ascribed to the ability of Ras to down-regulate PKR activity 
(Bergmann et al., 2001, Mundschau & Faller, 1992), which might otherwise inhibit 
PR8delNS1 replication. However, it is also possible that PR8delNS1 virus was able to 
replicate efficiently in Ras-overexpressing cells due to aberrant PI3K activation. The 
ability to activate PI3K would be lacking in PR8delNS1, but could be complemented 
by Ras acting directly on p110 (Fig. 1.15). Thus, given that deregulation of the PI3K 
pathway is commonly associated with numerous human cancers [reviewed in 
(Nicholson & Anderson, 2002)], it may be that influenza A viruses expressing NS1 
truncations/mutants could be developed to specifically target tumour cells with 
constitutively active PI3K. 
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A.1 Plasmid map for the pdl'MCS(C'V5) vector: 
 
 
 
 
 
 
 
 
 
 
• Plasmid generated by Dr. Yun-Hsiang Chen, University of St. Andrews, U.K. 
• ~10710bp in size. 
• Ampicillin resistance. 
• Multiple cloning site (MCS): 
5'-ggatctgcggccgcataccggtgcactagtcgacgcgtgacatatgttccggatcc-V5-3' 
··············NotI··········AgeI·······SpeI·······MluI·······NdeI········BamHI·········· 
• NotI and AgeI (underlined) are not unique. 
• SpeI, MluI, NdeI and BamHI are recommended cloning sites. 
• V5 epitope sequence (immediately downstream of MCS): 
························G···K··P···I···P···N···P··L··L·G···L··D··S··T···*···*···*····· 
5'-MCS-ggatccggaaagccgatcccaaaccctctattaggtctggactccacctaatagtgagatcc-3' 
·············BamHI······················································································· 
The 5' BamHI site shown above (V5 sequence) is also shown at the 3' end of the 
MCS. 
1
pdlNotI'MCS'R'Pk
10710bp
LTR
LTR/dU3
RRE
psi
SFFVpromoter(500bp)
cPPT
IRES
Puro
WPRE(730bp)
MCS'R'Pk
NheI
XbaI
XhoI
KpnI
ClaI
ClaI
XbaI
NotI(x)
NotI
NheI
EcoRI
BstEII
NruI
ClaI(methylated)
BamHI(x)
BamHI
Appendices 
 - 180 - 
A.2 Publications: 
Hale, B.G., et al. (2006). Influenza A virus NS1 protein binds p85β and activates 
phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci U S A 103, 14194-9. 
Hale, B.G. & Randall, R.E. (2007). PI3K signalling during influenza A virus 
infections. Biochem Soc Trans 35, 186-7. 
Hale, B.G. et al. (2008). Binding of influenza A virus NS1 protein to the inter-SH2 
domain of p85β suggests a novel mechanism for PI3K activation. J Biol Chem E-pub. 
 
A.3 Presentations: 
“Influenza A virus NS1 protein binds p85β and activates PI3K/Akt signalling” –      
3rd Focused Meeting on PI3K Signalling and Disease (Bath, U.K., Nov. 2006). 
“Activation of the PI3K/Akt signalling pathway during influenza A virus infection” – 
12th Annual Glasgow Virology Workshop (Glasgow, U.K., Feb. 2007). 
“Activation of PI3K by the NS1 protein of influenza A virus” –                               
160th Society for General Microbiology Meeting (Manchester, U.K., March 2007). 
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